

# ALEXANDRIA REAL ESTATE EQUITIES, INC.

EARNINGS PRESS RELEASE & SUPPLEMENTAL INFORMATION  
THIRD QUARTER ENDED SEPTEMBER 30, 2024

“Alexandria has achieved  
the three outputs that  
define a great company:  
*Superior Results,*  
*Distinctive Impact,* and  
*Lasting Endurance.*”

JIM COLLINS  
Renowned Author & Business Strategist



# Table of Contents

September 30, 2024

<b>COMPANY HIGHLIGHTS</b>		Page	Page
Mission and Cluster Model .....	iii	Industry and Corporate Responsibility Leadership .....	xxiv
<b>EARNINGS PRESS RELEASE</b>		Page	Page
Third Quarter Ended September 30, 2024 Financial and Operating Results .....	1	Earnings Call Information and About the Company .....	8
Guidance .....	5	Consolidated Statements of Operations .....	9
Acquisitions .....	6	Consolidated Balance Sheets .....	10
Dispositions .....	7	Funds From Operations and Funds From Operations per Share .....	11
<b>SUPPLEMENTAL INFORMATION</b>		Page	Page
Company Profile .....	14	<b>External Growth / Investments in Real Estate</b>	
Investor Information .....	15	Investments in Real Estate .....	33
Financial and Asset Base Highlights .....	16	New Class A/A+ Development and Redevelopment Properties:	
High-Quality and Diverse Client Base .....	18	Recent deliveries .....	35
Occupancy .....	20	Current Projects .....	37
		Summary of Pipeline .....	41
		Construction Spending and Capitalization of Interest .....	46
		Joint Venture Financial Information .....	48
		<b>Balance Sheet Management</b>	
		Investments .....	50
		Key Credit Metrics .....	51
		Summary of Debt .....	52
		<b>Definitions and Reconciliations</b>	
		Definitions and Reconciliations .....	56
<b>Internal Growth</b>			
Key Operating Metrics .....	21		
Same Property Performance .....	22		
Leasing Activity .....	23		
Contractual Lease Expirations .....	24		
Top 20 Tenants .....	25		
Summary of Properties and Occupancy .....	26		
Property Listing .....	27		

## CONFERENCE CALL INFORMATION:

Tuesday, October 22, 2024

3:00 p.m. Eastern Time  
12:00 p.m. Pacific Time

(833) 366-1125 or  
(412) 902-6738

Ask to join the conference call for Alexandria Real Estate Equities, Inc.

## CONTACT INFORMATION:

Alexandria Real Estate Equities, Inc.  
corporateinformation@are.com

**JOEL S. MARCUS**  
Executive Chairman &  
Founder

**PETER M. MOGLIA**  
Chief Executive Officer &  
Chief Investment Officer

**DANIEL J. RYAN**  
Co-President & Regional Market  
Director - San Diego

**HUNTER L. KASS**  
Co-President & Regional Market  
Director - Greater Boston

**MARC E. BINDA**  
Chief Financial Officer &  
Treasurer

**PAULA SCHWARTZ**  
Managing Director,  
Rx Communications Group  
(917) 633-7790

**SARA M. KABAKOFF**  
Senior Vice President -  
Chief Content Officer



ALEXANDRIA®  
Building the Future of Life-Changing Innovation®

#### OUR MISSION

*To create and grow life science ecosystems and clusters that ignite and accelerate the world's leading innovators in their noble pursuit to advance human health by curing disease and improving nutrition*

#### OUR CLUSTER MODEL

Alexandria has identified four critical components for life science companies to thrive: *location, innovation, talent, and capital.*

Our proven cluster model unites cutting-edge innovation with leading scientific and managerial talent and strategic investment capital in best-in-class locations immediately adjacent to some of the world's top academic institutions.



THAT'S WHAT'S IN  
OUR DNA®

# ALEXANDRIA'S ESSENTIAL LABSPACE<sup>®</sup> INFRASTRUCTURE

As the pioneering and trusted brand for life science real estate, Alexandria has been providing the infrastructure needed to enable the development of new medicines for over three decades. Our tenants require our essential, 24/7 integrated laboratory and nontechnical infrastructure to house, operate, and help safeguard billions of dollars of mission-critical equipment and scientific research.

# 24/7



# ALEXANDRIA'S COMPETITIVE ADVANTAGES

- ▶ First mover advantage in the top life science clusters
- ▶ High-quality assets aggregated in desirable and well-amenitized mega campuses
- ▶ High-quality cash flows and substantial embedded future net operating income
- ▶ Longstanding tenant relationships that demonstrate stellar brand loyalty
- ▶ Fortress balance sheet with significant liquidity
- ▶ Unique and deep life science industry expertise
- ▶ Long-tenured and highly experienced management team

IRREPLACEABLE  
LABSPACE® REAL ESTATE  
PLATFORM THAT LEADS THE  
ASSET CLASS WE PIONEERED

MEGA CAMPUSES ENCOMPASS

76%

OF OUR ANNUAL RENTAL REVENUE

OPERATING RSF  
41.8M

“A truly great business must have an enduring ‘moat’ that protects excellent returns on invested capital.”

WARREN BUFFETT

# ALEXANDRIA'S MEGA CAMPUS PLATFORM DRIVES SUPERIOR OPERATING RESULTS




MEGA CAMPUS:  
ONE ALEXANDRIA SQUARE | SAN DIEGO

## MEGA CAMPUSES ENCOMPASS



## MEGA CAMPUS OCCUPANCY OUTPERFORMANCE

Average Occupancy<sup>(1)</sup> Since 2020




As of September 30, 2024. Refer to "Definitions and reconciliations" in the Supplemental Information for additional details.

(1) Represents the average occupancy percentage of operating properties as of December 31 for 2020–2023 and September 30, 2024.

# ALEXANDRIA'S OUTSTANDING LONG-TERM VALUE

Total Shareholder Return From ARE's IPO on May 27, 1997<sup>(1)</sup> to September 30, 2024



Source: S&P Global Market Intelligence. Assumes reinvestment of dividends.

The REITs presented individually in the chart above are only those constituents of the FTSE NAREIT Equity Health Care Index as of September 30, 2024 for which TSR information since May 27, 1997 is available.

(1) Alexandria's initial public offering ("IPO") was priced at \$20.00 per share on May 27, 1997.


# ALEXANDRIA'S INTERNAL GROWTH




ALEXANDRIA®  
*Building the Future of Life-Changing Innovation®*



# ALEXANDRIA 3Q24 LEASING VOLUME EXCEEDS PREVIOUS FOUR-QUARTER AVERAGE




# ALEXANDRIA'S OPERATIONAL EXCELLENCE DRIVES STEADY AND CONSISTENTLY HIGH OCCUPANCY



(1) Represents the midpoint of our 2024 guidance range for occupancy percentage in North America as of December 31, 2024. Refer to "Guidance" in the Earnings Press Release for additional details.

(2) Represents occupancy percentage of operating properties in North America as of each period-end.

# ALEXANDRIA'S REIT INDUSTRY-LEADING CLIENT BASE OF APPROXIMATELY 800 TENANTS DRIVES STABLE, RESILIENT, AND LONG-DURATION CASH FLOWS



**92%**

of Top 20 Tenant Annual Rental Revenue as of 3Q24 Is From Investment-Grade or Publicly Traded Large Cap Tenants


**80%**

of Leasing Activity During the Last Twelve Months Was Generated From Alexandria's Existing Client Base

As of September 30, 2024. Annual rental revenue represents amounts in effect as of September 30, 2024. Refer to "Definitions and reconciliations" in the Supplemental Information for additional details, including our methodology of calculating annual rental revenue from unconsolidated real estate joint ventures.

(1) Represents the percentage of our annual rental revenue generated by technology, professional services, finance, telecommunications, and construction/real estate companies, as well as retail-related tenants, which generate less than 1.0% of our annual rental revenue.

# ALEXANDRIA'S SUSTAINED OPERATIONAL EXCELLENCE AND STRENGTH IN TENANT COLLECTIONS



TENANT RENTS AND RECEIVABLES COLLECTED<sup>(1)</sup>

**99.8%**

Average Tenant Collections  
1Q21-3Q24

Tenant Receivables Represent

**0.9%**

of 3Q24 Rental Revenues

(1) Represents tenant rents and receivables collected for each quarter-end as of each respective earnings release date.

# ALEXANDRIA'S FORTRESS BALANCE SHEET AND STRONG EXECUTION OF ASSET RECYCLING



ALEXANDRIA®  
*Building the Future of Life-Changing Innovation®*

# ALEXANDRIA'S STRONG AND FLEXIBLE BALANCE SHEET WITH SIGNIFICANT LIQUIDITY

## TOP 10%

CREDIT RATING RANKING  
AMONG ALL PUBLICLY  
TRADED U.S. REITS<sup>(1)</sup>

**Baa1**

Stable

**MOODY'S**  
RATINGS

**BBB+**

Stable

**S&P Global**  
Ratings

SIGNIFICANT  
LIQUIDITY<sup>(2)</sup>

**\$5.4B**

PERCENTAGE OF  
DEBT MATURING  
2049 & BEYOND

**31%**

PERCENTAGE OF  
FIXED RATE DEBT  
SINCE 2020<sup>(3)</sup>

**97.7%**

NET DEBT AND  
PREFERRED STOCK TO  
ADJUSTED EBITDA<sup>(4)</sup>

**≤5.1x**

4Q24 TARGET

REMAINING  
DEBT TERM

**12.6**

YEARS

INTEREST  
RATE

**3.91%**

WEIGHTED AVERAGE




As of September 30, 2024.

- (1) A credit rating is not a recommendation to buy, sell, or hold securities and may be subject to revision or withdrawal at any time. Top 10% ranking represents credit rating levels from Moody's Ratings and S&P Global Ratings for publicly traded U.S. REITs, from Bloomberg Professional Services and Nareit.
- (2) Refer to "Key credit metrics" in the Supplemental Information for additional details.
- (3) Represents the average fixed rate debt as of each December 31 from 2020 through 2023 and as of September 30, 2024.
- (4) Quarter annualized. Refer to "Definitions and reconciliations" in the Supplemental Information for additional details.

# ALEXANDRIA'S HISTORICALLY CONSISTENT, STRONG, AND INCREASING DIVIDENDS WITH A FOCUS ON RETAINING SIGNIFICANT CASH FLOWS FROM OPERATING ACTIVITIES AFTER DIVIDENDS FOR REINVESTMENT

For 3Q24, we declared a cash dividend of \$1.30 per common share



(1) Dividend yield is calculated as the dividend declared for the three months ended September 30, 2024 of \$1.30 per common share annualized divided by the closing price of our common stock on September 30, 2024 of \$118.75.  
(2) Represents the years ended December 31, 2020 through 2023 and the three months ended September 30, 2024 annualized.  
(3) Represents the years ended December 31, 2020 through 2023 and the midpoint of our 2024 guidance range. Refer to "Guidance" in the Earnings Press Release for additional details.  
(4) Represents common stock dividend declared for the three months ended September 30, 2024 annualized.

# ALEXANDRIA'S STRONG EXECUTION OF OUR ASSET RECYCLING PROGRAM

## STRATEGIC DISPOSITIONS AND SALES OF PARTIAL INTERESTS SINCE 2019<sup>(1)</sup>



**\$8.7 BILLION**  
IN SALES<sup>(2)</sup>

**\$3.0 BILLION**  
IN GAINS<sup>(3)</sup>

(1) Includes amounts related to real estate dispositions and sales of partial interests completed from January 1, 2019 through October 21, 2024.

(2) Dispositions in 100% interest in properties completed since 2019, excluding sales of partial interests, had annual rental revenues of \$202.0 million based on the quarter preceding the date on which each property is sold.

(3) Represents aggregate gains on real estate sales and associated real estate impairments and consideration in excess of book value of partial interests sold that were accounted as equity transactions.



# ALEXANDRIA CONTINUES STRATEGIC VALUE-HARVESTING DURING 3Q24 WITH DISPOSITION OF 1165 EASTLAKE AVENUE EAST IN LAKE UNION, SEATTLE

Alexandria's opportunistic sale to Fred Hutchinson Cancer Center, a longstanding tenant, deepens our relationship and enables Fred Hutch to expand its South Lake Union footprint within the Alexandria Center® for Life Science – Eastlake mega campus ecosystem.

**\$150.0M**

SALES PRICE

**4.7%**

CAPITALIZATION RATE

**4.9%**

CAPITALIZATION RATE  
(CASH BASIS)

**\$1,499**

SALES PRICE  
PER RSF

**\$21.5M**

GAIN ON SALE  
OF REAL ESTATE



1165 EASTLAKE AVENUE EAST | SEATTLE

# ALEXANDRIA'S STRATEGIC VALUE-HARVESTING DISPOSITION OF A NON-CORE, STAND-ALONE ASSET: 14225 NEWBROOK DRIVE IN NORTHERN VIRGINIA

Demonstrating the long-term enduring value of our laboratory facilities, Alexandria successfully operated this property from its acquisition in 1997 (prior to our IPO) through its sale in October 2024.

**\$80.5M**

SALES PRICE

**7.6%**

CAPITALIZATION RATE

**7.4%**

CAPITALIZATION RATE  
(CASH BASIS)

**\$37.1M**

GAIN ON SALE  
OF REAL ESTATE



14225 NEWBROOK DRIVE | NORTHERN VIRGINIA

# ALEXANDRIA: AT THE VANGUARD AND HEART OF THE \$5 TRILLION<sup>(1)</sup> SECULARLY GROWING LIFE SCIENCE INDUSTRY



ALEXANDRIA®  
*Building the Future of Life-Changing Innovation®*


(1) Source: YCharts. Represents the aggregate market capitalization for the life science industry, including companies in the biotechnology and pharmaceutical sectors, as of July 12, 2024.

# THE \$5 TRILLION<sup>(1)</sup> SECULARLY GROWING LIFE SCIENCE INDUSTRY, WITH OVER \$470 BILLION IN ANNUAL R&D FUNDING FROM DIVERSE SOURCES, DRIVES DEMAND FOR ALEXANDRIA'S LABSPACE<sup>®</sup> ASSETS

TOTAL LIFE SCIENCE R&D FUNDING<sup>(2)</sup>

**\$2.1T+**  
2019-2023

**42%**  
INCREASE IN TOTAL FUNDING COMPARED TO 2014-2018



2023 LIFE SCIENCE R&D FUNDING BY SOURCE

- (1) Source: YCharts. Represents the aggregate market capitalization for the life science industry, including companies in the biotechnology and pharmaceutical sectors, as of July 12, 2024.
- (2) Dollar amount represents aggregate funding from all sources presented, and percentage represents the aggregate increase in funding compared to the previous five-year period (2014–2018).
- (3) Source: Evaluate Pharma, March 2024. Represents consensus forecast for global biopharma R&D spend in 2023.
- (4) Sources: PitchBook, BioCentury, and NASDAQ. Includes venture capital investments in U.S.-based life science companies and IPOs, follow-ons, and public equity financings raised by U.S. listed biopharma companies in 2023.
- (5) Sources: National Institutes of Health (“NIH”) and National Science Foundation (“NSF”). Includes FY2023 NIH funding and FY2023 NSF research and related activities.
- (6) Source: The Giving Institute, “Giving USA 2024: The Annual Report on Philanthropy for the Year 2023.”

# ALEXANDRIA TENANTS ARE RESPONSIBLE FOR 50% OF NOVEL FDA-APPROVED THERAPIES SINCE 2013

34 FDA (CDER) Approvals in YTD 3Q24

## NOVEL THERAPIES FROM ALEXANDRIA TENANTS IN 2024

*Lilly*

### KISUNLA

Therapy treating adults with early symptomatic Alzheimer's disease

 Bristol Myers Squibb™

### COBENFY

First therapy approved to treat schizophrenia by targeting cholinergic receptors


Johnson & Johnson

### LAZCLUZE

First chemotherapy-free regimen approved to treat non-small lung cancer with specific genetic mutations

**>2x**  
INCREASE  
SINCE 2003

Near-Record Level of FDA Approvals in 2023 Reflects the Strength of the Life Science Industry




NOVEL THERAPIES APPROVED BY THE FDA (CDER) IN 2023 COMPARED TO PRIOR 10-YEAR AVERAGES

Source: U.S. Food and Drug Administration. Novel therapies approved by the FDA (Center for Drug Evaluation and Research ("CDER")) include new molecular entities and new biologics defined as products containing active moieties that have not previously been approved by the FDA.

# INNOVATIVE MEDICINE APPROVALS BY CBER HAVE BEEN RAMPING UP OVER THE PAST SEVERAL YEARS

The promise of next-generation medicine is being realized



# 83%

5 out of 6 of innovative medicine approvals by the FDA (CBER) in YTD 3Q24<sup>(1)</sup> went to ALEXANDRIA TENANTS, reflecting the cutting-edge science occurring within our asset base

## NOTABLE TENANT APPROVALS

moderna®

The first non-COVID mRNA vaccine, mRESVIA for RSV

IOVANCE  
BIOTHERAPEUTICS

The first tumor-infiltrating lymphocyte (TIL) cell therapy, Amtagvi for melanoma

Adaptimmune  
TRANSFORMING T CELL THERAPY

The first T-cell receptor cell therapy (TCR-T), Tecelra for synovial sarcoma

Source: U.S. Food and Drug Administration. Innovative medicine approvals by the FDA (Center for Biologics Evaluation and Research ("CBER")) include novel vaccines and next-generation modalities such as cell therapies, gene therapies, mRNA products, live biotherapeutics, and oncolytic viruses. These are distinct from the FDA CDER approvals on the prior slide.


(1) YTD 3Q24 represents the period from January 1, 2024 through September 19, 2024.

# INNOVATION IN MEDICINE IS IMPERATIVE TO SAVING LIVES AND DRIVING DOWN HEALTHCARE COSTS

**~10,000**  
KNOWN DISEASES

Less Than 10% Are Currently Addressable With Treatments<sup>(3)</sup>

## Prescription Medicine's Share of National Healthcare Expenditures<sup>(1)</sup>



**Over 50%**

of Prescription Drug Costs Go to Middlemen, Including PBMs, Hospitals, and Insurers, Inflating the Costs of Medicines<sup>(1)</sup>

(1) Source: PhRMA, "Understanding Prescription Medicine Spending," 2022.

(2) Source: Centers for Medicare & Medicaid Services, "National Health Expenditures 2022 Highlights," 2022.

(3) Source: U.S. House Committee on Energy and Commerce, "The 21st Century Cures Discussion Document White Paper," January 27, 2015.

# ALEXANDRIA'S INDUSTRY AND CORPORATE RESPONSIBILITY LEADERSHIP



ALEXANDRIA®  
*Building the Future of Life-Changing Innovation®*



# ALEXANDRIA'S HIGHLY IMPACTFUL CORPORATE RESPONSIBILITY PILLARS

Developing and implementing collaborative and innovative solutions to some of the nation's most pressing challenges



↑ Accelerating medical innovation to save lives




Former Congressman Patrick Kennedy at the Alexandria Summit on Mental Health in 2023

↑ Prioritizing the mental health crisis



↑ Harnessing agtech to combat hunger and improve nutrition



The Honor Foundation headquarters in San Diego, CA

← Supporting our military, our veterans, and their families

↓ Building principled leaders through education



Graduates of the Emily K Center in Durham, NC



OneFifteen campus in Dayton, OH



Future National Medal of Honor Museum in Arlington, TX

↑ Inspiring future generations with the stories and values of our nation's heroes

↑ Revolutionizing addiction treatment



← Approaching homelessness as a healthcare problem, not a housing issue


# ALEXANDRIA'S LATEST AWARDS AND RECOGNITIONS

**NAMED ONE OF THE  
WORLD'S MOST  
TRUSTWORTHY  
COMPANIES 2024  
BY NEWSWEEK**



**1 of only 3  
S&P 500 REITs**

recognized by *Newsweek*  
in the Real Estate &  
Housing category





# ALEXANDRIA

AT THE VANGUARD AND HEART OF THE LIFE SCIENCE ECOSYSTEM™

## Alexandria Real Estate Equities, Inc. Reports:

**3Q24 and YTD 3Q24 Net Income per Share – Diluted of \$0.96 and \$2.18, respectively; and 3Q24 and YTD 3Q24 FFO per Share – Diluted, as Adjusted, of \$2.37 and \$7.08, respectively**

PASADENA, Calif. – October 21, 2024 – Alexandria Real Estate Equities, Inc. (NYSE: ARE) announced financial and operating results for the third quarter ended September 30, 2024.

### Key highlights

Operating results	YTD			
	3Q24	3Q23	3Q24	3Q23
Total revenues:				
In millions	\$ 791.6	\$ 713.8	\$ 2,327.4	\$ 2,128.5
Growth	10.9%		9.3%	
Net income attributable to Alexandria's common stockholders – diluted:				
In millions	\$ 164.7	\$ 21.9	\$ 374.5	\$ 184.4
Per share	\$ 0.96	\$ 0.13	\$ 2.18	\$ 1.08
Funds from operations attributable to Alexandria's common stockholders – diluted, as adjusted:				
In millions	\$ 407.9	\$ 386.4	\$ 1,217.3	\$ 1,142.5
Per share	\$ 2.37	\$ 2.26	\$ 7.08	\$ 6.69

### An industry-leading REIT with a high-quality, diverse tenant base and strong margins

(As of September 30, 2024, unless stated otherwise)

Occupancy of operating properties in North America	94.7%
Percentage of annual rental revenue in effect from mega campuses	76%
Percentage of annual rental revenue in effect from investment-grade or publicly traded large cap tenants	53%
Operating margin	71%
Adjusted EBITDA margin	70%
Percentage of leases containing annual rent escalations	96%
Weighted-average remaining lease term:	
Top 20 tenants	9.5 years
All tenants	7.5 years
Sustained strength in tenant collections:	
Tenant receivables as a percentage of 3Q24 rental revenues	0.9%
October 2024 tenant rents and receivables collected as of October 21, 2024	99.6%
3Q24 tenant rents and receivables collected as of October 21, 2024	99.9%

### Strong and flexible balance sheet with significant liquidity; top 10% credit rating ranking among all publicly traded U.S. REITs

- Net debt and preferred stock to Adjusted EBITDA of 5.5x and fixed-charge coverage ratio of 4.4x for 3Q24 annualized (targets for 4Q24 annualized of  $\leq 5.1x$  and  $\geq 4.5x$ , respectively).
- Significant liquidity of \$5.4 billion.
- 31% of our total debt matures in 2049 and beyond.
- 12.6 years weighted-average remaining term of debt.
- Since 2020, an average of 97.7% of our debt has been fixed rate.
- Total debt and preferred stock to gross assets of 29%.
- \$1.0 billion of capital contribution commitments from existing consolidated real estate joint venture partners to fund construction from 4Q24 through 2027.

### Strong leasing volume and solid rental rate changes

- Strong leasing volume aggregating 1.5 million RSF during 3Q24, up 48% compared to our previous four-quarter average of 1.0 million RSF.
- Rental rate changes on lease renewals and re-leasing of space were 5.1% and 1.5% (cash basis) for 3Q24 and 16.4% and 8.9% (cash basis) for YTD 3Q24.
- 80% of our leasing activity during the last twelve months was generated from our existing tenant base.

	3Q24	YTD 3Q24
Total leasing activity – RSF	1,486,097	3,742,955
Leasing of development and redevelopment space – RSF	39,121	480,342
Lease renewals and re-leasing of space:		
RSF (included in total leasing activity above)	1,278,857	2,863,277
Rental rate changes	5.1% <sup>(1)</sup>	16.4%
Rental rate changes (cash basis)	1.5% <sup>(1)</sup>	8.9%

- (1) Includes a five-year lease extension to an investment-grade rated technology tenant aggregating 357,136 RSF of recently acquired tech R&D space in our Texas market that was renewed with rental rate changes of (33.6)% and (4.8)% (cash basis). These spaces were originally targeted for a future change in use at acquisition, but we instead renewed them with a lower capital investment while we continue to evaluate options to convert these spaces in the future, subject to market conditions. Excluding this lease, rental rate changes for renewed/re-leased space for 3Q24 were 13.0% and 2.3% (cash basis).

### Attractive dividend strategy to share net cash flows from operating activities with stockholders while retaining a significant portion for reinvestment

- Common stock dividend declared for 3Q24 of \$1.30 per common share aggregating \$5.14 per common share for the twelve months ended September 30, 2024, up 24 cents, or 5%, over the twelve months ended September 30, 2023.
- Dividend yield of 4.4% as of September 30, 2024.
- Dividend payout ratio of 55% for the three months ended September 30, 2024.
- Average annual dividend per-share growth of 5.4% from 2020 through 3Q24 annualized.
- Significant net cash flows from operating activities after dividends retained for reinvestment aggregating \$2.1 billion for the years ended December 31, 2020 through 2023 and including the midpoint of our 2024 guidance range for net cash provided by operating activities after dividends.

### Ongoing successful execution of Alexandria's 2024 capital strategy

We expect to continue pursuing our strategy to fund a significant portion of our capital requirements for the year ending December 31, 2024 with dispositions primarily focused on sales of properties and land parcels not integral to our mega campus strategy. Refer to "Dispositions" in the Earnings Press Release for additional details.

(in millions)

Completed dispositions of 100% interest in properties	\$ 319
Pending dispositions subject to non-refundable deposits	577
Pending dispositions subject to executed letters of intent and/or purchase and sale agreements	603
Forward equity sales agreements	28
Total	<u>\$ 1,527</u>
2024 guidance midpoint for dispositions and common equity	\$ 1,550

# Third Quarter Ended September 30, 2024 Financial and Operating Results (continued)

September 30, 2024



## Ongoing successful execution of Alexandria's 2024 capital strategy (continued)

- In September 2024, we completed the following transactions with our longstanding tenant, Fred Hutchinson Cancer Center ("Fred Hutch"), in the Lake Union submarket:
  - Sale of 1165 Eastlake Avenue East, a fully leased 100,086 RSF single-tenant Class A+ life science facility that was developed in 2021. We sold the property for \$150.0 million, or \$1,499 per RSF, at strong capitalization rates of 4.7% and 4.9% (cash basis). Upon completion of the sale, we recognized a gain on sale of real estate aggregating \$21.5 million.
  - Fred Hutch executed early renewals aggregating 117,479 RSF at our 1201 and 1208 Eastlake Avenue East properties, including a 15-year lease extension at 1201 Eastlake Avenue East.
  - Our prior joint venture partner sold their partial interest ownership in each of 1201 and 1208 Eastlake Avenue East to Fred Hutch. Our ownership interest in both properties remains unchanged at 30.0%. This sale, lease extensions, and new joint venture affirm Fred Hutch's commitment to South Lake Union.

## Alexandria's development and redevelopment pipeline delivered incremental annual net operating income of \$21 million commencing during 3Q24 and is expected to deliver incremental annual net operating income aggregating \$510 million primarily by 1Q28

- During 3Q24, we placed into service development and redevelopment projects aggregating 316,691 RSF that are 100% leased across multiple submarkets and delivered incremental annual net operating income of \$21 million. 3Q24 deliveries included 250,000 RSF at 9820 Darnestown Road on the Alexandria Center<sup>®</sup> for Life Science – Shady Grove mega campus in our Rockville submarket.
- Annual net operating income (cash basis) is expected to increase by \$57 million upon the burn-off of initial free rent, with a weighted-average burn-off period of approximately six months, from recently delivered projects.
- 69% of the RSF in our total development and redevelopment pipeline is within our mega campuses.

Development and Redevelopment Projects (dollars in millions)	Incremental Annual Net Operating Income	RSF	Leased/ Negotiating Percentage
Placed into service:			
1H24	\$ 42	628,427	100%
3Q24	21	316,691	100
Placed into service in YTD 3Q24	<u>\$ 63</u>	<u>945,118</u>	<u>100%</u>
Expected to be placed into service <sup>(1)</sup> :			
4Q24 through 4Q25	\$ 158 <sup>(2)</sup>	5,467,897	55% <sup>(3)</sup>
1Q26 through 1Q28	352		
	<u>\$ 510</u>		

- Represents expected incremental annual net operating income to be placed into service from deliveries of projects undergoing construction and one committed near-term project expected to commence construction in the next two years.
- Includes (i) 1.0 million RSF that is expected to stabilize through 2025 and is 92% leased/negotiating and (ii) expected partial deliveries through 4Q25 from projects expected to stabilize in 2026 and beyond. Refer to the initial and stabilized occupancy years under "New Class A/A+ development and redevelopment properties: current projects" in the Supplemental Information for additional details.
- 70% of the leased RSF of our development and redevelopment projects was generated from our existing tenant base.

## Continued solid net operating income and internal growth

- Net operating income (cash basis) of \$2.0 billion for 3Q24 annualized, up \$274.2 million, or 15.5%, compared to 3Q23 annualized.
- Same property net operating income growth of 1.5% and 6.5% (cash basis) for 3Q24 over 3Q23 and 1.6% and 4.6% (cash basis) for YTD 3Q24 over YTD 3Q23.
- 96% of our leases contain contractual annual rent escalations approximating 3%.

## Strong balance sheet management

### Key metrics as of or for the three months ended September 30, 2024

- \$33.1 billion in total market capitalization.
- \$20.5 billion in total equity capitalization, which ranks in the top 10% among all publicly traded U.S. REITs.

	3Q24		Target
	Quarter Annualized	Trailing 12 Months	4Q24 Annualized
Net debt and preferred stock to Adjusted EBITDA	5.5x	5.6x	Less than or equal to 5.1x
Fixed-charge coverage ratio	4.4x	4.5x	Greater than or equal to 4.5x

## Key capital events

- In September 2024, we amended and restated our unsecured senior line of credit to, among other changes, extend the maturity date from January 22, 2028 to January 22, 2030, including extension options that we control.
- During 3Q24, we had no activity under our ATM program. As of October 21, 2024, the remaining aggregate amount available for future sales of common stock was \$1.47 billion.

## Investments

- As of September 30, 2024:
  - Our non-real estate investments aggregated \$1.5 billion.
  - Unrealized gains presented in our consolidated balance sheet were \$166.2 million, comprising gross unrealized gains and losses aggregating \$284.4 million and \$118.2 million, respectively.
- Investment income of \$15.2 million for 3Q24 presented in our consolidated statement of operations consisted of \$23.0 million of realized gains and \$2.6 million of unrealized gains, partially offset by \$10.3 million of impairment charges.

## Third Quarter Ended September 30, 2024 Financial and Operating Results (continued)

September 30, 2024



### Other key highlights

Key items included in net income attributable to Alexandria's common stockholders:

(in millions, except per share amounts)	3Q24		3Q23		YTD			
	Amount		Per Share – Diluted		Amount		Per Share – Diluted	
	3Q24	3Q23	3Q24	3Q23	3Q24	3Q23	3Q24	3Q23
Unrealized gains (losses) on non-real estate investments	\$ 2.6	\$ (77.2)	\$ 0.02	\$ (0.45)	\$ (32.5)	\$ (221.0)	\$ (0.19)	\$ (1.29)
Gain on sales of real estate	27.1	—	0.16	—	27.5	214.8	0.16	1.26
Impairment of non-real estate investments	(10.3)	(28.5)	(0.06)	(0.17)	(37.8)	(51.5)	(0.22)	(0.30)
Impairment of real estate	(5.7)	(20.6)	(0.03)	(0.12)	(36.5)	(189.2)	(0.22)	(1.11)
Acceleration of stock compensation expense due to executive officer resignations	—	(1.9)	—	(0.01)	—	(1.9)	—	(0.01)
<b>Total</b>	<b>\$ 13.7</b>	<b>\$ (128.2)</b>	<b>\$ 0.09</b>	<b>\$ (0.75)</b>	<b>\$ (79.3)</b>	<b>\$ (248.8)</b>	<b>\$ (0.47)</b>	<b>\$ (1.45)</b>

Refer to "Funds from operations and funds from operations per share" in the Earnings Press Release for additional details.

### Subsequent events

- In October 2024, we agreed to sell four properties located in our Greater Boston market for a sales price of \$369.4 million to the current tenant of the properties with whom we have a long-established relationship. The sales price represents capitalization rates of 8.5% and 6.3% (cash basis) based upon net operating income and net operating income (cash basis), respectively, for 3Q24 annualized. These properties, acquired primarily during 2020–2021, are currently 100% leased with a weighted-average remaining lease term of 18 years. In October 2024, we recognized an impairment charge aggregating \$40.9 million to reduce the carrying amounts of these properties by approximately 10% to the expected sales price less costs to sell. Our decision to dispose of these properties is based on their non-strategic location and the significant capital that the expected sales proceeds provide for immediate reinvestment into our development and redevelopment pipeline.
- In October 2024, we agreed to sell five operating properties aggregating 203,223 RSF and land parcels aggregating 1.5 million SF in our Sorrento Mesa and University Town Center submarkets to buyers that are expected to develop residential properties on these sites for an aggregate sales price of approximately \$314.0 million. In October 2024, we recognized impairment charges aggregating \$65.9 million to reduce the carrying amounts of these properties to the expected aggregate sales price less costs to sell. Our decision to dispose of these assets, which are not integral to our mega campus strategy, is primarily based on the substantial capital that the sales proceeds will provide for immediate reinvestment into our development and redevelopment pipeline.

### Industry and corporate responsibility leadership: catalyzing and leading the way for positive change to benefit human health and society

- In September 2024, Alexandria was named one of the World's Most Trustworthy Companies by *Newsweek*. This significant distinction builds on the Company's recognition by the publication as one of America's Most Trustworthy Companies in 2023 and 2024. Alexandria is one of only three S&P 500 REITs recognized in the real estate and housing category.
- In September 2024, Alexandria and its executive chairman and founder, Joel S. Marcus, were honored with the inaugural Bisnow Life Sciences Icon & Influencer Award. This prestigious award highlights Mr. Marcus and the Company's significant long-term contributions to and lasting impact on the life science real estate sector and broader life science industry. Mr. Marcus accepted the award on his own behalf and that of Alexandria at Bisnow's International Life Sciences & Biotech Conference, where he was also the keynote speaker.
- Alexandria continued to receive broad recognition for our operational excellence in asset management, design, development, and sustainability, including the following recent awards:
  - In our Greater Boston market, the atrium at 325 Binney Street, located on the Alexandria Center<sup>®</sup> at One Kendall Square mega campus, is a light-filled collaboration space with a terraced garden and communal staircase that was celebrated for design excellence in the Science & Research – Small (under 50,000 SF) category of the 2024 International Interior Design Association New England (IIDA NE) Design Awards and also received the award program's top honor, Best in Show.
  - In our Maryland market, we were awarded three 2024 NAIOP DC|MD Awards of Excellence for developments and enhancements on the Alexandria Center<sup>®</sup> for Life Science – Shady Grove mega campus: 9810 and 9820 Darnestown Road for Best Life Science Facility, 9800 Medical Center Drive for Best Amenity Space, and 9950 Medical Center Drive for Best Industrial/Flex.
  - We received a 2024 Nareit Sustainable Design Impact Award for our groundbreaking approach to utilizing alternative energy sources such as geothermal energy and wastewater heat recovery systems to reduce operational greenhouse gas emissions in Labspace<sup>®</sup> development projects in our Greater Boston and Seattle markets.
  - Alexandria GradLabs<sup>®</sup> at 9880 Campus Point Drive, located on the Campus Point by Alexandria mega campus in our San Diego market, earned a 2024 International Institute for Sustainable Laboratories (I2SL) Lab Buildings and Projects Award for Excellence in Energy Efficiency. The state-of-the-art building was designed to operate as a highly energy-efficient research facility. In 2023, the LEED Platinum certified facility earned an I2SL Labs2Zero pilot Energy Score of 96 out of 100, indicating its operational energy performance is better than 96% of similar facilities.

### **About Alexandria Real Estate Equities, Inc.**

Alexandria Real Estate Equities, Inc. (NYSE: ARE), an S&P 500<sup>®</sup> company, is a best-in-class, mission-driven life science REIT making a positive and lasting impact on the world. As the pioneer of the life science real estate niche with our founding in 1994, Alexandria is the preeminent and longest-tenured owner, operator, and developer of collaborative mega campuses in AAA life science innovation cluster locations, including Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle, and New York City. As of September 30, 2024, Alexandria has a total market capitalization of \$33.1 billion and an asset base in North America that includes 41.8 million RSF of operating properties, 5.3 million RSF of Class A/A+ properties undergoing construction, and one committed near-term project expected to commence construction in the next two years. Alexandria has a longstanding and proven track record of developing Class A/A+ properties clustered in mega campuses that provide our innovative tenants with highly dynamic and collaborative environments that enhance their ability to successfully recruit and retain world-class talent and inspire productivity, efficiency, creativity, and success. Alexandria also provides strategic capital to transformative life science companies through our venture capital platform. We believe our unique business model and diligent underwriting ensure a high-quality and diverse tenant base that results in higher occupancy levels, longer lease terms, higher rental income, higher returns, and greater long-term asset value. For more information on Alexandria, please visit [www.are.com](http://www.are.com).

## Guidance

September 30, 2024

(Dollars in millions, except per share amounts)



The following guidance for 2024 has been updated to reflect our current view of existing market conditions and assumptions for the year ending December 31, 2024. There can be no assurance that actual results will not be materially higher or lower than these expectations. Also, refer to our discussion of “forward-looking statements” on page 8 of the Earnings Press Release for additional details.

Summary of Key Changes in Guidance	As of 10/21/24	As of 7/22/24	2024 Guidance Midpoint	
			As of 10/21/24	As of 7/22/24
EPS, FFO per share, and FFO per share, as adjusted	See updates below			
Straight-line rent revenue	\$147 to \$162	\$169 to \$184		
General and administrative expenses	\$176 to \$186	\$181 to \$191		

### Projected 2024 Earnings per Share and Funds From Operations per Share Attributable to Alexandria's Common Stockholders – Diluted

	As of 10/21/24	As of 7/22/24
Earnings per share <sup>(2)</sup>	\$2.60 to \$2.64	\$2.98 to \$3.10
Depreciation and amortization of real estate assets	6.05	5.95
Gain on sales of real estate <sup>(3)</sup>	(0.38)	—
Impairment of real estate – rental properties and land <sup>(4)</sup>	0.67	0.01
Allocation to unvested restricted stock awards	(0.06)	(0.05)
Funds from operations per share <sup>(1)</sup>	\$8.88 to \$8.92	\$8.89 to \$9.01
Unrealized losses on non-real estate investments	0.19	0.20
Impairment of non-real estate investments	0.22	0.16
Impairment of real estate	0.17	0.17
Allocation to unvested restricted stock awards	(0.01)	(0.01)
Funds from operations per share, as adjusted <sup>(1)</sup>	<u>\$9.45 to \$9.49</u>	<u>\$9.41 to \$9.53</u>
Midpoint	\$9.47	\$9.47

### Key Assumptions

	Low	High
Occupancy percentage in North America as of December 31, 2024	94.6%	95.6%
Lease renewals and re-leasing of space:		
Rental rate changes	11.0%	19.0%
Rental rate changes (cash basis)	5.0%	13.0%
Same property performance:		
Net operating income changes	0.5%	2.5%
Net operating income changes (cash basis)	3.0%	5.0%
Straight-line rent revenue <sup>(9)</sup>	\$ 147	\$ 162
General and administrative expenses <sup>(10)</sup>	\$ 176	\$ 186
Capitalization of interest	\$ 325	\$ 355
Interest expense	\$ 154	\$ 184
Realized gains on non-real estate investments <sup>(11)</sup>	\$ 95	\$ 125

### Summary of Key Changes in Sources and Uses of Capital

Cash expected to be held at December 31, 2024	\$150	\$—
---	-------	-----

### Key Credit Metric Targets<sup>(1)</sup>

Net debt and preferred stock to Adjusted EBITDA – 4Q24 annualized	Less than or equal to 5.1x
Fixed-charge coverage ratio – 4Q24 annualized	Greater than or equal to 4.5x

### Key Sources and Uses of Capital

	Range	Midpoint	Certain Completed Items
<i>Sources of capital:</i>			
Incremental debt	\$ 885 \$ 1,185	\$ 1,035	See below
Net cash provided by operating activities after dividends	400	500	450
Dispositions and common equity <sup>(5)</sup> (refer to page 7)	1,050	2,050	1,550 <sup>(5)</sup>
Total sources of capital	<u>\$ 2,335</u>	<u>\$ 3,735</u>	<u>\$ 3,035</u>
<i>Uses of capital:</i>			
Construction	\$ 1,950 \$ 2,550	\$ 2,250	
Acquisitions (refer to page 6)	250	750	\$ 249
Ground lease prepayment <sup>(6)</sup>	135	135	135
Cash expected to be held at December 31, 2024 <sup>(7)</sup>	—	300	150
Total uses of capital	<u>\$ 2,335</u>	<u>\$ 3,735</u>	<u>\$ 3,035</u>
<i>Incremental debt (included above):</i>			
Issuance of unsecured senior notes payable <sup>(8)</sup>	\$ 1,000 \$ 1,000	\$ 1,000	\$ 1,000 <sup>(8)</sup>
Unsecured senior line of credit, commercial paper, and other	(115)	185	35
Net incremental debt	<u>\$ 885</u>	<u>\$ 1,185</u>	<u>\$ 1,035</u>

(1) Refer to “Definitions and reconciliations” in the Supplemental Information for additional details.

(2) Excludes unrealized gains or losses on non-real estate investments after September 30, 2024 that are required to be recognized in earnings and are excluded from funds from operations per share, as adjusted.

(3) Includes \$37.1 million of gain on sales of real estate recognized in October 2024. Refer to “Dispositions” in the Earnings Press Release for additional details.

(4) Includes \$106.8 million of real estate impairments recognized in October 2024. Refer to “Subsequent Events” in the Earnings Press Release for additional details.

(5) We expect to fund our remaining capital requirements for the year ending December 31, 2024 with real estate dispositions. As of October 21, 2024, we completed real estate dispositions aggregating \$319.2 million, have additional pending transactions subject to (i) non-refundable deposits aggregating \$577.2 million and (ii) executed letters of intent and/or purchase and sale agreements aggregating \$602.5 million and forward equity sales agreements aggregating \$28 million, which in aggregate, represents 98% of the \$1.55 billion midpoint of our guidance range. We do not expect to issue additional equity in 2024 beyond the existing forward equity sales agreements outstanding.

(6) In July 2024, we executed an amendment to our existing ground lease agreement at the Alexandria Technology Square<sup>®</sup> mega campus in our Cambridge submarket, which requires that we prepay our entire rent obligation for the extended lease term aggregating \$270.0 million in two equal installments during the fourth quarter of 2024 and the first quarter of 2025.

(7) The increase in cash expected to be held at December 31, 2024 is primarily due to changes in the mix and timing of pending dispositions that are subject to non-refundable deposits or subject to executed letters of intent and/or purchase and sale agreements that are expected to close in 4Q24. This cash is expected to reduce our 2025 debt capital needs.

(8) Represents \$1.0 billion of unsecured senior notes payable issued in February 2024. Subject to market conditions, we may seek additional opportunities in 2024 to fund all or a portion of the proceeds necessary for the repayment of our \$600.0 million of 3.45% unsecured senior notes payable due on April 30, 2025 through the issuance of additional unsecured senior notes payable that is not assumed in our current 2024 guidance.

(9) Reduction in the midpoint of our guidance range for straight-line rent revenue by \$22 million is primarily attributable to (i) the write-off of a deferred rent receivable of \$9 million related to the lease termination and a payment of \$10 million from a tenant at 409 Illinois Street in our Mission Bay submarket, a 234,249 RSF property owned by our consolidated real estate joint venture for which we have an ownership interest of 25%, and (ii) a change in the expected stabilization date from 4Q24 to 1Q25 at our fully leased development project at 230 Harriet Tubman Way in our South San Francisco submarket as reported in our 2Q24 Earnings Press Release and Supplemental Information.

(10) Reduction in the midpoint of our guidance range for general and administrative expense by \$5 million is primarily attributable to the realization of savings associated with overall efficiencies, including enhanced cost control measures, incremental use of technology, streamlined processes, and optimization of execution in connection with the sale of non-core assets not integral to our mega campus strategy.

(11) Represents realized gains and losses included in funds from operations per share – diluted, as adjusted, and excludes significant impairments realized on non-real estate investments, if any. Refer to “Investments” in the Supplemental Information for additional details.

## Acquisitions

September 30, 2024

(Dollars in thousands)

Property	Submarket/Market	Date of Purchase	Number of Properties	Operating Occupancy	Square Footage		Purchase Price
					Future Development <sup>(1)</sup>	Operating With Future Development/ Redevelopment <sup>(1)</sup>	
Completed in 1H24:							
285, 299, 307, and 345 Dorchester Avenue (60% interest in consolidated JV)	Seaport Innovation District/Greater Boston	1/30/24	—	N/A	1,040,000	—	\$ 155,321
Other							46,490
							<u>201,811</u>
Completed in October 2024:							
428 Westlake Avenue North	Lake Union/Seattle	10/1/24	1	100%	—	88,514	47,600
							<u>\$ 249,411</u>
2024 guidance range for acquisitions							<u>\$250,000 – \$750,000</u>

(1) We expect to provide total estimated costs and related yields for development and significant redevelopment projects in the future, subsequent to the commencement of construction.



## Dispositions

September 30, 2024

(Dollars in thousands)

Property	Submarket/Market	Date of Sale	Interest Sold	RSF	Capitalization Rate	Capitalization Rate (Cash Basis)	Sales Price	Sales Price per RSF
Completed in 1H24							\$ 17,213	
Completed in 3Q24:								
<i>Sale to longstanding tenant</i>								
1165 Eastlake Avenue East	Lake Union/Seattle	9/12/24	100%	100,086	4.7%	4.9%	149,985 <sup>(1)</sup>	\$ 1,499
<i>Dispositions of properties not integral to our mega campus strategy</i>								
219 East 42nd Street	New York City/New York City	7/9/24	100%	349,947	N/A	N/A	60,000 <sup>(2)</sup>	N/A
Other							11,511	
							<u>221,496</u> <sup>(3)</sup>	
							<u>238,709</u>	
Dispositions completed in YTD 3Q24								
Completed in October 2024:								
<i>Dispositions of properties not integral to our mega campus strategy</i>								
14225 Newbrook Drive	Northern Virginia/Maryland	10/15/24	100%	248,186	7.6%	7.4%	80,500 <sup>(4)</sup>	\$ 324
							<u>319,209</u>	
Pending 4Q24 dispositions subsequent to October 21, 2024:								
Subject to non-refundable deposits								
Sale to longstanding tenant	Greater Boston	4Q24	100%		8.5%	6.3%	369,439 <sup>(5)</sup>	
Other							<u>207,713</u>	
							577,152	
Subject to executed letters of intent and/or purchase and sale agreements							<u>602,500</u> <sup>(5)</sup>	
							<u>1,179,652</u> <sup>(6)</sup>	
							<u>\$ 1,498,861</u>	
2024 guidance range for dispositions and common equity							\$1,050,000 – \$2,050,000	

(1) Upon completion of the sale, we recognized a gain on sale of real estate aggregating \$21.5 million.

(2) The property was leased to a single tenant with a July 2024 lease expiration and had annual net operating income of \$18.6 million based on 2Q24 annualized. This property was previously considered to be a potential development project upon expiration of the in-place non-laboratory space lease.

(3) Dispositions completed during the three months ended September 30, 2024 had annual net operating income of \$26.5 million (based on 2Q24 annualized) with a weighted-average disposition date of July 28, 2024 (weighted by net operating income for 2Q24 annualized).

(4) Demonstrating the long-term enduring value of our laboratory facilities, Alexandria successfully operated our only asset in the Northern Virginia submarket from its acquisition in 1997 (prior to our IPO) through its sale in October 2024. Upon completion of the sale, we recognized a gain on sale of real estate aggregating \$37.1 million.

(5) Refer to "Subsequent events" in the Earnings Press Release for additional details.

(6) Pending dispositions subsequent to October 21, 2024 have estimated annual net operating income of approximately \$95.8 million (based on 3Q24 annualized) with a weighted-average estimated disposition date of December 5, 2024 (weighted by net operating income for 3Q24 annualized). Approximately half of our pending dispositions are non-core stabilized stand-alone properties with weighted-average capitalization rates of 8.5% and 7.0% (cash basis), and the remaining half are land and non-stabilized properties that have vacancy or significant near-term lease expirations that will require capital to re-tenant, including one building with approximately 72% of non-laboratory space.

# Earnings Call Information and About the Company

September 30, 2024



We will host a conference call on Tuesday, October 22, 2024, at 3:00 p.m. Eastern Time (“ET”)/noon Pacific Time (“PT”), which is open to the general public, to discuss our financial and operating results for the third quarter ended September 30, 2024. To participate in this conference call, dial (833) 366-1125 or (412) 902-6738 shortly before 3:00 p.m. ET/noon PT and ask the operator to join the call for Alexandria Real Estate Equities, Inc. The audio webcast can be accessed at [www.alexandria-re.com](http://www.alexandria-re.com) in the “For Investors” section. A replay of the call will be available for a limited time from 5:00 p.m. ET/2:00 p.m. PT on Tuesday, October 22, 2024. The replay number is (877) 344-7529 or (412) 317-0088, and the access code is 1168152.

Additionally, a copy of this Earnings Press Release and Supplemental Information for the third quarter ended September 30, 2024 is available in the “For Investors” section of our website at [www.alexandria-re.com](http://www.alexandria-re.com) or by following this link: <https://www.alexandria-re.com/fs/2024q3.pdf>.

For any questions, please contact [corporateinformation@alexandria-re.com](mailto:corporateinformation@alexandria-re.com); Joel S. Marcus, executive chairman and founder; Peter M. Moglia, chief executive officer and chief investment officer; Marc E. Binda, chief financial officer and treasurer; Paula Schwartz, managing director of Rx Communications Group, at (917) 633-7790; or Sara M. Kabakoff, senior vice president – chief content officer.

## About the Company

Alexandria Real Estate Equities, Inc. (NYSE: ARE), an S&P 500<sup>®</sup> company, is a best-in-class, mission-driven life science REIT making a positive and lasting impact on the world. As the pioneer of the life science real estate niche with our founding in 1994, Alexandria is the preeminent and longest-tenured owner, operator, and developer of collaborative mega campuses in AAA life science innovation cluster locations, including Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle, and New York City. As of September 30, 2024, Alexandria has a total market capitalization of \$33.1 billion and an asset base in North America that includes 41.8 million RSF of operating properties, 5.3 million RSF of Class A/A+ properties undergoing construction, and one committed near-term project expected to commence construction in the next two years. Alexandria has a longstanding and proven track record of developing Class A/A+ properties clustered in mega campuses that provide our innovative tenants with highly dynamic and collaborative environments that enhance their ability to successfully recruit and retain world-class talent and inspire productivity, efficiency, creativity, and success. Alexandria also provides strategic capital to transformative life science companies through our venture capital platform. We believe our unique business model and diligent underwriting ensure a high-quality and diverse tenant base that results in higher occupancy levels, longer lease terms, higher rental income, higher returns, and greater long-term asset value. For more information on Alexandria, please visit [www.alexandria-re.com](http://www.alexandria-re.com).

## Forward-Looking Statements

This document includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, without limitation, statements regarding our 2024 earnings per share, 2024 funds from operations per share, 2024 funds from operations per share, as adjusted, net operating income, and our projected sources and uses of capital. You can identify the forward-looking statements by their use of forward-looking words, such as “forecast,” “guidance,” “goals,” “projects,” “estimates,” “anticipates,” “believes,” “expects,” “intends,” “may,” “plans,” “seeks,” “should,” “targets,” or “will,” or the negative of those words or similar words. These forward-looking statements are based on our current expectations, beliefs, projections, future plans and strategies, anticipated events or trends, and similar expressions concerning matters that are not historical facts, as well as a number of assumptions concerning future events. There can be no assurance that actual results will not be materially higher or lower than these expectations. These statements are subject to risks, uncertainties, assumptions, and other important factors that could cause actual results to differ materially from the results discussed in the forward-looking statements. Factors that might cause such a difference include, without limitation, our failure to obtain capital (debt, construction financing, and/or equity) or refinance debt maturities, lower than expected yields, increased interest rates and operating costs, adverse economic or real estate developments in our markets, our failure to successfully place into service and lease any properties undergoing development or redevelopment and our existing space held for future development or redevelopment (including new properties acquired for that purpose), our failure to successfully operate or lease acquired properties, decreased rental rates, increased vacancy rates or failure to renew or replace expiring leases, defaults on or non-renewal of leases by tenants, adverse general and local economic conditions, an unfavorable capital market environment, decreased leasing activity or lease renewals, failure to obtain LEED and other healthy building certifications and efficiencies, and other risks and uncertainties detailed in our filings with the Securities and Exchange Commission (“SEC”). Accordingly, you are cautioned not to place undue reliance on such forward-looking statements. All forward-looking statements are made as of the date of this Earnings Press Release and Supplemental Information, and unless otherwise stated, we assume no obligation to update this information and expressly disclaim any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. For more discussion relating to risks and uncertainties that could cause actual results to differ materially from those anticipated in our forward-looking statements, and risks to our business in general, please refer to our SEC filings, including our most recent annual report on Form 10-K and any subsequent quarterly reports on Form 10-Q.

This document is not an offer to sell or a solicitation to buy securities of Alexandria Real Estate Equities, Inc. Any offers to sell or solicitations to buy our securities shall be made only by means of a prospectus approved for that purpose. Unless otherwise indicated, the “Company,” “Alexandria,” “ARE,” “we,” “us,” and “our” refer to Alexandria Real Estate Equities, Inc. and our consolidated subsidiaries. Alexandria<sup>®</sup>, Lighthouse Design<sup>®</sup> logo, Building the Future of Life-Changing Innovation<sup>®</sup>, That’s What’s in Our DNA<sup>®</sup>, Labspace<sup>®</sup>, At the Vanguard and Heart of the Life Science Ecosystem<sup>™</sup>, Alexandria Center<sup>®</sup>, Alexandria Technology Square<sup>®</sup>, Alexandria Technology Center<sup>®</sup>, and Alexandria Innovation Center<sup>®</sup> are copyrights and trademarks of Alexandria Real Estate Equities, Inc. All other company names, trademarks, and logos referenced herein are the property of their respective owners.

# Consolidated Statements of Operations

September 30, 2024

(Dollars in thousands, except per share amounts)



	Three Months Ended				Nine Months Ended		
	9/30/24	6/30/24	3/31/24	12/31/23	9/30/23	9/30/23	
Revenues:							
Income from rentals	\$ 775,744	\$ 755,162	\$ 755,551	\$ 742,637	\$ 707,531	\$ 2,286,457	\$ 2,099,819
Other income	15,863	11,572	13,557	14,579	6,257	40,992	28,664
Total revenues	791,607	766,734	769,108	757,216	713,788	2,327,449	2,128,483
Expenses:							
Rental operations	233,265	217,254	218,314	222,726	217,687	668,833	636,454
General and administrative	43,945	44,629	47,055	59,289	45,987	135,629	140,065
Interest	43,550	45,789	40,840	31,967	11,411	130,179	42,237
Depreciation and amortization	293,998	290,720	287,554	285,246	269,370	872,272	808,227
Impairment of real estate	5,741	30,763	—	271,890	20,649	36,504	189,224
Total expenses	620,499	629,155	593,763	871,118	565,104	1,843,417	1,816,207
Equity in earnings of unconsolidated real estate joint ventures	139	130	155	363	242	424	617
Investment income (loss)	15,242	(43,660)	43,284	8,654	(80,672)	14,866	(204,051)
Gain on sales of real estate	27,114	—	392	62,227	—	27,506	214,810
Net income (loss)	213,603	94,049	219,176	(42,658)	68,254	526,828	323,652
Net income attributable to noncontrolling interests	(45,656)	(47,347)	(48,631)	(45,771)	(43,985)	(141,634)	(131,584)
Net income (loss) attributable to Alexandria Real Estate Equities, Inc.'s stockholders	167,947	46,702	170,545	(88,429)	24,269	385,194	192,068
Net income attributable to unvested restricted stock awards	(3,273)	(3,785)	(3,659)	(3,498)	(2,414)	(10,717)	(7,697)
Net income (loss) attributable to Alexandria Real Estate Equities, Inc.'s common stockholders	\$ 164,674	\$ 42,917	\$ 166,886	\$ (91,927)	\$ 21,855	\$ 374,477	\$ 184,371
Net income (loss) per share attributable to Alexandria Real Estate Equities, Inc.'s common stockholders:							
Basic	\$ 0.96	\$ 0.25	\$ 0.97	\$ (0.54)	\$ 0.13	\$ 2.18	\$ 1.08
Diluted	\$ 0.96	\$ 0.25	\$ 0.97	\$ (0.54)	\$ 0.13	\$ 2.18	\$ 1.08
Weighted-average shares of common stock outstanding:							
Basic	172,058	172,013	171,949	171,096	170,890	172,007	170,846
Diluted	172,058	172,013	171,949	171,096	170,890	172,007	170,846
Dividends declared per share of common stock	\$ 1.30	\$ 1.30	\$ 1.27	\$ 1.27	\$ 1.24	\$ 3.87	\$ 3.69

# Consolidated Balance Sheets

September 30, 2024

(In thousands)



	<u>9/30/24</u>	<u>6/30/24</u>	<u>3/31/24</u>	<u>12/31/23</u>	<u>9/30/23</u>
<b>Assets</b>					
Investments in real estate	\$ 32,951,777	\$ 32,673,839	\$ 32,323,138	\$ 31,633,511	\$ 31,712,731
Investments in unconsolidated real estate joint ventures	40,170	40,535	40,636	37,780	37,695
Cash and cash equivalents	562,606	561,021	722,176	618,190	532,390
Restricted cash	17,031	4,832	9,519	42,581	35,321
Tenant receivables	6,980	6,822	7,469	8,211	6,897
Deferred rent	1,216,176	1,190,336	1,138,936	1,050,319	1,012,666
Deferred leasing costs	516,872	519,629	520,616	509,398	512,216
Investments	1,519,327	1,494,348	1,511,588	1,449,518	1,431,766
Other assets	1,657,189	1,356,503	1,424,968	1,421,894	1,501,611
<b>Total assets</b>	<b><u>\$ 38,488,128</u></b>	<b><u>\$ 37,847,865</u></b>	<b><u>\$ 37,699,046</u></b>	<b><u>\$ 36,771,402</u></b>	<b><u>\$ 36,783,293</u></b>
<b>Liabilities, Noncontrolling Interests, and Equity</b>					
Secured notes payable	\$ 145,000	\$ 134,942	\$ 130,050	\$ 119,662	\$ 109,110
Unsecured senior notes payable	12,092,012	12,089,561	12,087,113	11,096,028	11,093,725
Unsecured senior line of credit and commercial paper	454,589	199,552	—	99,952	—
Accounts payable, accrued expenses, and other liabilities	2,865,886	2,529,535	2,503,831	2,610,943	2,653,126
Dividends payable	227,191	227,408	222,134	221,824	214,450
<b>Total liabilities</b>	<b><u>15,784,678</u></b>	<b><u>15,180,998</u></b>	<b><u>14,943,128</u></b>	<b><u>14,148,409</u></b>	<b><u>14,070,411</u></b>
<b>Commitments and contingencies</b>					
Redeemable noncontrolling interests	16,510	16,440	16,620	16,480	51,658
<b>Alexandria Real Estate Equities, Inc.'s stockholders' equity:</b>					
Common stock	1,722	1,720	1,720	1,719	1,710
Additional paid-in capital	18,238,438	18,284,611	18,434,690	18,485,352	18,651,185
Accumulated other comprehensive loss	(22,529)	(27,710)	(23,815)	(15,896)	(24,984)
<b>Alexandria Real Estate Equities, Inc.'s stockholders' equity</b>	<b><u>18,217,631</u></b>	<b><u>18,258,621</u></b>	<b><u>18,412,595</u></b>	<b><u>18,471,175</u></b>	<b><u>18,627,911</u></b>
Noncontrolling interests	4,469,309	4,391,806	4,326,703	4,135,338	4,033,313
<b>Total equity</b>	<b><u>22,686,940</u></b>	<b><u>22,650,427</u></b>	<b><u>22,739,298</u></b>	<b><u>22,606,513</u></b>	<b><u>22,661,224</u></b>
<b>Total liabilities, noncontrolling interests, and equity</b>	<b><u>\$ 38,488,128</u></b>	<b><u>\$ 37,847,865</u></b>	<b><u>\$ 37,699,046</u></b>	<b><u>\$ 36,771,402</u></b>	<b><u>\$ 36,783,293</u></b>

## Funds From Operations and Funds From Operations per Share

September 30, 2024

(In thousands)



The following table presents a reconciliation of net income (loss) attributable to Alexandria's common stockholders, the most directly comparable financial measure presented in accordance with U.S. generally accepted accounting principles ("GAAP"), including our share of amounts from consolidated and unconsolidated real estate joint ventures, to funds from operations attributable to Alexandria's common stockholders – diluted, and funds from operations attributable to Alexandria's common stockholders – diluted, as adjusted, for the periods below:

	Three Months Ended				Nine Months Ended		
	9/30/24	6/30/24	3/31/24	12/31/23	9/30/23	9/30/23	
<b>Net income (loss) attributable to Alexandria's common stockholders – basic and diluted</b>	<b>\$ 164,674</b>	<b>\$ 42,917</b>	<b>\$ 166,886</b>	<b>\$ (91,927)</b>	<b>\$ 21,855</b>	<b>\$ 374,477</b>	<b>\$ 184,371</b>
Depreciation and amortization of real estate assets	291,258	288,118	284,950	281,939	266,440	864,326	798,590
Noncontrolling share of depreciation and amortization from consolidated real estate JVs	(32,457)	(31,364)	(30,904)	(30,137)	(28,814)	(94,725)	(85,212)
Our share of depreciation and amortization from unconsolidated real estate JVs	1,075	1,068	1,034	965	910	3,177	2,624
Gain on sales of real estate	(27,114)	—	(392)	(62,227)	—	(27,506)	(214,810)
Impairment of real estate – rental properties and land	5,741 <sup>(1)</sup>	2,182	—	263,982	19,844	7,923	186,446
Allocation to unvested restricted stock awards	(2,908)	(1,305)	(3,469)	(2,268)	(838)	(7,657)	(3,050)
<b>Funds from operations attributable to Alexandria's common stockholders – diluted<sup>(2)</sup></b>	<b>400,269</b>	<b>301,616</b>	<b>418,105</b>	<b>360,327</b>	<b>279,397</b>	<b>1,120,015</b>	<b>868,959</b>
Unrealized (gains) losses on non-real estate investments	(2,610)	64,238	(29,158)	(19,479)	77,202	32,470	220,954
Impairment of non-real estate investments	10,338 <sup>(3)</sup>	12,788	14,698	23,094	28,503	37,824	51,456
Impairment of real estate	—	28,581	—	7,908	805	28,581	2,778
Acceleration of stock compensation expense due to executive officer resignations	—	—	—	18,436	1,859	—	1,859
Allocation to unvested restricted stock awards	(125)	(1,738)	247	(472)	(1,330)	(1,640)	(3,503)
<b>Funds from operations attributable to Alexandria's common stockholders – diluted, as adjusted</b>	<b>\$ 407,872</b>	<b>\$ 405,485</b>	<b>\$ 403,892</b>	<b>\$ 389,814</b>	<b>\$ 386,436</b>	<b>\$1,217,250</b>	<b>\$1,142,503</b>

Refer to "Definitions and reconciliations" in the Supplemental Information for additional details.

- (1) Primarily to reduce the carrying amount of one property in Canada that continued to meet the held-for-sale classification to the sales price under negotiation with a potential buyer less costs to sell.
- (2) Calculated in accordance with standards established by the Nareit Board of Governors.
- (3) Primarily related to two non-real estate investments in privately held entities that do not report NAV.

## Funds From Operations and Funds From Operations per Share (continued)

September 30, 2024

(In thousands, except per share amounts)



The following table presents a reconciliation of net income (loss) per share attributable to Alexandria's common stockholders, the most directly comparable financial measure presented in accordance with GAAP, including our share of amounts from consolidated and unconsolidated real estate joint ventures, to funds from operations per share attributable to Alexandria's common stockholders – diluted, and funds from operations per share attributable to Alexandria's common stockholders – diluted, as adjusted, for the periods below. Per share amounts may not add due to rounding.

	Three Months Ended					Nine Months Ended	
	9/30/24	6/30/24	3/31/24	12/31/23	9/30/23	9/30/24	9/30/23
<b>Net income (loss) per share attributable to Alexandria's common stockholders – diluted</b>	<b>\$ 0.96</b>	<b>\$ 0.25</b>	<b>\$ 0.97</b>	<b>\$ (0.54)</b>	<b>\$ 0.13</b>	<b>\$ 2.18</b>	<b>\$ 1.08</b>
Depreciation and amortization of real estate assets	1.51	1.50	1.48	1.48	1.40	4.49	4.19
Gain on sales of real estate	(0.16)	—	—	(0.36)	—	(0.16)	(1.26)
Impairment of real estate – rental properties and land	0.03	0.01	—	1.54	0.12	0.05	1.09
Allocation to unvested restricted stock awards	(0.01)	(0.01)	(0.02)	(0.01)	(0.01)	(0.05)	(0.01)
<b>Funds from operations per share attributable to Alexandria's common stockholders – diluted</b>	<b>2.33</b>	<b>1.75</b>	<b>2.43</b>	<b>2.11</b>	<b>1.64</b>	<b>6.51</b>	<b>5.09</b>
Unrealized (gains) losses on non-real estate investments	(0.02)	0.37	(0.17)	(0.11)	0.45	0.19	1.29
Impairment of non-real estate investments	0.06	0.08	0.09	0.13	0.17	0.22	0.30
Impairment of real estate	—	0.17	—	0.05	—	0.17	0.02
Acceleration of stock compensation expense due to executive officer resignations	—	—	—	0.11	0.01	—	0.01
Allocation to unvested restricted stock awards	—	(0.01)	—	(0.01)	(0.01)	(0.01)	(0.02)
<b>Funds from operations per share attributable to Alexandria's common stockholders – diluted, as adjusted</b>	<b>\$ 2.37</b>	<b>\$ 2.36</b>	<b>\$ 2.35</b>	<b>\$ 2.28</b>	<b>\$ 2.26</b>	<b>\$ 7.08</b>	<b>\$ 6.69</b>
Weighted-average shares of common stock outstanding – diluted	172,058	172,013	171,949	171,096	170,890	172,007	170,846

Refer to "Definitions and reconciliations" in the Supplemental Information for additional details.

# **SUPPLEMENTAL INFORMATION**

Alexandria Real Estate Equities, Inc. (NYSE: ARE), an S&P 500® company, is a best-in-class, mission-driven life science REIT making a positive and lasting impact on the world. As the pioneer of the life science real estate niche with our founding in 1994, Alexandria is the preeminent and longest-tenured owner, operator, and developer of collaborative mega campuses in AAA life science innovation cluster locations, including Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle, and New York City. As of September 30, 2024, Alexandria has a total market capitalization of \$33.1 billion and an asset base in North America that includes 41.8 million RSF of operating properties, 5.3 million RSF of Class A/A+ properties undergoing construction, and one committed near-term project expected to commence construction in the next two years. Alexandria has a longstanding and proven track record of developing Class A/A+ properties clustered in mega campuses that provide our innovative tenants with highly dynamic and collaborative environments that enhance their ability to successfully recruit and retain world-class talent and inspire productivity, efficiency, creativity, and success. Alexandria also provides strategic capital to transformative life science companies through our venture capital platform. We believe our unique business model and diligent underwriting ensure a high-quality and diverse tenant base that results in higher occupancy levels, longer lease terms, higher rental income, higher returns, and greater long-term asset value. For more information on Alexandria, please visit [www.are.com](http://www.are.com).

### Tenant base

Alexandria is known for our high-quality and diverse tenant base, with 53% of our annual rental revenue being generated from tenants that are investment-grade rated or publicly traded large cap companies. The quality, diversity, breadth, and depth of our significant relationships with our tenants provide Alexandria with high-quality and stable cash flows. Alexandria's underwriting team and long-term industry relationships positively distinguish us from all other publicly traded REITs and real estate companies.

### Executive and senior management team

Alexandria's executive and senior management team has unique experience and expertise in creating, owning, and operating highly dynamic and collaborative mega campuses in key life science cluster locations to catalyze innovation. From design to development to the management of our high-quality, sustainable real estate, as well as our ongoing cultivation of collaborative environments with unique amenities and events, the Alexandria team has a best-in-class reputation of excellence in life science real estate. Alexandria's highly experienced management team includes regional market directors with leading reputations and longstanding relationships within the life science communities in their respective innovation clusters. We believe that our experience, expertise, reputation, and key relationships in the real estate and life science industries provide Alexandria significant competitive advantages in attracting new business opportunities.

Alexandria's executive and senior management team consists of 63 individuals, averaging 24 years of real estate experience, including 13 years with Alexandria. Our executive management team alone averages 19 years with Alexandria.

### EXECUTIVE MANAGEMENT TEAM

#### Joel S. Marcus

Executive Chairman &  
Founder

#### Daniel J. Ryan

Co-President & Regional Market  
Director – San Diego

#### Marc E. Binda

Chief Financial Officer &  
Treasurer

#### Lawrence J. Diamond

Co-Chief Operating Officer & Regional  
Market Director – Maryland

#### Hart Cole

Executive Vice President – Capital  
Markets/Strategic Operations &  
Co-Regional Market Director – Seattle

#### Gary D. Dean

Executive Vice President –  
Real Estate Legal Affairs

#### Onn C. Lee

Executive Vice President –  
Accounting

#### Madeleine T. Alsbrook

Executive Vice President –  
Talent Management

#### Peter M. Moglia

Chief Executive Officer &  
Chief Investment Officer

#### Hunter L. Kass

Co-President & Regional Market  
Director – Greater Boston

#### Vincent R. Ciruzzi

Chief Development Officer

#### Joseph Hakman

Co-Chief Operating Officer &  
Chief Strategic Transactions Officer

#### Jackie B. Clem

General Counsel & Secretary

#### Andres R. Gavinet

Chief Accounting Officer

#### Kristina A. Fukuzaki-Carlson

Executive Vice President –  
Business Operations



## Corporate Headquarters

26 North Euclid Avenue  
Pasadena, California 91101  
www.are.com

## New York Stock Exchange Trading Symbol

Common stock: ARE

## Information Requests

Phone: (626) 578-0777  
Email: corporateinformation@are.com  
Website: investor.are.com

## Equity Research Coverage

Alexandria is currently covered by the following research analysts. This list may be incomplete and is subject to change as firms initiate or discontinue coverage of our company. Please note that any opinions, estimates, or forecasts regarding our historical or predicted performance made by these analysts are theirs alone and do not represent opinions, estimates, or forecasts of Alexandria or our management. Alexandria does not by our reference or distribution of the information below imply our endorsement of or concurrence with any opinions, estimates, or forecasts of these analysts. Interested persons may obtain copies of analysts' reports on their own as we do not distribute these reports. Several of these firms may, from time to time, own our stock and/or hold other long or short positions in our stock and may provide compensated services to us.

### BNP Paribas Exane

Nate Crossett / Monir Koummal  
(646) 342-1588 / (646) 342-1554

### BofA Securities

Jeff Spector / Joshua Dennerlein  
(646) 855-1363 / (646) 855-1681

### BTIG, LLC

Tom Catherwood / Michael Tompkins  
(212) 738-6140 / (212) 527-3566

### CFRA

Paige Meyer  
(800) 220-0502

### Citigroup Global Markets Inc.

Nicholas Joseph / Michael Griffin  
(212) 816-1909 / (212) 816-5871

### Citizens JMP Securities, LLC

Aaron Hecht  
(415) 835-3963

### Evercore ISI

Steve Sakwa / James Kammert  
(212) 446-9462 / (312) 705-4233

### Green Street

Dylan Burzinski  
(949) 640-8780

### Jefferies Research Services, LLC

Peter Abramowitz / Katie Elders  
(212) 336-7241 / (212) 284-2300

### J.P. Morgan Securities LLC

Anthony Paolone / Ray Zhong  
(212) 622-6682 / (212) 622-5411

### Mizuho Securities USA LLC

Vikram Malhotra / Georgi Dinkov  
(212) 282-3827 / (617) 352-1721

### RBC Capital Markets

Michael Carroll / Aditi Balachandran  
(440) 715-2649 / (212) 428-6200

### Robert W. Baird & Co. Incorporated

Wesley Golladay / Nicholas Thillman  
(216) 737-7510 / (414) 298-5053

### Wedbush Securities

Richard Anderson / Jay Kornreich  
(212) 931-7001 / (212) 938-9942

## Fixed Income Research Coverage

### Barclays Capital Inc.

Srinjoy Banerjee / Japheth Otieno  
(212) 526-3521 / (212) 526-6961

### J.P. Morgan Securities LLC

Mark Streeter  
(212) 834-5086

## Rating Agencies

### Moody's Ratings

(212) 553-0376

### S&P Global Ratings

Alan Zigman  
(416) 507-2556

## Financial and Asset Base Highlights

September 30, 2024

(Dollars in thousands, except per share amounts)



	Three Months Ended (unless stated otherwise)				
	9/30/24	6/30/24	3/31/24	12/31/23	9/30/23
<i>Selected financial data from consolidated financial statements and related information</i>					
Rental revenues	\$ 579,569	\$ 576,835	\$ 581,400	\$ 561,428	\$ 526,352
Tenant recoveries	\$ 196,175	\$ 178,327	\$ 174,151	\$ 181,209	\$ 181,179
General and administrative expenses	\$ 43,945	\$ 44,629	\$ 47,055	\$ 59,289	\$ 45,987
General and administrative expenses as a percentage of net operating income – trailing 12 months	8.9%	9.2%	9.5%	9.8%	9.3%
Operating margin	71%	72%	72%	71%	70%
Adjusted EBITDA margin	70%	72%	72%	69%	69%
Adjusted EBITDA – quarter annualized	\$ 2,219,632	\$ 2,216,144	\$ 2,206,428	\$ 2,094,988	\$ 1,971,440
Adjusted EBITDA – trailing 12 months	\$ 2,184,298	\$ 2,122,250	\$ 2,064,904	\$ 1,997,518	\$ 1,935,505
Net debt at end of period	\$ 12,191,574	\$ 11,940,144	\$ 11,569,666	\$ 10,731,200	\$ 10,713,620
Net debt and preferred stock to Adjusted EBITDA – quarter annualized	5.5x	5.4x	5.2x	5.1x	5.4x
Net debt and preferred stock to Adjusted EBITDA – trailing 12 months	5.6x	5.6x	5.6x	5.4x	5.5x
Total debt and preferred stock at end of period	\$ 12,691,601	\$ 12,424,055	\$ 12,217,163	\$ 11,315,642	\$ 11,202,835
Gross assets at end of period	\$ 44,112,770	\$ 43,305,279	\$ 42,915,903	\$ 41,756,421	\$ 41,639,729
Total debt and preferred stock to gross assets at end of period	29%	29%	28%	27%	27%
Fixed-charge coverage ratio – quarter annualized	4.4x	4.5x	4.7x	4.5x	4.8x
Fixed-charge coverage ratio – trailing 12 months	4.5x	4.6x	4.7x	4.7x	4.9x
Unencumbered net operating income as a percentage of total net operating income	99.1%	99.1%	99.3%	99.8%	99.8%
Closing stock price at end of period	\$ 118.75	\$ 116.97	\$ 128.91	\$ 126.77	\$ 100.10
Common shares outstanding (in thousands) at end of period	172,244	172,018	172,008	171,911	170,997
Total equity capitalization at end of period	\$ 20,454,023	\$ 20,120,907	\$ 22,173,547	\$ 21,793,107	\$ 17,116,784
Total market capitalization at end of period	\$ 33,145,624	\$ 32,544,962	\$ 34,390,710	\$ 33,108,749	\$ 28,319,619
Dividend per share – quarter/annualized	\$1.30/\$5.20	\$1.30/\$5.20	\$1.27/\$5.08	\$1.27/\$5.08	\$1.24/\$4.96
Dividend payout ratio for the quarter	55%	55%	54%	56%	55%
Dividend yield – annualized	4.4%	4.4%	3.9%	4.0%	5.0%
Amounts related to operating leases:					
Operating lease liabilities at end of period	\$ 648,338 <sup>(1)</sup>	\$ 379,223	\$ 381,578	\$ 382,883	\$ 384,958
Rent expense	\$ 10,180	\$ 9,412	\$ 8,683	\$ 8,964	\$ 8,317
Capitalized interest	\$ 86,496	\$ 81,039	\$ 81,840	\$ 89,115	\$ 96,119
Average real estate basis capitalized during the period	\$ 8,281,318	\$ 7,936,612	\$ 8,163,289	\$ 9,116,700	\$ 9,872,650
Weighted-average interest rate for capitalization of interest during the period	3.98%	3.96%	3.92%	3.92%	3.77%

Refer to "Definitions and reconciliations" in the Supplemental Information for additional details.

(1) Includes a ground lease liability related to an amendment to our existing ground lease agreement at the Alexandria Technology Square® mega campus in our Cambridge submarket, which extended its term by 24 years from January 1, 2065 to December 31, 2088. The amendment requires that we prepay our entire rent obligation for the extended lease term aggregating \$270.0 million in two equal installments in 4Q24 and 1Q25. Upon the execution of the amendment in July 2024, we recognized the present value of our rent obligation aggregating \$265.1 million related to the amendment as an operating lease liability.

## Financial and Asset Base Highlights (continued)

September 30, 2024

(Dollars in thousands, except annual rental revenue per occupied RSF amounts)




	Three Months Ended (unless stated otherwise)				
	9/30/24	6/30/24	3/31/24	12/31/23	9/30/23
<i>Amounts included in funds from operations and non-revenue-enhancing capital expenditures</i>					
Straight-line rent revenue	\$ 29,087	\$ 48,338	\$ 48,251	\$ 41,586	\$ 29,805
Amortization of acquired below-market leases	\$ 17,312	\$ 22,515	\$ 30,340	\$ 23,684	\$ 23,222
Amortization of deferred revenue related to tenant-funded and -built landlord improvements	\$ 329	\$ —	\$ —	\$ —	\$ —
Straight-line rent expense on ground leases	\$ 789	\$ 341	\$ 358	\$ 366	\$ 372
Stock compensation expense	\$ 15,525	\$ 14,507	\$ 17,125	\$ 34,592	\$ 16,288
Amortization of loan fees	\$ 4,222	\$ 4,146	\$ 4,142	\$ 4,059	\$ 4,059
Amortization of debt discounts	\$ 330	\$ 328	\$ 318	\$ 309	\$ 306
Non-revenue-enhancing capital expenditures:					
Building improvements	\$ 4,270	\$ 4,210	\$ 4,293	\$ 4,167	\$ 4,510
Tenant improvements and leasing commissions	\$ 55,920 <sup>(1)</sup>	\$ 15,724	\$ 21,144	\$ 12,155	\$ 7,560
Funds from operations attributable to noncontrolling interests	\$ 78,113	\$ 78,711	\$ 79,535	\$ 75,908	\$ 72,799
<i>Operating statistics and related information (at end of period)</i>					
Number of properties – North America	406	408	410	411	419
RSF – North America (including development and redevelopment projects under construction)	46,748,734	47,085,993	47,206,639	47,228,485	47,089,826
Total square feet – North America	73,611,815	74,103,404	74,069,321	73,532,305	75,057,289
Annual rental revenue per occupied RSF – North America	\$ 57.09	\$ 56.87	\$ 56.86	\$ 56.08	\$ 53.34
Occupancy of operating properties – North America	94.7%	94.6%	94.6%	94.6%	93.7%
Occupancy of operating and redevelopment properties – North America	89.7%	89.9%	90.2%	90.2%	89.4%
Weighted-average remaining lease term (in years)	7.5	7.4	7.5	7.4	7.0
Total leasing activity – RSF	1,486,097	1,114,001	1,142,857	889,737	867,582
Lease renewals and re-leasing of space – change in average new rental rates over expiring rates:					
Rental rate changes	5.1%	7.4%	33.0%	9.2%	28.8%
Rental rate changes (cash basis)	1.5%	3.7%	19.0%	5.5%	19.7%
RSF (included in total leasing activity above)	1,278,857	589,650	994,770	477,142	396,334
Top 20 tenants:					
Annual rental revenue	\$ 796,898	\$ 805,751	\$ 802,605	\$ 769,066	\$ 655,990
Annual rental revenue from investment-grade or publicly traded large cap tenants	92%	92%	92%	92%	91%
Weighted-average remaining lease term (in years)	9.5	9.4	9.7	9.6	8.9
Same property – percentage change over comparable quarter from prior year:					
Net operating income changes	1.5%	1.5%	1.0%	0.7%	3.1%
Net operating income changes (cash basis)	6.5%	3.9%	4.2%	0.8%	4.6%

Refer to "Definitions and reconciliations" in the Supplemental Information for additional details.

(1) Includes tenant improvements and leasing commissions related to a 10.5-year extension of a recently acquired lease aggregating 85,019 RSF in our Fenway submarket to an investment-grade rated academic institution. Excluding this extension, tenant improvements and leasing commissions for the three months ended September 30, 2024 aggregated \$39.6 million, which approximates our trailing five-year quarterly average of \$38.2 million. Refer to "Leasing Activity" in the Supplemental Information for additional details.

## Stable Cash Flows From Our High-Quality and Diverse Mix of Approximately 800 Tenants



### Investment-Grade or Publicly Traded Large Cap Tenants

**92%**

of ARE's Top 20 Tenant Annual Rental Revenue

**53%**

of ARE's Annual Rental Revenue

As of September 30, 2024. Annual rental revenue represents amounts in effect as of September 30, 2024. Refer to "Definitions and reconciliations" in the Supplemental Information for additional details, including our methodology of calculating annual rental revenue from unconsolidated real estate joint ventures.

(1) Represents the percentage of our annual rental revenue generated by technology, professional services, finance, telecommunications, and construction/real estate companies, as well as retail-related tenants, which generate less than 1.0% of our annual rental revenue.

## Long-Duration and Stable Cash Flows From High-Quality and Diverse Tenants

### Sustained Strength in Tenant Collections<sup>(1)</sup>

**99.9%**

3Q24

**99.6%**

October 2024

### Long-Duration Lease Terms

**9.5 Years**

Top 20 Tenants

**7.5 Years**

All Tenants


Weighted-Average Remaining Term<sup>(2)</sup>

(1) Represents the portion of total receivables billed for each period collected as of October 21, 2024.


(2) Based on annual rental revenue in effect as of September 30, 2024.

# Solid Historical Occupancy of 96% Over Past 10 Years<sup>(1)</sup> From Historically Strong Demand for Our Class A/A+ Properties in AAA Locations

## Mega Campuses



## Occupancy Across Key Locations




As of September 30, 2024. Annual rental revenue represents amounts in effect as of September 30, 2024. Refer to "Definitions and reconciliations" in the Supplemental Information for additional details.

- (1) Represents average occupancy of operating properties as of each December 31 from 2015 through 2023 and as of September 30, 2024.
- (2) Refer to footnote 1 under "Summary of occupancy" in "Summary of properties and occupancy" in the Supplemental Information for additional details.


## Key Operating Metrics

September 30, 2024

### Same Property Net Operating Income Growth



### Rental Rate Growth: Renewed/Re-Leased Space



### Margins<sup>(1)</sup>

Operating

71%

Adjusted EBITDA

70%

Weighted-Average Lease Term  
of Executed Leases<sup>(3)</sup>

8.8 Years

### Favorable Lease Structure<sup>(2)</sup>

Strategic Lease Structure by Owner and  
Operator of Collaborative Mega Campuses

*Increasing cash flows*

Percentage of leases containing  
annual rent escalations

96%

*Stable cash flows*

Percentage of triple  
net leases

93%

*Lower capex burden*

Percentage of leases providing for the  
recapture of capital expenditures

92%

Refer to "Same property performance" and "Definitions and reconciliations" in the Supplemental Information for additional details. "Definitions and reconciliations" contains the definition of "Net operating income" and its reconciliation from the most directly comparable financial measure presented in accordance with GAAP.

(1) For the three months ended September 30, 2024.

(2) Percentages calculated based on our annual rental revenue in effect as of September 30, 2024.

(3) Represents the weighted-average lease term of executed leases based on annual rental revenue for the 10-year period from December 31, 2015 through September 30, 2024.

## Same Property Performance

September 30, 2024

(Dollars in thousands)



Same Property Financial Data	September 30, 2024		Same Property Statistical Data	September 30, 2024	
	Three Months Ended	Nine Months Ended		Three Months Ended	Nine Months Ended
Percentage change over comparable period from prior year:					
<b>Net operating income changes</b>	<b>1.5%</b>	<b>1.6%</b>	Number of same properties	344	339
<b>Net operating income changes (cash basis)</b>	<b>6.5%</b>	<b>4.6%</b>	Rentable square feet	34,652,674	33,720,609
Operating margin	68%	69%	Occupancy – current-period average	94.8%	94.4%
			Occupancy – same-period prior-year average	94.1%	94.3%

	Three Months Ended September 30,				Nine Months Ended September 30,			
	2024	2023	\$ Change	% Change	2024	2023	\$ Change	% Change
Income from rentals:								
Same properties	\$ 452,417	\$ 439,541	\$ 12,876	2.9%	\$ 1,342,463	\$ 1,307,866	\$ 34,597	2.6%
Non-same properties	127,152	86,811	40,341	46.5	395,341	274,677	120,664	43.9
Rental revenues	579,569	526,352	53,217	10.1	1,737,804	1,582,543	155,261	9.8
Same properties	168,923	165,226	3,697	2.2	473,061	461,555	11,506	2.5
Non-same properties	27,252	15,953	11,299	70.8	75,592	55,721	19,871	35.7
Tenant recoveries	196,175	181,179	14,996	8.3	548,653	517,276	31,377	6.1
Income from rentals	775,744	707,531	68,213	9.6	2,286,457	2,099,819	186,638	8.9
Same properties	386	619	(233)	(37.6)	1,102	1,356	(254)	(18.7)
Non-same properties	15,477	5,638	9,839	174.5	39,890	27,308	12,582	46.1
Other income	15,863	6,257	9,606	153.5	40,992	28,664	12,328	43.0
Same properties	621,726	605,386	16,340	2.7	1,816,626	1,770,777	45,849	2.6
Non-same properties	169,881	108,402	61,479	56.7	510,823	357,706	153,117	42.8
<b>Total revenues</b>	<b>791,607</b>	<b>713,788</b>	<b>77,819</b>	<b>10.9</b>	<b>2,327,449</b>	<b>2,128,483</b>	<b>198,966</b>	<b>9.3</b>
Same properties	199,369	189,368	10,001	5.3	559,427	532,942	26,485	5.0
Non-same properties	33,896	28,319	5,577	19.7	109,406	103,512	5,894	5.7
Rental operations	233,265	217,687	15,578	7.2	668,833	636,454	32,379	5.1
Same properties	422,357	416,018	6,339	1.5	1,257,199	1,237,835	19,364	1.6
Non-same properties	135,985	80,083	55,902	69.8	401,417	254,194	147,223	57.9
Net operating income	\$ 558,342	\$ 496,101	\$ 62,241	12.5%	\$ 1,658,616	\$ 1,492,029	\$ 166,587	11.2%
<b>Net operating income – same properties</b>	<b>\$ 422,357</b>	<b>\$ 416,018</b>	<b>\$ 6,339</b>	<b>1.5%</b>	<b>\$ 1,257,199</b>	<b>\$ 1,237,835</b>	<b>\$ 19,364</b>	<b>1.6%</b>
Straight-line rent revenue	(4,974)	(23,981)	19,007	(79.3)	(37,251)	(73,626)	36,375	(49.4)
Amortization of acquired below-market leases	(14,582)	(13,792)	(790)	5.7	(44,993)	(40,410)	(4,583)	11.3
<b>Net operating income – same properties (cash basis)</b>	<b>\$ 402,801</b>	<b>\$ 378,245</b>	<b>\$ 24,556</b>	<b>6.5%</b>	<b>\$ 1,174,955</b>	<b>\$ 1,123,799</b>	<b>\$ 51,156</b>	<b>4.6%</b>

Refer to "Same property comparisons" under "Definitions and reconciliations" in the Supplemental Information for additional details, including a reconciliation of same properties to total properties. "Definitions and reconciliations" also contains definitions of "Tenant recoveries" and "Net operating income" and their respective reconciliations from the most directly comparable financial measures presented in accordance with GAAP.



## Leasing Activity

September 30, 2024

(Dollars per RSF)

	Three Months Ended September 30, 2024		Nine Months Ended September 30, 2024		Year Ended December 31, 2023	
	Including Straight-Line Rent	Cash Basis	Including Straight-Line Rent	Cash Basis	Including Straight-Line Rent	Cash Basis
<i>Leasing activity:</i>						
Renewed/re-leased space <sup>(1)</sup>						
<b>Rental rate changes</b>	<b>5.1%</b> <sup>(2)</sup>	<b>1.5%</b> <sup>(2)</sup>	<b>16.4%</b>	<b>8.9%</b>	<b>29.4%</b>	<b>15.8%</b>
New rates	\$56.60	\$55.77	\$63.43	\$62.39	\$52.35	\$50.82
Expiring rates	\$53.86	\$54.95	\$54.47	\$57.28	\$40.46	\$43.87
RSF	1,278,857		2,863,277		3,046,386	
Tenant improvements/leasing commissions	\$43.73 <sup>(3)</sup>		\$33.92 <sup>(3)</sup>		\$26.09	
Weighted-average lease term	9.7 years		8.7 years		8.7 years	
Developed/redeveloped/previously vacant space leased <sup>(4)</sup>						
New rates	\$52.66	\$52.18	\$64.59	\$62.90	\$65.66	\$59.74
RSF	207,240		879,678 <sup>(5)</sup>		1,259,686	
Weighted-average lease term	10.6 years		8.1 years		13.8 years	
<i>Leasing activity summary (totals):</i>						
New rates	\$56.05	\$55.27	\$63.69	\$62.50	\$56.09	\$53.33
RSF	1,486,097		3,742,955		4,306,072	
Weighted-average lease term	9.8 years		8.6 years		11.3 years	
<i>Lease expirations<sup>(1)</sup></i>						
Expiring rates	\$51.62	\$53.17	\$52.01	\$54.40	\$43.84	\$45.20
RSF	1,500,213		3,801,559		5,027,773	

Leasing activity includes 100% of results for properties in North America in which we have an investment.

- (1) Excludes month-to-month leases aggregating 355,698 RSF and 86,092 RSF as of September 30, 2024 and December 31, 2023, respectively. Month-to-month leases aggregating 355,698 RSF as of September 30, 2024 include 226,144 RSF in our University Town Center submarket primarily related to space being temporarily held over by an expiring tenant at buildings that are targeted for the future development of laboratory space, subject to market conditions and leasing. During the trailing twelve months ended September 30, 2024, we granted free rent concessions averaging 0.7 months per annum.
- (2) Includes a five-year lease extension to an investment-grade rated technology tenant aggregating 357,136 RSF of recently acquired tech R&D space in our Texas market that was renewed with rental rate changes of (33.6)% and (4.8)% (cash basis). These spaces were originally targeted for a future change in use at acquisition, but we instead renewed them with a lower capital investment while we continue to evaluate options to convert these spaces in the future, subject to market conditions. Excluding this lease, rental rate changes for renewed/re-leased space for 3Q24 were 13.0% and 2.3% (cash basis). Rental rate changes may experience volatility from quarter to quarter based on the volume and mix of leases executed. Refer to "Guidance" in the Earnings Press Release for rental rate changes expected from leases executed for the year ending December 31, 2024.
- (3) Includes tenant improvements and leasing commissions related to a 10.5-year extension of a recently acquired lease aggregating 85,019 RSF in our Fenway submarket to an investment-grade rated academic institution. Excluding this lease, tenant improvements and leasing commissions per RSF for the three and nine months ended September 30, 2024 were \$33.16 and \$28.85, respectively, which are consistent with the five-year quarterly average of \$32.17 per RSF.
- (4) Refer to "New Class A/A+ development and redevelopment properties: summary of pipeline" in the Supplemental Information for additional details, including total project costs.
- (5) Includes the five-year extension of 171,102 RSF at our 4155 Campus Point Court property in San Diego, a fully leased development project expected to deliver in 4Q24.

# Contractual Lease Expirations

September 30, 2024

Year	RSF	Percentage of Occupied RSF	Annual Rental Revenue (per RSF) <sup>(1)</sup>	Percentage of Annual Rental Revenue
2024 <sup>(2)</sup>	518,665	1.4%	\$ 69.19	1.7%
2025	3,785,573	10.0%	\$ 49.64	8.8%
2026	2,714,170	7.1%	\$ 53.21	6.7%
2027	3,242,737	8.5%	\$ 51.87	7.9%
2028	4,332,150	11.4%	\$ 51.78	10.5%
2029	2,437,921	6.4%	\$ 51.25	5.8%
2030	3,135,445	8.3%	\$ 43.25	6.3%
2031	3,425,338	9.0%	\$ 55.11	8.8%
2032	1,093,311	2.9%	\$ 59.53	3.0%
2033	2,772,455	7.3%	\$ 50.81	6.6%
Thereafter	10,541,840	27.7%	\$ 68.66	33.9%

## 2024 Contractual Lease Expirations (in RSF)

## 2025 Contractual Lease Expirations (in RSF)

Market	2024 Contractual Lease Expirations (in RSF)						2025 Contractual Lease Expirations (in RSF)						
	Leased	Negotiating/Anticipating	Committed Near-Term/Priority Anticipated	Future	Remaining Expiring Leases	Total <sup>(2)</sup>	Leased	Negotiating/Anticipating	Targeted for Future Development/Redevelopment <sup>(3)</sup>	Remaining Expiring Leases <sup>(4)</sup>	Total	Annual Rental Revenue (per RSF) <sup>(1)</sup>	
Greater Boston	73,614	21,621	—	104,500	80,788 <sup>(5)</sup>	280,523	\$ 86.07	172,446	145,715	25,312	659,355 <sup>(5)</sup>	1,002,828	\$ 76.13
San Francisco Bay Area	12,847	13,943	107,250	—	14,682	148,722	49.58	72,162	247,827	—	547,092	867,081	51.33
San Diego	27,119	—	—	—	17,408	44,527	55.30	83,546	—	269,048	260,627	613,221	22.98
Seattle	—	—	—	—	3,652	3,652	N/A	—	—	—	196,419	196,419	25.10
Maryland	—	—	—	—	182	182	N/A	35,055	6,926	—	151,958	193,939	27.51
Research Triangle	10,478	—	—	—	8,202	18,680	28.31	—	—	—	306,916	306,916	51.16
New York City	—	—	—	—	9,058	9,058	109.57	—	13,273	—	54,966	68,239	105.86
Texas	—	—	—	—	—	—	—	—	—	198,972	247,246	446,218	40.09
Canada	13,321	—	—	—	—	13,321	26.54	—	—	—	88,412	88,412	20.28
Non-cluster/other markets	—	—	—	—	—	—	—	—	—	—	2,300	2,300	40.17
<b>Total</b>	<b>137,379</b>	<b>35,564</b>	<b>107,250</b>	<b>104,500</b>	<b>133,972</b>	<b>518,665</b>	<b>\$ 69.19</b>	<b>363,209</b>	<b>413,741</b>	<b>493,332 <sup>(3)</sup></b>	<b>2,515,291</b>	<b>3,785,573</b>	<b>\$ 49.64</b>
Percentage of expiring leases	26%	7%	21%	20%	26%	100%		10%	11%	13%	66%	100%	

Contractual lease expirations at properties classified as held for sale as of September 30, 2024 are excluded from the information on this page.

- Represents amounts in effect as of September 30, 2024.
- Excludes month-to-month leases aggregating 355,698 RSF as of September 30, 2024. Refer to "Leasing Activity" in the Supplemental Information for additional details.
- Primarily represents assets that were recently acquired for future development and redevelopment opportunities, for which we expect, subject to market conditions and leasing, to commence first-time conversion from non-laboratory space to laboratory space, or to commence future ground-up development. As of September 30, 2024, annual rental revenue from these leases expiring in 2024, including 226,144 RSF of month-to-month leases in our University Town Center submarket primarily related to space being temporarily held over by an expiring tenant, and 2025 is \$20.9 million and \$17.5 million, respectively. The weighted-average expiration date of these leases expiring in 2024 and 2025 is October 20, 2024 and January 10, 2025, respectively. Refer to "Investments in real estate" under "Definitions and reconciliations" in the Supplemental Information for additional details, including development and redevelopment square feet currently included in rental properties.
- Includes 768,080 RSF in four submarkets with a weighted-average expiration date of January 21, 2025 and annual rental revenue aggregating approximately \$47 million, with our share of this annual rental revenue aggregating \$35 million, comprising the following: (i) existing laboratory spaces for which we are evaluating options to re-lease or reposition from single tenancy to multi-tenancy that will remain in our same property pool at Alexandria Technology Square<sup>®</sup> in our Cambridge submarket for 182,054 RSF and at 409 Illinois Street, where we have an ownership interest of 25.0%, in our Mission Bay submarket for 234,249 RSF (we are in early discussions with a tenant to lease approximately 50% of this space); and (ii) non-laboratory space for which we are evaluating options to re-lease generally in their current condition, reposition, or, subject to market conditions, may undergo a conversion through redevelopment in our Austin submarket for 247,246 RSF and in our Research Triangle market for 104,531 RSF. Should we commence redevelopment efforts, these properties would be placed into our active pipeline and removed from our same property pool; otherwise, they would remain in our same property pool. We expect downtime on the 768,080 RSF to range from 12 to 24 months on a weighted-average basis.
- Includes 41,908 RSF and 210,868 RSF expiring in 2024 and 2025, respectively, related to properties that are under executed letters of intent and/or purchase and sale agreements to sell. Approximately 95% of the 2025 remaining expiring leases in Greater Boston are located in our Cambridge/Inner Suburbs submarket. Refer to footnote 4 for additional details.

## Top 20 Tenants

September 30, 2024

(Dollars in thousands, except average market cap amounts)

# 92% of Top 20 Tenant Annual Rental Revenue Is From Investment-Grade or Publicly Traded Large Cap Tenants<sup>(1)</sup>

Tenant	Remaining Lease Term <sup>(1)</sup> (in years)	Aggregate RSF	Annual Rental Revenue <sup>(1)</sup>	Percentage of Annual Rental Revenue <sup>(1)</sup>	Investment-Grade Credit Ratings		Average Market Cap (in billions)
					Moody's	S&P	
1 Moderna, Inc.	12.6	1,385,678	\$ 127,387	5.8%	—	—	\$ 38.6
2 Eli Lilly and Company	8.2	1,166,754	94,814	4.3	A1	A+	\$ 712.4
3 Bristol-Myers Squibb Company	6.4	999,379	76,363	3.5	A2	A	\$ 99.1
4 Takeda Pharmaceutical Company Limited	10.7	549,759	47,899	2.2	Baa1	BBB+	\$ 44.5
5 Roche	6.7	770,279	47,104	2.2	Aa2	AA	\$ 227.8
6 Illumina, Inc.	7.4	857,967	35,362	1.6	Baa3	BBB	\$ 19.7
7 Alphabet Inc.	3.1	625,015	34,899	1.6	Aa2	AA+	\$ 1,916.3
8 2seventy bio, Inc. <sup>(2)</sup>	8.9	312,805	33,543	1.5	—	—	\$ 0.2
9 Novartis AG	3.8	450,664	30,969	1.4	Aa3	AA-	\$ 231.8
10 United States Government	5.9	429,359	28,593	1.3	Aaa	AA+	\$ —
11 Cloud Software Group, Inc.	2.4 <sup>(3)</sup>	292,013	28,537	1.3	—	—	\$ —
12 Uber Technologies, Inc.	58.0 <sup>(4)</sup>	1,009,188	27,776	1.3	Baa2	BBB-	\$ 137.1
13 AstraZeneca PLC	5.1	450,848	27,156	1.2	A2	A+	\$ 222.8
14 Harvard University	7.2	343,858	27,084	1.2	Aaa	AAA	\$ —
15 The Regents of the University of California	6.6	372,647	23,670	1.1	Aa2	AA	\$ —
16 Sanofi	6.3	267,278	21,444	1.0	A1	AA	\$ 126.6
17 Merck & Co., Inc.	8.8	337,703	21,401	1.0	A1	A+	\$ 300.8
18 Amgen Inc.	8.3	428,227	21,314	1.0	Baa1	BBB+	\$ 159.2
19 New York University	7.4	218,983	21,056	1.0	Aa2	AA-	\$ —
20 Massachusetts Institute of Technology	4.7	246,725	20,527	0.9	Aaa	AAA	\$ —
<b>Total/weighted-average</b>	<b>9.5<sup>(4)</sup></b>	<b>11,515,129</b>	<b>\$ 796,898</b>	<b>36.4%</b>			

Annual rental revenue and RSF include 100% of each property managed by us in North America. Refer to "Annual rental revenue" and "Investment-grade or publicly traded large cap tenants" under "Definitions and reconciliations" in the Supplemental Information for additional details, including our methodology of calculating annual rental revenue from unconsolidated real estate joint ventures and average market capitalization, respectively.

(1) Based on annual rental revenue in effect as of September 30, 2024.

(2) As of June 30, 2024, 2seventy bio, Inc. held \$201.9 million of cash, cash equivalents, and marketable securities. In March 2024, Regeneron Pharmaceuticals, Inc., a publicly traded biotechnology company with investment-grade credit ratings of Baa1 and BBB+ assigned by Moody's and S&P, respectively, entered into a sublease for approximately 195,000 RSF, or 62.8% of our annual rental revenue generated from 2seventy bio as of September 30, 2024. Additionally, 90.2% of the annual rental revenue generated by 2seventy bio is guaranteed by another related public biotechnology company.

(3) Consists of one lease at a property acquired in 2022 with future development and redevelopment opportunities. This lease with Cloud Software Group, Inc. (formerly known as TIBCO Software, Inc.) was in place when we acquired the property.

(4) Includes (i) ground leases for land at 1455 and 1515 Third Street (two buildings aggregating 422,980 RSF) and (ii) leases at 1655 and 1725 Third Street (two buildings aggregating 586,208 RSF) in our Mission Bay submarket owned by our unconsolidated real estate joint venture in which we have an ownership interest of 10%. Annual rental revenue is presented using 100% of the annual rental revenue from our consolidated properties and our share of annual rental revenue from our unconsolidated real estate joint ventures. Excluding these ground leases, the weighted-average remaining lease term for our top 20 tenants was 7.8 years as of September 30, 2024.

## Summary of Properties and Occupancy

September 30, 2024

(Dollars in thousands, except per RSF amounts)



### Summary of properties

Market	RSF					Number of Properties	Annual Rental Revenue		
	Operating	Development	Redevelopment	Total	% of Total		Total	% of Total	Per RSF
Greater Boston	10,352,695	764,036	1,762,974 <sup>(1)</sup>	12,879,705	28%	72	\$ 833,562	38%	\$ 85.09
San Francisco Bay Area	7,784,590	498,142	259,689	8,542,421	18	65	432,102	20	63.54
San Diego	7,673,315	1,186,104	—	8,859,419	19	87	330,596	15	44.90
Seattle	3,108,593	227,577	34,306	3,370,476	7	45	137,044	6	47.78
Maryland	3,819,512	29,890	—	3,849,402	8	50	145,847	7	40.12
Research Triangle	3,770,927	—	—	3,770,927	8	38	116,318	5	31.64
New York City	921,686	—	—	921,686	2	4	72,439	3	92.37
Texas	1,845,159	—	73,298	1,918,457	4	15	54,958	3	31.19
Canada	887,737	—	139,311	1,027,048	2	11	19,790	1	23.33
Non-cluster/other markets	347,806	—	—	347,806	1	10	14,623	1	57.76
Properties held for sale	1,261,387	—	—	1,261,387	3	9	26,796	1	N/A
<b>North America</b>	<b>41,773,407</b>	<b>2,705,749</b>	<b>2,269,578</b>	<b>46,748,734</b>	<b>100%</b>	<b>406</b>	<b>\$ 2,184,075</b>	<b>100%</b>	<b>\$ 57.09</b>
			<b>4,975,327</b>						

(1) Primarily includes our active redevelopment projects aggregating 735,744 RSF at 40, 50, and 60 Sylvan Road and 840 Winter Street located on the Alexandria Center<sup>®</sup> for Life Science – Waltham mega campus. This mega campus project is expected to capture demand in our Route 128 submarket.

### Summary of occupancy

Market	Operating Properties			Operating and Redevelopment Properties		
	9/30/24	6/30/24	9/30/23	9/30/24	6/30/24	9/30/23
Greater Boston	94.6%	94.2%	93.2%	80.9%	81.7%	83.3%
San Francisco Bay Area	94.1	94.0	95.3	91.1	90.7	91.9
San Diego	96.0	95.1	90.9	96.0	95.1	90.9
Seattle	92.3 <sup>(1)</sup>	94.7	95.1	91.3	93.7	90.3
Maryland	96.2	96.5	96.6	96.2	96.5	96.6
Research Triangle	97.5	97.4	96.9	97.5	97.4	96.9
New York City	85.1 <sup>(2)</sup>	85.1	89.4	85.1	85.1	89.4
Texas	95.5	95.5	95.1	91.8	91.8	91.5
Subtotal	94.9	94.7	93.9	90.0	90.2	89.9
Canada	95.5	94.9	88.9	82.6	82.5	75.7
Non-cluster/other markets	72.8	75.6	80.5	72.8	75.6	80.5
<b>North America</b>	<b>94.7%</b>	<b>94.6%</b>	<b>93.7%</b>	<b>89.7%</b>	<b>89.9%</b>	<b>89.4%</b>

(1) Decline in occupancy relates to the expiration of an acquired non-laboratory lease aggregating 87,273 RSF at one property in our Bothell submarket that is expected to be converted to laboratory space subject to market conditions and leasing.

(2) The Alexandria Center<sup>®</sup> for Life Science – New York City mega campus is 95.3% occupied as of September 30, 2024. Occupancy percentage in our New York City market reflects vacancy at the Alexandria Center<sup>®</sup> for Life Science – Long Island City property, which was 42.8% occupied as of September 30, 2024.

## Mega Campuses Encompass 76% of Our Annual Rental Revenue

Market / Submarket / Address	RSF			Total	Number of Properties	Annual Rental Revenue	Occupancy Percentage	
	Operating	Development	Redevelopment				Operating	Operating and Redevelopment
<b>Greater Boston</b>								
<i>Cambridge/Inner Suburbs</i>								
<b>Mega Campus: Alexandria Center® at Kendall Square</b> 50 <sup>(1)</sup> , 60 <sup>(1)</sup> , 75/125 <sup>(1)</sup> , 100 <sup>(1)</sup> , and 225 <sup>(1)</sup> Binney Street, 140 and 215 First Street, 150 Second Street, 300 Third Street <sup>(1)</sup> , 11 Hurley Street, and 100 Edwin H. Land Boulevard	2,856,043	—	—	2,856,043	11	\$ 275,724	97.5%	97.5%
<b>Mega Campus: Alexandria Center® at One Kendall Square</b> One Kendall Square (Buildings 100, 200, 300, 400, 500, 600/700, 1400, 1800, and 2000), 325 and 399 Binney Street, and One Hampshire Street	1,281,583	—	104,956	1,386,539	12	144,595	93.7	86.6
<b>Mega Campus: Alexandria Technology Square®</b> 100, 200, 300, 400, 500, 600, and 700 Technology Square	1,185,286	—	—	1,185,286	7	114,942	100.0	100.0
<b>Mega Campus: The Arsenal on the Charles</b> 311, 321, and 343 Arsenal Street, 300, 400, and 500 North Beacon Street, 1, 2, 3, and 4 Kingsbury Avenue, and 100, 200, and 400 Talcott Avenue	702,745	109,481	308,446	1,120,672	13	53,481	99.3	69.0
<b>Mega Campus: 480 Arsenal Way, 446, 458, 500, and 550 Arsenal Street, and 99 Coolidge Avenue<sup>(1)</sup></b> <i>Cambridge/Inner Suburbs</i>	633,056	204,395	—	837,451	6	39,618	100.0	100.0
	6,658,713	313,876	413,402	7,385,991	49	628,360	97.7	91.9
<i>Fenway</i>								
<b>Mega Campus: Alexandria Center® for Life Science – Fenway</b> 401 and 421 <sup>(1)</sup> Park Drive and 201 Brookline Avenue <sup>(1)</sup>	1,218,257	450,160	159,959	1,828,376	3	90,984	89.3	78.9
<i>Seaport Innovation District</i>								
5 and 15 <sup>(1)</sup> Necco Street	441,396	—	—	441,396	2	40,401	75.7	75.7
Seaport Innovation District	441,396	—	—	441,396	2	40,401	75.7	75.7
<i>Route 128</i>								
<b>Mega Campus: Alexandria Center® for Life Science – Waltham</b> 40, 50, and 60 Sylvan Road, 35 Gatehouse Drive, and 840 Winter Street	326,110	—	735,744	1,061,854	5	23,198	100.0	30.7
<b>Mega Campus: One Moderna Way</b> 19, 225, and 235 Presidential Way	722,130	—	—	722,130	4	31,422	100.0	100.0
Route 128	585,226	—	—	585,226	3	14,381	100.0	100.0
Other	1,633,466	—	735,744	2,369,210	12	69,001	100.0	68.9
	400,863	—	453,869	854,732	6	4,816	59.7	28.0
<b>Greater Boston</b>	<b>10,352,695</b>	<b>764,036</b>	<b>1,762,974</b>	<b>12,879,705</b>	<b>72</b>	<b>\$ 833,562</b>	<b>94.6%</b>	<b>80.9%</b>

Refer to “New Class A/A+ development and redevelopment properties: summary of pipeline” and “Definitions and reconciliations” in the Supplemental Information for additional details.

(1) We own a partial interest in this property through a real estate joint venture. Refer to “Joint venture financial information” in the Supplemental Information for additional details.

## Property Listing (continued)

September 30, 2024

(Dollars in thousands)

Market / Submarket / Address	RSF				Number of Properties	Annual Rental Revenue	Occupancy Percentage	
	Operating	Development	Redevelopment	Total			Operating	Operating and Redevelopment
<b>San Francisco Bay Area</b>								
<i>Mission Bay</i>								
<b>Mega Campus: Alexandria Center® for Science and Technology – Mission Bay<sup>(1)</sup></b> 1455 <sup>(2)</sup> , 1515 <sup>(2)</sup> , 1655, and 1725 Third Street, 409 and 499 Illinois Street, 1450, 1500, and 1700 Owens Street, and 455 Mission Bay Boulevard South	2,005,369	212,796	—	2,218,165	10	\$ 74,676	95.1%	95.1%
<i>Mission Bay</i>	2,005,369	212,796	—	2,218,165	10	74,676	95.1	95.1
<i>South San Francisco</i>								
<b>Mega Campus: Alexandria Technology Center® – Gateway<sup>(1)</sup></b> 600 <sup>(2)</sup> , 601, 611, 630 <sup>(2)</sup> , 650 <sup>(2)</sup> , 651, 681, 685, 701, 751, 901 <sup>(2)</sup> , and 951 <sup>(2)</sup> Gateway Boulevard	1,409,825	—	259,689	1,669,514	12	76,150	82.9	70.0
<b>Mega Campus: Alexandria Center® for Advanced Technologies – South San Francisco</b> 213 <sup>(1)</sup> , 249, 259, 269, and 279 East Grand Avenue	919,703	—	—	919,703	5	57,788	100.0	100.0
Alexandria Center® for Life Science – South San Francisco 201 Haskins Way and 400 and 450 East Jamie Court	504,053	—	—	504,053	3	32,767	93.9	93.9
<b>Mega Campus: Alexandria Center® for Advanced Technologies – Tanforan</b> 1122 and 1150 El Camino Real	445,232	—	—	445,232	2	4,020	100.0	100.0
Alexandria Center® for Life Science – Millbrae <sup>(1)</sup> 230 Harriet Tubman Way	—	285,346	—	285,346	1	—	N/A	N/A
500 Forbes Boulevard <sup>(1)</sup>	155,685	—	—	155,685	1	10,680	100.0	100.0
<i>South San Francisco</i>	3,434,498	285,346	259,689	3,979,533	24	181,405	92.1	85.6
<i>Greater Stanford</i>								
<b>Mega Campus: Alexandria Center® for Life Science – San Carlos</b> 825, 835, 960, and 1501-1599 Industrial Road	739,157	—	—	739,157	9	49,891	97.4	97.4
Alexandria Stanford Life Science District 3160, 3165, 3170, and 3181 Porter Drive and 3301, 3303, 3305, 3307, and 3330 Hillview Avenue	703,843	—	—	703,843	9	66,558	98.6	98.6
3412, 3420, 3440, 3450, and 3460 Hillview Avenue	340,103	—	—	340,103	5	23,603	82.9	82.9
3875 Fabian Way	228,000	—	—	228,000	1	9,402	100.0	100.0
2475 and 2625/2627/2631 Hanover Street and 1450 Page Mill Road	193,688	—	—	193,688	3	16,994	100.0	100.0
2100, 2200, and 2400 Geng Road	78,501	—	—	78,501	3	4,803	100.0	100.0
3350 West Bayshore Road	61,431	—	—	61,431	1	4,770	100.0	100.0
<i>Greater Stanford</i>	2,344,723	—	—	2,344,723	31	176,021	96.3	96.3
<b>San Francisco Bay Area</b>	<b>7,784,590</b>	<b>498,142</b>	<b>259,689</b>	<b>8,542,421</b>	<b>65</b>	<b>\$ 432,102</b>	<b>94.1%</b>	<b>91.1%</b>

Refer to “New Class A/A+ development and redevelopment properties: summary of pipeline” and “Definitions and reconciliations” in the Supplemental Information for additional details.

(1) We own a partial interest in this property through a real estate joint venture. Refer to “Joint venture financial information” in the Supplemental Information for additional details.

(2) We own 100% of this property.

## Property Listing (continued)

September 30, 2024

(Dollars in thousands)

Market / Submarket / Address	RSF				Number of Properties	Annual Rental Revenue	Occupancy Percentage	
	Operating	Development	Redevelopment	Total			Operating	Operating and Redevelopment
<b>San Diego</b>								
<i>Torrey Pines</i>								
<b>Mega Campus: One Alexandria Square</b> 3115 and 3215 <sup>(1)</sup> Merryfield Row, 3010, 3013, and 3033 Science Park Road, 10935, 10945, and 10955 Alexandria Way, 10975 North Torrey Pines Road, and 10996 Torreyana Road, and 3545 Cray Court	748,674	334,996	—	1,083,670	10	\$ 43,059	98.8%	98.8%
ARE Torrey Ridge 10578, 10618, and 10628 Science Center Drive	297,784	—	—	297,784	3	13,661	85.9	85.9
ARE Nautilus 3530 and 3550 John Hopkins Court and 3535 and 3565 General Atomics Court	218,459	—	—	218,459	4	12,743	86.3	86.3
<i>Torrey Pines</i>	1,264,917	334,996	—	1,599,913	17	69,463	93.6	93.6
<i>University Town Center</i>								
<b>Mega Campus: Campus Point by Alexandria<sup>(1)</sup></b> 9880 <sup>(2)</sup> , 10010 <sup>(2)</sup> , 10140 <sup>(2)</sup> , 10210, 10260, 10290, and 10300 Campus Point Drive and 4135, 4155, 4161, 4224, 4242, and 4275 <sup>(2)</sup> Campus Point Court	1,666,590	598,029	—	2,264,619	13	80,167	99.0	99.0
<b>Mega Campus: 5200 Illumina Way<sup>(1)</sup></b> ARE Esplanade	792,687	—	—	792,687	6	29,978	100.0	100.0
4755, 4757, and 4767 Nexus Center Drive and 4796 Executive Drive	243,084	—	—	243,084	4	11,976	74.6	74.6
9625 Towne Centre Drive <sup>(1)</sup>	163,648	—	—	163,648	1	6,520	100.0	100.0
Costa Verde by Alexandria 8505 Costa Verde Boulevard and 4260 Nobel Drive	8,730	—	—	8,730	2	941	100.0	100.0
<i>University Town Center</i>	2,874,739	598,029	—	3,472,768	26	129,582	97.3	97.3
<i>Sorrento Mesa</i>								
<b>Mega Campus: SD Tech by Alexandria<sup>(1)</sup></b> 9605, 9645, 9675, 9725, 9735, 9808, 9855, and 9868 Scranton Road, 5505 Morehouse Drive <sup>(2)</sup> , and 10055, 10065, 10075, 10121 <sup>(2)</sup> , and 10151 <sup>(2)</sup> Barnes Canyon Road	981,195	253,079	—	1,234,274	14	41,534	94.3	94.3
<b>Mega Campus: Sequence District by Alexandria</b> 6260, 6290, 6310, 6340, 6350, 6420, and 6450 Sequence Drive	801,575	—	—	801,575	7	28,766	100.0	100.0
Pacific Technology Park <sup>(1)</sup> 9389, 9393, 9401, 9455, and 9477 Waples Street	544,352	—	—	544,352	5	8,936	89.1	89.1
Summers Ridge Science Park <sup>(1)</sup> 9965, 9975, 9985, and 9995 Summers Ridge Road	316,531	—	—	316,531	4	11,521	100.0	100.0
Scripps Science Park by Alexandria 10102 Hoyt Park Drive	144,113	—	—	144,113	1	11,379	100.0	100.0
ARE Portola 6175, 6225, and 6275 Nancy Ridge Drive	101,857	—	—	101,857	3	4,022	100.0	100.0
5810/5820 Nancy Ridge Drive	83,354	—	—	83,354	1	4,581	100.0	100.0
9877 Waples Street	63,774	—	—	63,774	1	2,680	100.0	100.0
5871 Oberlin Drive	33,842	—	—	33,842	1	1,909	100.0	100.0
<i>Sorrento Mesa</i>	3,070,593	253,079	—	3,323,672	37	\$ 115,328	96.2%	96.2%

Refer to "New Class A/A+ development and redevelopment properties: summary of pipeline" and "Definitions and reconciliations" in the Supplemental Information for additional details.

(1) We own a partial interest in this property through a real estate joint venture. Refer to "Joint venture financial information" in the Supplemental Information for additional details.

(2) We own 100% of this property.

## Property Listing (continued)

September 30, 2024

(Dollars in thousands)



**ALEXANDRIA**  
Building the Future of Life-Changing Innovation®

Market / Submarket / Address	RSF				Number of Properties	Annual Rental Revenue	Occupancy Percentage	
	Operating	Development	Redevelopment	Total			Operating	Operating and Redevelopment
<b>San Diego (continued)</b>								
<i>Sorrento Valley</i>								
3911, 3931, and 3985 Sorrento Valley Boulevard	108,812	—	—	108,812	3	\$ 3,834	68.5%	68.5%
11045 and 11055 Roselle Street	43,233	—	—	43,233	2	2,191	100.0	100.0
<i>Sorrento Valley</i>								
	152,045	—	—	152,045	5	6,025	77.4	77.4
<i>Other</i>								
	311,021	—	—	311,021	2	10,198	100.0	100.0
<b>San Diego</b>	<b>7,673,315</b>	<b>1,186,104</b>	<b>—</b>	<b>8,859,419</b>	<b>87</b>	<b>330,596</b>	<b>96.0</b>	<b>96.0</b>
<b>Seattle</b>								
<i>Lake Union</i>								
<b>Mega Campus: Alexandria Center® for Life Science – Eastlake</b>	1,153,742	—	—	1,153,742	9	81,380	95.2	95.2
<i>1150, 1201<sup>(1)</sup>, 1208<sup>(1)</sup>, 1551, 1600, and 1616 Eastlake Avenue East, 188 and 199<sup>(1)</sup> East Blaine Street, and 1600 Fairview Avenue East</i>								
<b>Mega Campus: Alexandria Center® for Life Science – South Lake Union</b>	290,754	227,577	—	518,331	2	17,501	100.0	100.0
<i>400<sup>(1)</sup> and 701 Dexter Avenue North</i>								
219 Terry Avenue North	31,797	—	—	31,797	1	1,311	56.9	56.9
<i>Lake Union</i>								
	1,476,293	227,577	—	1,703,870	12	100,192	95.3	95.3
<i>SoDo</i>								
830 4th Avenue South	45,615	—	—	45,615	1	676	29.8	29.8
<i>Elliott Bay</i>								
410 West Harrison Street and 410 Elliott Avenue West	20,101	—	—	20,101	2	672	100.0	100.0
<i>Bothell</i>								
<b>Mega Campus: Alexandria Center® for Advanced Technologies – Canyon Park</b>	1,061,778	—	—	1,061,778	22	22,235	87.9	87.9
<i>22121 and 22125 17th Avenue Southeast, 22021, 22025, 22026, 22030, 22118, and 22122 20th Avenue Southeast, 22333, 22422, 22515, 22522, 22722, and 22745 29th Drive Southeast, 21540, 22213 and 22309 30th Drive Southeast, and 1629, 1631, 1725, 1916, and 1930 220th Street Southeast</i>								
Alexandria Center® for Advanced Technologies – Monte Villa Parkway	429,143	—	34,306	463,449	6	12,420	97.5	90.3
<i>3301, 3303, 3305, 3307, 3555, and 3755 Monte Villa Parkway</i>								
<i>Bothell</i>								
	1,490,921	—	34,306	1,525,227	28	34,655	90.7	88.6
<i>Other</i>								
	75,663	—	—	75,663	2	849	100.0	100.0
<b>Seattle</b>	<b>3,108,593</b>	<b>227,577</b>	<b>34,306</b>	<b>3,370,476</b>	<b>45</b>	<b>\$ 137,044</b>	<b>92.3%</b>	<b>91.3%</b>

Refer to "New Class A/A+ development and redevelopment properties: summary of pipeline" and "Definitions and reconciliations" in the Supplemental Information for additional details.

(1) We own a partial interest in this property through a real estate joint venture. Refer to "Joint venture financial information" in the Supplemental Information for additional details.



## Property Listing (continued)

September 30, 2024

(Dollars in thousands)



**ALEXANDRIA**  
Building the Future of Life-Changing Innovation®

Market / Submarket / Address	RSF				Number of Properties	Annual Rental Revenue	Occupancy Percentage	
	Operating	Development	Redevelopment	Total			Operating	Operating and Redevelopment
<b>Maryland</b>								
<i>Rockville</i>								
<b>Mega Campus: Alexandria Center® for Life Science – Shady Grove</b> <i>9601, 9603, 9605, 9704, 9708, 9712, 9714, 9800, 9804, 9808, 9900, and 9950 Medical Center Drive, 14920 and 15010 Broschart Road, 9920 Belward Campus Drive, and 9810 and 9820 Darnestown Road</i>	1,662,460	29,890	—	1,692,350	20	\$ 80,356	99.3%	99.3%
1330 Piccard Drive	131,508	—	—	131,508	1	4,210	100.0	100.0
1405 and 1450 <sup>(1)</sup> Research Boulevard	114,849	—	—	114,849	2	3,029	73.3	73.3
1500 and 1550 East Gude Drive	91,359	—	—	91,359	2	1,844	100.0	100.0
5 Research Place	63,852	—	—	63,852	1	3,073	100.0	100.0
5 Research Court	51,520	—	—	51,520	1	1,779	100.0	100.0
12301 Parklawn Drive	49,185	—	—	49,185	1	1,598	100.0	100.0
<i>Rockville</i>	2,164,733	29,890	—	2,194,623	28	95,889	98.0	98.0
<i>Gaithersburg</i>								
Alexandria Technology Center® – Gaithersburg I <i>9, 25, 35, 45, 50, and 55 West Watkins Mill Road and 910, 930, and 940 Clopper Road</i>	619,061	—	—	619,061	9	19,486	93.1	93.1
Alexandria Technology Center® – Gaithersburg II <i>700, 704, and 708 Quince Orchard Road and 19, 20, 21, and 22 Firstfield Road</i>	486,301	—	—	486,301	7	18,788	100.0	100.0
20400 Century Boulevard	81,006	—	—	81,006	1	3,016	100.0	100.0
401 Professional Drive	63,154	—	—	63,154	1	1,930	90.1	90.1
950 Wind River Lane	50,000	—	—	50,000	1	1,234	100.0	100.0
620 Professional Drive	27,950	—	—	27,950	1	1,207	100.0	100.0
<i>Gaithersburg</i>	1,327,472	—	—	1,327,472	20	45,661	96.3	96.3
<i>Beltsville</i>								
8000/9000/10000 Virginia Manor Road	191,884	—	—	191,884	1	2,974	97.7	97.7
101 West Dickman Street <sup>(1)</sup>	135,423	—	—	135,423	1	1,323	64.4	64.4
<i>Beltsville</i>	327,307	—	—	327,307	2	4,297	83.9	83.9
<b>Maryland</b>	<b>3,819,512</b>	<b>29,890</b>	<b>—</b>	<b>3,849,402</b>	<b>50</b>	<b>145,847</b>	<b>96.2</b>	<b>96.2</b>
<b>Research Triangle</b>								
<i>Research Triangle</i>								
<b>Mega Campus: Alexandria Center® for Life Science – Durham</b> <i>6, 8, 10, 12, 14, 40, 42, and 65 Moore Drive, 21, 25, 27, 29, and 31 Alexandria Way, 2400 Ellis Road, and 14 TW Alexander Drive</i>	2,152,397	—	—	2,152,397	15	53,168	97.5	97.5
<b>Mega Campus: Alexandria Center® for Advanced Technologies and AgTech – Research Triangle</b> <i>6, 8, 10, and 12 Davis Drive and 5 and 9 Laboratory Drive</i>	687,467	—	—	687,467	6	32,633	99.1	99.1
<b>Mega Campus: Alexandria Center® for Sustainable Technologies</b> <i>104, 108, 110, 112, and 114 TW Alexander Drive and 5 and 7 Triangle Drive</i>	364,493	—	—	364,493	7	\$ 12,117	93.0%	93.0%

Refer to “New Class A/A+ development and redevelopment properties: summary of pipeline” and “Definitions and reconciliations” in the Supplemental Information for additional details.

(1) We own a partial interest in this property through a real estate joint venture. Refer to “Joint venture financial information” in the Supplemental Information for additional details.

## Property Listing (continued)

September 30, 2024

(Dollars in thousands)

Market / Submarket / Address	RSF				Number of Properties	Annual Rental Revenue	Occupancy Percentage	
	Operating	Development	Redevelopment	Total			Operating	Operating and Redevelopment
<b>Research Triangle (continued)</b>								
<i>Research Triangle (continued)</i>								
Alexandria Technology Center® – Alston 100, 800, and 801 Capitola Drive	155,731	—	—	155,731	3	\$ 4,168	94.7%	94.7%
Alexandria Innovation Center® – Research Triangle 7010, 7020, and 7030 Kit Creek Road	136,692	—	—	136,692	3	4,260	100.0	100.0
2525 East NC Highway 54	82,996	—	—	82,996	1	3,651	100.0	100.0
407 Davis Drive	81,956	—	—	81,956	1	3,323	100.0	100.0
601 Keystone Park Drive	77,595	—	—	77,595	1	2,137	100.0	100.0
6101 Quadrangle Drive	31,600	—	—	31,600	1	861	100.0	100.0
<b>Research Triangle</b>	<b>3,770,927</b>	<b>—</b>	<b>—</b>	<b>3,770,927</b>	<b>38</b>	<b>116,318</b>	<b>97.5</b>	<b>97.5</b>
<b>New York City</b>								
<i>New York City</i>								
<b>Mega Campus: Alexandria Center® for Life Science – New York City</b> 430 and 450 East 29th Street	742,586	—	—	742,586	3	67,220	95.3	95.3
Alexandria Center® for Life Science – Long Island City 30-02 48th Avenue	179,100	—	—	179,100	1	5,219	42.8	42.8
<b>New York City</b>	<b>921,686</b>	<b>—</b>	<b>—</b>	<b>921,686</b>	<b>4</b>	<b>72,439</b>	<b>85.1</b>	<b>85.1</b>
<b>Texas</b>								
<i>Austin</i>								
<b>Mega Campus: Intersection Campus</b> 507 East Howard Lane, 13011 McCallen Pass, 13813 and 13929 Center Lake Drive, and 12535, 12545, 12555, and 12565 Riata Vista Circle	1,525,359	—	—	1,525,359	12	40,156	99.2	99.2
1001 Trinity Street and 1020 Red River Street	198,972	—	—	198,972	2	11,630	100.0	100.0
<i>Austin</i>	1,724,331	—	—	1,724,331	14	51,786	99.3	99.3
<i>Greater Houston</i>								
Alexandria Center® for Advanced Technologies at The Woodlands 8800 Technology Forest Place	120,828	—	73,298	194,126	1	3,172	41.5	25.8
<b>Texas</b>	<b>1,845,159</b>	<b>—</b>	<b>73,298</b>	<b>1,918,457</b>	<b>15</b>	<b>54,958</b>	<b>95.5</b>	<b>91.8</b>
<b>Canada</b>	887,737	—	139,311	1,027,048	11	19,790	95.5	82.6
<b>Non-cluster/other markets</b>	347,806	—	—	347,806	10	14,623	72.8	72.8
<b>North America, excluding properties held for sale</b>	<b>40,512,020</b>	<b>2,705,749</b>	<b>2,269,578</b>	<b>45,487,347</b>	<b>397</b>	<b>2,157,279</b>	<b>94.7%</b>	<b>89.7%</b>
<b>Properties held for sale</b>	1,261,387	—	—	1,261,387	9	26,796	66.7%	66.7%
<b>Total – North America</b>	<b>41,773,407</b>	<b>2,705,749</b>	<b>2,269,578</b>	<b>46,748,734</b>	<b>406</b>	<b>\$ 2,184,075</b>		

Refer to “New Class A/A+ development and redevelopment properties: summary of pipeline” and “Definitions and reconciliations” in the Supplemental Information for additional details.

# ALEXANDRIA'S FUTURE GROWTH IN ANNUAL NET OPERATING INCOME FROM DEVELOPMENT AND REDEVELOPMENT DELIVERIES

## \$510 MILLION<sup>(1)</sup>

Placed Into Service		Expected to Be Placed Into Service <sup>(2)</sup>	
YTD 3Q24	3Q24	4Q24-4Q25	1Q26-1Q28
<b>\$63M</b>	<b>\$21M</b>	<b>\$158M<sup>(3)</sup></b>	<b>\$352M</b>
945,118 RSF	316,691 RSF	Aggregating 5.5M RSF	
100% Leased		55% Leased/Negotiating	

Refer to "Net operating income" under "Definitions and reconciliations" in the Supplemental Information for additional details, including its reconciliation from the most directly comparable financial measure presented in accordance with GAAP.

- (1) Our share of incremental annual net operating income from development and redevelopment projects expected to be placed into service primarily commencing from 4Q24 through 1Q28 is projected to be \$407 million.
- (2) Represents expected incremental annual net operating income to be placed into service from deliveries of projects undergoing construction and one committed near-term project expected to commence construction in the next two years.
- (3) Includes (i) 1.0 million RSF that is expected to stabilize through 2025 and is 92% leased/negotiating and (ii) expected partial deliveries through 4Q25 from projects expected to stabilize in 2026 and beyond. Refer to the initial and stabilized occupancy years under "New Class A/A+ development and redevelopment properties: current projects" in the Supplemental Information for details.

## Investments in Real Estate

September 30, 2024

(Dollars in thousands)

### Investments in real estate

	Development and Redevelopment						
	Operating	Active and Near-Term Construction		Future Opportunities Subject to Market Conditions and Leasing		Subtotal	Total
		Under Construction 55% Leased/ Negotiating	Committed Near Term 51% Leased/ Negotiating <sup>(1)</sup>	Priority Anticipated	Future		
<b>Square footage</b>							
Operating	40,512,020	—	—	—	—	—	40,512,020
New Class A/A+ development and redevelopment properties	—	4,975,327	492,570	2,163,784	27,582,766	35,214,447	35,214,447
Future development and redevelopment square feet currently included in rental properties <sup>(2)</sup>	—	—	(159,884)	(258,596)	(2,957,559)	(3,376,039)	(3,376,039)
Total square footage, excluding properties held for sale	40,512,020	4,975,327	332,686	1,905,188	24,625,207	31,838,408	72,350,428
Properties held for sale	1,261,387	—	—	—	—	—	1,261,387
Total square footage	<u>41,773,407</u>	<u>4,975,327</u>	<u>332,686</u>	<u>1,905,188</u>	<u>24,625,207</u>	<u>31,838,408</u>	<u>73,611,815</u> <sup>(3)</sup>
<b>Investments in real estate</b>							
Gross book value as of September 30, 2024 <sup>(4)</sup>	<u>\$ 29,235,994</u>	<u>\$ 4,335,573</u>	<u>\$ 69,521</u>	<u>\$ 578,694</u>	<u>\$ 4,356,637</u>	<u>\$ 9,340,425</u>	<u>\$ 38,576,419</u>

(1) Represents one committed near-term project expected to commence construction during the next two years after September 30, 2024.

(2) Refer to "Investments in real estate" under "Definitions and reconciliations" in the Supplemental Information for additional details, including future development and redevelopment square feet currently included in rental properties.

(3) We expect to continue pursuing our strategy to fund a significant portion of our capital requirements for the year ending December 31, 2024 with dispositions primarily focused on sales of properties and land parcels not integral to our mega campus strategy.

(4) Balances exclude accumulated depreciation and our share of the cost basis associated with our properties held by our unconsolidated real estate joint ventures, which is classified as investments in unconsolidated real estate joint ventures in our consolidated balance sheets. Refer to "Investments in real estate" under "Definitions and reconciliations" in the Supplemental Information for additional details.

# New Class A/A+ Development and Redevelopment Properties: Recent Deliveries

September 30, 2024

## 500 North Beacon Street and 4 Kingsbury Avenue<sup>(1)</sup>

Greater Boston/  
Cambridge/Inner Suburbs  
138,537 RSF  
100% Occupancy



## 651 Gateway Boulevard

San Francisco Bay Area/  
South San Francisco  
67,017 RSF  
100% Occupancy



## 1150 Eastlake Avenue East

Seattle/Lake Union  
311,631 RSF  
100% Occupancy



## 9810 Darnestown Road

Maryland/Rockville  
195,435 RSF  
100% Occupancy



## 9820 Darnestown Road

Maryland/Rockville  
250,000 RSF  
100% Occupancy



## 9808 Medical Center Drive

Maryland/Rockville  
65,171 RSF  
100% Occupancy



(1) Image represents 500 North Beacon Street on The Arsenal on the Charles mega campus.

## New Class A/A+ Development and Redevelopment Properties: Recent Deliveries (continued)

September 30, 2024

(Dollars in thousands)



### Incremental Annual Net Operating Income Generated From YTD 3Q24 Deliveries Aggregated \$63 Million, Including \$21 Million in 3Q24

Property/Market/Submarket	3Q24 Delivery Date <sup>(1)</sup>	Our Ownership Interest	RSF Placed in Service					Occupancy Percentage <sup>(2)</sup>	Total Project		Unlevered Yields	
			Prior to 1/1/24	1Q24	2Q24	3Q24	Total		RSF	Investment	Initial Stabilized	Initial Stabilized (Cash Basis)
<b>Development projects</b>												
99 Coolidge Avenue/Greater Boston/Cambridge/Inner Suburbs	N/A	75.0%	43,568	72,846	—	—	116,414	100%	320,809	\$ 468,000	7.1%	7.0%
500 North Beacon Street and 4 Kingsbury Avenue/Greater Boston/Cambridge/Inner Suburbs	N/A	100%	—	100,624	37,913	—	138,537	100%	248,018	427,000	6.2	5.5
1150 Eastlake Avenue East/Seattle/Lake Union	7/16/24	100%	278,282	—	2,079	31,270	311,631	100%	311,631	442,000	6.6	6.7
9810 Darnestown Road/Maryland/Rockville	N/A	100%	—	—	195,435	—	195,435	100%	195,435	135,000	7.1	6.2
9820 Darnestown Road/Maryland/Rockville	8/21/24	100%	—	—	—	250,000	250,000	100%	250,000	177,000	8.7	5.6
9808 Medical Center Drive/Maryland/Rockville	7/25/24	100%	26,460	—	25,655	13,056	65,171	100%	95,061	115,000	5.4	5.4
<b>Redevelopment projects</b>												
651 Gateway Boulevard/San Francisco Bay Area/South San Francisco	7/12/24	50.0%	—	44,652	—	22,365	67,017	100%	326,706	487,000	5.0	5.1
Alexandria Center <sup>®</sup> for Advanced Technologies – Monte Villa Parkway/Seattle/Bothell	N/A	100%	65,086	115,598	—	—	180,684	100%	460,934	229,000	6.3	6.2
Canada	N/A	100%	44,862	9,725	23,900	—	78,487	100%	250,790	113,000	6.4	6.3
Weighted average/total	<u>8/11/24</u>		<u>458,258</u>	<u>343,445</u>	<u>284,982</u>	<u>316,691</u>	<u>1,403,376</u>		<u>2,459,384</u>	<u>\$ 2,593,000</u>	<u>6.4%</u>	<u>6.0%</u>











Refer to “New Class A/A+ development and redevelopment properties: current projects” in the Supplemental Information for details on the square footage in service and under construction, if applicable.

(1) Represents the average delivery date for deliveries that occurred during the current quarter, weighted by annual rental revenue.

(2) Occupancy relates to total operating RSF placed in service as of the most recent delivery.

# New Class A/A+ Development and Redevelopment Properties: Current Projects

September 30, 2024

99 Coolidge Avenue	500 North Beacon Street and 4 Kingsbury Avenue <sup>(1)</sup>	311 Arsenal Street	201 Brookline Avenue	401 Park Drive
Greater Boston/ Cambridge/Inner Suburbs 204,395 RSF 40% Leased/Negotiating	Greater Boston/ Cambridge/Inner Suburbs 109,481 RSF 92% Leased	Greater Boston/ Cambridge/Inner Suburbs 308,446 RSF 21% Leased	Greater Boston/Fenway 58,149 RSF 100% Leased	Greater Boston/Fenway 159,959 RSF 14% Leased
				
421 Park Drive	40, 50, and 60 Sylvan Road <sup>(2)</sup>	840 Winter Street	1450 Owens Street <sup>(3)</sup>	651 Gateway Boulevard
Greater Boston/Fenway 392,011 RSF 13% Leased	Greater Boston/Route 128 596,064 RSF 31% Leased	Greater Boston/Route 128 139,680 RSF 100% Leased	San Francisco Bay Area/ Mission Bay 212,796 RSF —% Leased/Negotiating	San Francisco Bay Area/ South San Francisco 259,689 RSF 25% Leased/Negotiating
				





(1) Image represents 500 North Beacon Street on The Arsenal on the Charles mega campus.

(2) Image represents 60 Sylvan Road on the Alexandria Center<sup>®</sup> for Life Science – Waltham mega campus. The project is expected to capture demand in our Route 128 submarket.

(3) Image represents a multi-tenant project expanding our existing Alexandria Center<sup>®</sup> for Science and Technology – Mission Bay mega campus, where our joint venture partner will fund 100% of the construction cost until it attains an ownership interest of 75%, after which it will contribute its respective share of additional capital. We are in negotiations with a biomedical institution for the sale of a 50% condominium interest in this property.

# New Class A/A+ Development and Redevelopment Properties: Current Projects (continued)

September 30, 2024

230 Harriet Tubman Way	10935, 10945, and 10955 Alexandria Way <sup>(1)</sup>	4135 Campus Point Court	4155 Campus Point Court
San Francisco Bay Area/ South San Francisco	San Diego/Torrey Pines	San Diego/ University Town Center	San Diego/ University Town Center
285,346 RSF	334,996 RSF	426,927 RSF	171,102 RSF
100% Leased	100% Leased	100% Leased	100% Leased
			

10075 Barnes Canyon Road	701 Dexter Avenue North <sup>(2)</sup>	Alexandria Center <sup>®</sup> for Advanced Technologies – Monte Villa Parkway <sup>(3)</sup>	9808 Medical Center Drive	8800 Technology Forest Place
San Diego/Sorrento Mesa	Seattle/Lake Union	Seattle/Bothell	Maryland/Rockville	Texas/Greater Houston
253,079 RSF	227,577 RSF	34,306 RSF	29,890 RSF	73,298 RSF
70% Leased	—% Leased/Negotiating	98% Leased	76% Leased/Negotiating	41% Leased
				

(1) Image represents 10955 Alexandria Way on the One Alexandria Square mega campus.

(2) We initially started this project due to strong demand from neighboring tenants but strategically paused in the first quarter of 2023. We have resumed construction activities at this project in order to maintain our existing entitlements and permits. We have interest from various prospective tenants, including from multinational pharmaceutical companies. Beyond this purpose-built life science asset, there is no competitive supply expected to be delivered in 2025 or 2026 in our Lake Union submarket. As of September 30, 2024, we are 95.3% occupied in our Lake Union submarket.

(3) Image represents 3755 Monte Villa Parkway.



## New Class A/A+ Development and Redevelopment Properties: Current Projects (continued)

September 30, 2024

Property/Market/Submarket	Dev/Redev	Square Footage			Percentage		Occupancy <sup>(1)</sup>	
		In Service	CIP	Total	Leased	Leased/ Negotiating	Initial	Stabilized
<b>Under construction</b>								
2024 and 2025 stabilization								
500 North Beacon Street and 4 Kingsbury Avenue/Greater Boston/ Cambridge/Inner Suburbs	Dev	138,537	109,481	248,018	92%	92%	1Q24	2025
201 Brookline Avenue/Greater Boston/Fenway	Dev	451,967	58,149	510,116	100	100	3Q22	4Q24
840 Winter Street/Greater Boston/Route 128	Redev	28,534	139,680	168,214	100	100	4Q24	2025
230 Harriet Tubman Way/San Francisco Bay Area/South San Francisco	Dev	—	285,346	285,346	100	100	1Q25	1Q25
4155 Campus Point Court/San Diego/University Town Center	Dev	—	171,102	171,102	100	100	4Q24	4Q24
Alexandria Center® for Advanced Technologies – Monte Villa Parkway/Seattle/Bothell	Redev	426,628	34,306	460,934	98	98	1Q23	4Q24
9808 Medical Center Drive/Maryland/Rockville	Dev	65,171	29,890	95,061	69	76	3Q23	4Q24
8800 Technology Forest Place/Texas/Greater Houston	Redev	50,094	73,298	123,392	41	41	2Q23	2025
Canada	Redev	111,479	139,311	250,790	73	73	3Q23	2025
		<u>1,272,410</u>	<u>1,040,563</u>	<u>2,312,973</u>	<u>91</u>	<u>92</u>		
2026 and beyond stabilization								
One Hampshire Street/Greater Boston/Cambridge	Redev	—	104,956	104,956	—	—	2027	2028
311 Arsenal Street/Greater Boston/Cambridge/Inner Suburbs	Redev	82,216 <sup>(2)</sup>	308,446	390,662	21	21	2027	2027
99 Coolidge Avenue/Greater Boston/Cambridge/Inner Suburbs	Dev	116,414	204,395	320,809	40	40	4Q23	2026
401 Park Drive/Greater Boston/Fenway	Redev	—	159,959	159,959	14	14	2024	2026
421 Park Drive/Greater Boston/Fenway	Dev	—	392,011	392,011	13	13	2026	2027
40, 50, and 60 Sylvan Road/Greater Boston/Route 128	Redev	—	596,064	596,064	31	31	2025	2027
Other/Greater Boston	Redev	—	453,869	453,869	—	— <sup>(3)</sup>	2027	2027
1450 Owens Street/San Francisco Bay Area/Mission Bay	Dev	—	212,796	212,796	—	— <sup>(4)</sup>	2025	2026
651 Gateway Boulevard/San Francisco Bay Area/South San Francisco	Redev	67,017	259,689	326,706	21	25	1Q24	2026
10935, 10945, and 10955 Alexandria Way/San Diego/Torrey Pines	Dev	—	334,996	334,996	100	100	4Q24	2026
4135 Campus Point Court/San Diego/University Town Center	Dev	—	426,927	426,927	100	100	2026	2026
10075 Barnes Canyon Road/San Diego/Sorrento Mesa	Dev	—	253,079	253,079	70	70	2025	2026
701 Dexter Avenue North/Seattle/Lake Union	Dev	—	227,577	227,577	—	— <sup>(5)</sup>	2026	2027
		<u>265,647</u>	<u>3,934,764</u>	<u>4,200,411</u>	<u>35</u>	<u>36</u>		
		<u>1,538,057</u>	<u>4,975,327</u>	<u>6,513,384</u>	<u>55</u>	<u>55</u>		
<b>Committed near-term project expected to commence construction in the next two years</b>								
4165 Campus Point Court/San Diego/University Town Center	Dev	—	492,570	492,570	—	51		
Total		<u>1,538,057</u>	<u>5,467,897</u>	<u>7,005,954</u>	<u>51%</u>	<u>55%</u>		

(1) Initial occupancy dates are subject to leasing and/or market conditions. Stabilized occupancy may vary depending on single tenancy versus multi-tenancy. Multi-tenant projects may increase in occupancy over a period of time.

(2) We expect to redevelop an additional 25,312 RSF of space occupied as of September 30, 2024 into laboratory space upon expiration of the existing leases through 1H25. Refer to "Investments in real estate" under "Definitions and reconciliations" in the Supplemental Information for additional details.

(3) Represents a project focused on demand from our existing tenants in our adjacent properties/campuses that will address demand from other non-Alexandria properties/campuses.

(4) Represents a multi-tenant project expanding our existing mega campus, where our joint venture partner will fund 100% of the construction cost until it attains an ownership interest of 75%, after which it will contribute its respective share of additional capital. We are in negotiations with a biomedical institution for the sale of a 50% condominium interest in this property.

(5) We initially started this project due to strong demand from neighboring tenants but strategically paused in the first quarter of 2023. We have resumed construction activities at this project in order to maintain our existing entitlements and permits. We have interest from various prospective tenants, including from multinational pharmaceutical companies. Beyond this purpose-built life science asset, there is no competitive supply expected to be delivered in 2025 or 2026 in our Lake Union submarket. As of September 30, 2024, we are 95.3% occupied in our Lake Union submarket.

# New Class A/A+ Development and Redevelopment Properties: Current Projects (continued)

September 30, 2024

(Dollars in thousands)



Property/Market/Submarket	Our Ownership Interest	At 100%				Unlevered Yields	
		In Service	CIP	Cost to Complete	Total at Completion	Initial Stabilized	Initial Stabilized (Cash Basis)
<b>Under construction</b>							
2024 and 2025 stabilization							
500 North Beacon Street and 4 Kingsbury Avenue/Greater Boston/Cambridge/Inner Suburbs	100%	\$ 284,645	\$ 115,506	\$ 26,849	\$ 427,000	6.2%	5.5%
201 Brookline Avenue/Greater Boston/Fenway	99.0%	665,877	91,610	17,513	775,000	7.2%	6.5%
840 Winter Street/Greater Boston/Route 128	100%	13,653	187,366	35,981	237,000	7.6%	6.5%
230 Harriet Tubman Way/San Francisco Bay Area/South San Francisco	47.9%	—	350,231	159,769	510,000	7.4%	6.4%
4155 Campus Point Court/San Diego/University Town Center	55.0%	—	140,300	43,700	184,000	8.0%	6.4%
Alexandria Center® for Advanced Technologies – Monte Villa Parkway/Seattle/Bothell	100%	193,823	11,977	23,200	229,000	6.3%	6.2%
9808 Medical Center Drive/Maryland/Rockville	100%	79,320	33,018	2,662	115,000	5.4%	5.4%
8800 Technology Forest Place/Texas/Greater Houston	100%	57,315	46,202	8,483	112,000	6.3%	6.0%
Canada	100%	50,219	50,044	12,737	113,000	6.4%	6.3%
		<u>1,344,852</u>	<u>1,026,254</u>				
2026 and beyond stabilization <sup>(1)</sup>							
One Hampshire Street/Greater Boston/Cambridge	100%	—	161,328			TBD	
311 Arsenal Street/Greater Boston/Cambridge/Inner Suburbs	100%	60,625	233,563				
99 Coolidge Avenue/Greater Boston/Cambridge/Inner Suburbs	75.0%	136,527	192,432	139,041	468,000	7.1%	7.0%
401 Park Drive/Greater Boston/Fenway	100%	—	194,421				
421 Park Drive/Greater Boston/Fenway	99.7%	—	422,278				
40, 50, and 60 Sylvan Road/Greater Boston/Route 128	100%	—	437,356			TBD	
Other/Greater Boston	100%	—	148,804				
1450 Owens Street/San Francisco Bay Area/Mission Bay	25.4%	—	234,665				
651 Gateway Boulevard/San Francisco Bay Area/South San Francisco	50.0%	87,357	256,413	143,230	487,000	5.0%	5.1%
10935, 10945, and 10955 Alexandria Way/San Diego/Torrey Pines	100%	—	359,926	143,074	503,000	6.2%	5.8%
4135 Campus Point Court/San Diego/University Town Center	55.0%	—	292,913	231,087	524,000	6.6%	6.2%
10075 Barnes Canyon Road/San Diego/Sorrento Mesa	50.0%	—	168,582	152,418	321,000	5.5%	5.7%
701 Dexter Avenue North/Seattle/Lake Union	100%	—	206,638			TBD	
		<u>284,509</u>	<u>3,309,319</u>				
		<u>1,629,361</u>	<u>4,335,573</u>				
<b>Committed near-term project expected to commence construction in the next two years</b>							
4165 Campus Point Court/San Diego/University Town Center	55.0%	—	69,521			TBD	
Total		<u>\$ 1,629,361</u>	<u>\$ 4,405,094</u>	<u>\$ 3,780,000</u> <sup>(2)</sup>	<u>\$ 9,820,000</u> <sup>(2)</sup>		
Our share of investment <sup>(2)(3)</sup>		\$ 1,550,000	\$ 3,570,000	\$ 3,030,000	\$ 8,150,000		

Refer to "Initial stabilized yield (unlevered)" under "Definitions and reconciliations" in the Supplemental Information for additional details.

(1) We expect to provide total estimated costs and related yields for each project with estimated stabilization in 2026 and beyond over the next several quarters.

(2) Represents dollar amount rounded to the nearest \$10 million and includes preliminary estimated amounts for projects listed as TBD.

(3) Represents our share of investment based on our ownership percentage upon completion of development or redevelopment projects.

## New Class A/A+ Development and Redevelopment Properties: Summary of Pipeline

September 30, 2024

(Dollars in thousands)



### 69% of Our Total Development and Redevelopment Pipeline RSF Is Within Our Mega Campuses

Market Property/Submarket	Our Ownership Interest	Book Value	Square Footage				Total <sup>(1)</sup>
			Development and Redevelopment				
			Active and Near-Term Construction		Future Opportunities Subject to Market Conditions and Leasing		
			Under Construction	Committed Near Term	Priority Anticipated	Future	
Greater Boston							
<b>Mega Campus: Alexandria Center<sup>®</sup> at One Kendall Square/Cambridge</b> <i>One Hampshire Street</i>	100%	\$ 161,328	104,956	—	—	—	104,956
<b>Mega Campus: The Arsenal on the Charles/Cambridge/Inner Suburbs</b> <i>311 Arsenal Street, 500 North Beacon Street, and 4 Kingsbury Avenue</i>	100%	360,538	417,927	—	25,312	34,157	477,396
<b>Mega Campus: 480 Arsenal Way and 446, 458, 500, and 550 Arsenal Street, and 99 Coolidge Avenue/Cambridge/Inner Suburbs</b> <i>446, 458, 500, and 550 Arsenal Street, and 99 Coolidge Avenue</i>	(2)	279,763	204,395	—	—	902,000	1,106,395
<b>Mega Campus: Alexandria Center<sup>®</sup> for Life Science – Fenway/Fenway</b> <i>201 Brookline Avenue and 401 and 421 Park Drive</i>	(3)	708,309	610,119	—	—	—	610,119
<b>Mega Campus: Alexandria Center<sup>®</sup> for Life Science – Waltham/Route 128</b> <i>40, 50, and 60 Sylvan Road, 35 Gatehouse Drive, and 840 Winter Street</i>	100%	687,346	735,744	—	—	515,000	1,250,744
<b>Mega Campus: Alexandria Center<sup>®</sup> at Kendall Square/Cambridge</b> <i>100 Edwin H. Land Boulevard</i>	100%	126,688	—	—	—	216,455	216,455
<b>Mega Campus: Alexandria Technology Square<sup>®</sup>/Cambridge</b>	100%	7,881	—	—	—	100,000	100,000
<b>Mega Campus: 285, 299, 307, and 345 Dorchester Avenue/Seaport Innovation District</b> <i>10 Necco Street/Seaport Innovation District</i>	60.0%	286,300	—	—	—	1,040,000	1,040,000
<b>Mega Campus: One Moderna Way/Route 128</b> <i>215 Presidential Way/Route 128</i>	100%	26,052	—	—	—	1,085,000	1,085,000
Other development and redevelopment projects	(4)	310,381	453,869	—	—	1,323,541	1,777,410
		<b>\$ 3,066,513</b>	<b>2,527,010</b>	<b>—</b>	<b>25,312</b>	<b>5,503,153</b>	<b>8,055,475</b>

Refer to "Mega campus" under "Definitions and reconciliations" in the Supplemental Information for additional details.

- (1) Represents total square footage upon completion of development or redevelopment of one or more new Class A/A+ properties. Square footage presented includes the RSF of buildings currently in operation at properties that also have future development or redevelopment opportunities. Upon expiration of existing in-place leases, we have the intent to demolish or redevelop the existing property subject to market conditions and leasing. Refer to "Investments in real estate" under "Definitions and reconciliations" in the Supplemental Information for additional details, including development and redevelopment square feet currently included in rental properties.
- (2) We have a 75.0% interest in 99 Coolidge Avenue aggregating 204,395 RSF and 100.0% interest in 446, 458, 500, and 550 Arsenal Street aggregating 902,000 RSF.
- (3) We have a 99.0% interest in 201 Brookline Avenue aggregating 58,149 RSF, a 100% interest in 401 Park Drive aggregating 159,959 RSF, and a 99.7% interest in 421 Park Drive aggregating 392,011 RSF.
- (4) Includes a property in which we own a partial interest through a real estate joint venture.

## New Class A/A+ Development and Redevelopment Properties: Summary of Pipeline (continued)

September 30, 2024

(Dollars in thousands)



Market Property/Submarket	Our Ownership Interest	Book Value	Square Footage				Total <sup>(1)</sup>
			Development and Redevelopment		Future Opportunities Subject to Market Conditions and Leasing		
			Active and Near-Term Construction	Committed Near Term	Priority Anticipated	Future	
San Francisco Bay Area							
<b>Mega Campus: Alexandria Center® for Science and Technology – Mission Bay/Mission Bay</b> <i>1450 Owens Street</i>	25.4%	\$ 234,665	212,796	—	—	—	212,796
Alexandria Center® for Life Science – Millbrae/South San Francisco <i>230 Harriet Tubman Way, 201 and 231 Adrian Road, and 6 and 30 Rollins Road</i>	47.9%	510,162	285,346	—	198,188	150,213	633,747
<b>Mega Campus: Alexandria Technology Center® – Gateway/ South San Francisco</b> <i>651 Gateway Boulevard</i>	50.0%	283,002	259,689	—	—	291,000	550,689
<b>Mega Campus: Alexandria Center® for Advanced Technologies – Tanforan/South San Francisco</b> <i>1122, 1150, and 1178 El Camino Real</i>	100%	397,159	—	—	150,000	1,780,000	1,930,000
<b>Mega Campus: Alexandria Center® for Advanced Technologies – South San Francisco/South San Francisco</b> <i>211<sup>(2)</sup> and 269 East Grand Avenue</i>	100%	6,655	—	—	107,250	90,000	197,250
<b>Mega Campus: Alexandria Center® for Life Science – San Carlos/Greater Stanford</b> <i>960 Industrial Road, 987 and 1075 Commercial Street, and 888 Bransten Road</i>	100%	446,892	—	—	105,000	1,392,830	1,497,830
3825 and 3875 Fabian Way/Greater Stanford	100%	154,174	—	—	—	478,000	478,000
2100, 2200, 2300, and 2400 Geng Road/Greater Stanford	100%	36,509	—	—	—	240,000	240,000
901 California Avenue/Greater Stanford	100%	19,770	—	—	—	56,924	56,924
<b>Mega Campus: 88 Bluxome Street/SoMa</b>	100%	392,785	—	—	—	1,070,925	1,070,925
Other development and redevelopment projects	100%	—	—	—	—	25,000	25,000
		<b>\$ 2,481,773</b>	<b>757,831</b>	<b>—</b>	<b>560,438</b>	<b>5,574,892</b>	<b>6,893,161</b>

Refer to "Mega campus" under "Definitions and reconciliations" in the Supplemental Information for additional details.

- (1) Represents total square footage upon completion of development or redevelopment of one or more new Class A/A+ properties. Square footage presented includes the RSF of buildings currently in operation at properties that also have future development or redevelopment opportunities. Upon expiration of existing in-place leases, we have the intent to demolish or redevelop the existing property subject to market conditions and leasing. Refer to "Investments in real estate" under "Definitions and reconciliations" in the Supplemental Information for additional details, including development and redevelopment square feet currently included in rental properties.
- (2) Includes a property in which we own a partial interest through a real estate joint venture. Refer to "Joint venture financial information" in the Supplemental Information for additional details.

## New Class A/A+ Development and Redevelopment Properties: Summary of Pipeline (continued)

September 30, 2024

(Dollars in thousands)



Market Property/Submarket	Our Ownership Interest	Book Value	Square Footage				Total <sup>(1)</sup>
			Development and Redevelopment		Future Opportunities Subject to Market Conditions and Leasing		
			Active and Near-Term Construction	Committed Near Term	Priority Anticipated	Future	
			Under Construction	Committed Near Term			
San Diego							
<b>Mega Campus: One Alexandria Square/Torrey Pines</b> <i>10935, 10945, and 10955 Alexandria Way and 10975 and 10995 Torreyana Road</i>	100%	\$ 417,621	334,996	—	—	125,280	460,276
<b>Mega Campus: Campus Point by Alexandria/University Town Center</b> <i>10010<sup>(2)</sup>, 10140<sup>(2)</sup>, and 10260 Campus Point Drive and 4135, 4155, 4161, 4165, and 4275<sup>(2)</sup> Campus Point Court</i>	55.0%	671,303	598,029	492,570	—	650,000	1,740,599
<b>Mega Campus: SD Tech by Alexandria/Sorrento Mesa</b> <i>9805 Scranton Road and 10065 and 10075 Barnes Canyon Road</i>	50.0%	317,172	253,079	—	250,000	243,845	746,924
11255 and 11355 North Torrey Pines Road/Torrey Pines	100%	150,187	—	—	153,000	62,000	215,000
Costa Verde by Alexandria/University Town Center <i>8410-8750 Genesee Avenue and 4282 Esplanade Court</i>	100%	138,107	—	—	—	537,000	537,000
<b>Mega Campus: 5200 Illumina Way/University Town Center</b> <i>9363, 9373, and 9393 Towne Centre Drive</i>	51.0%	17,441	—	—	—	451,832	451,832
ARE Towne Centre/University Town Center <i>9625 Towne Centre Drive/University Town Center</i>	100%	19,869	—	—	—	230,000	230,000
<b>Mega Campus: Sequence District by Alexandria/Sorrento Mesa</b> <i>6260, 6290, 6310, 6340, 6350, and 6450 Sequence Drive</i>	100%	46,323	—	—	—	1,798,915	1,798,915
Scripps Science Park by Alexandria/Sorrento Mesa <i>10048, 10219, 10256, and 10260 Meanley Drive and 10277 Scripps Ranch Boulevard</i>	100%	120,941	—	—	—	598,349	598,349
Pacific Technology Park/Sorrento Mesa <i>9444 Waples Street</i>	50.0%	23,857	—	—	—	149,000	149,000
4025, 4031, 4045, and 4075 Sorrento Valley Boulevard/Sorrento Valley	100%	43,641	—	—	—	247,000	247,000
Other development and redevelopment projects	<sup>(3)</sup>	75,716	—	—	—	475,000	475,000
		<b>\$ 2,043,015</b>	<b>1,186,104</b>	<b>492,570</b>	<b>403,000</b>	<b>5,668,221</b>	<b>7,749,895</b>

Refer to "Mega campus" under "Definitions and reconciliations" in the Supplemental Information for additional details.

(1) Represents total square footage upon completion of development or redevelopment of one or more new Class A/A+ properties. Square footage presented includes the RSF of buildings currently in operation at properties that also have future development or redevelopment opportunities. Upon expiration of existing in-place leases, we have the intent to demolish or redevelop the existing property subject to market conditions and leasing. Refer to "Investments in real estate" under "Definitions and reconciliations" in the Supplemental Information for additional details, including development and redevelopment square feet currently included in rental properties.

(2) We have a 100% interest in this property.

(3) Includes a property in which we own a partial interest through a real estate joint venture.

## New Class A/A+ Development and Redevelopment Properties: Summary of Pipeline (continued)

September 30, 2024

(Dollars in thousands)



Market Property/Submarket	Our Ownership Interest	Book Value	Square Footage				Total <sup>(1)</sup>
			Development and Redevelopment		Future Opportunities Subject to Market Conditions and Leasing		
			Active and Near-Term Construction	Committed Near Term	Priority Anticipated	Future	
Seattle							
<b>Mega Campus: Alexandria Center® for Life Science – South Lake Union/Lake Union</b> <i>601 and 701 Dexter Avenue North and 800 Mercer Street</i>	(2)	\$ 485,628	227,577	—	869,000	188,400	1,284,977
Alexandria Center® for Advanced Technologies – Monte Villa Parkway/Bothell <i>3301 Monte Villa Parkway</i>	100%	11,977	34,306	—	—	—	34,306
830 and 1010 4th Avenue South/SoDo	100%	59,262	—	—	—	597,313	597,313
410 West Harrison Street/Elliott Bay	100%	—	—	—	—	91,000	91,000
<b>Mega Campus: Alexandria Center® for Advanced Technologies – Canyon Park/Bothell</b> <i>21660 20th Avenue Southeast</i>	100%	17,439	—	—	—	230,000	230,000
Other development and redevelopment projects	100%	142,484	—	—	—	706,087	706,087
		<b>716,790</b>	<b>261,883</b>	<b>—</b>	<b>869,000</b>	<b>1,812,800</b>	<b>2,943,683</b>
Maryland							
<b>Mega Campus: Alexandria Center® for Life Science – Shady Grove/Rockville</b> <i>9808 Medical Center Drive and 9830 Darnestown Road</i>	100%	54,904	29,890	—	—	296,000	325,890
		<b>54,904</b>	<b>29,890</b>	<b>—</b>	<b>—</b>	<b>296,000</b>	<b>325,890</b>
Research Triangle							
<b>Mega Campus: Alexandria Center® for Advanced Technologies and AgTech – Research Triangle/Research Triangle</b> <i>4 and 12 Davis Drive</i>	100%	103,653	—	—	180,000	990,000	1,170,000
<b>Mega Campus: Alexandria Center® for Life Science – Durham/Research Triangle</b> <i>41 Moore Drive</i>	100%	176,524	—	—	—	2,210,000	2,210,000
<b>Mega Campus: Alexandria Center® for NextGen Medicines/Research Triangle</b> <i>3029 East Cornwallis Road</i>	100%	\$ 108,035	—	—	—	1,055,000	1,055,000

Refer to “Mega campus” under “Definitions and reconciliations” in the Supplemental Information for additional details.

- (1) Represents total square footage upon completion of development or redevelopment of one or more new Class A/A+ properties. Square footage presented includes the RSF of buildings currently in operation at properties that also have future development or redevelopment opportunities. Upon expiration of existing in-place leases, we have the intent to demolish or redevelop the existing property subject to market conditions and leasing. Refer to “Investments in real estate” under “Definitions and reconciliations” in the Supplemental Information for additional details, including development and redevelopment square feet currently included in rental properties.
- (2) We have a 100% interest in 601 and 701 Dexter Avenue North aggregating 415,977 RSF and a 60% interest in the priority anticipated development project at 800 Mercer Street aggregating 869,000 RSF.

## New Class A/A+ Development and Redevelopment Properties: Summary of Pipeline (continued)

September 30, 2024

(Dollars in thousands)



Market Property/Submarket	Our Ownership Interest	Book Value	Square Footage				Total <sup>(1)</sup>
			Development and Redevelopment		Future Opportunities Subject to Market Conditions and Leasing		
			Active and Near-Term Construction		Priority Anticipated	Future	
			Under Construction	Committed Near Term			
Research Triangle (continued)							
<b>Mega Campus: Alexandria Center<sup>®</sup> for Sustainable Technologies/Research Triangle</b>	100%	\$ 53,326	—	—	—	750,000	750,000
<i>120 TW Alexander Drive, 2752 East NC Highway 54, and 10 South Triangle Drive</i>							
100 Capitola Drive/Research Triangle	100%	—	—	—	—	65,965	65,965
Other development and redevelopment projects	100%	4,185	—	—	—	76,262	76,262
		<b>445,723</b>	<b>—</b>	<b>—</b>	<b>180,000</b>	<b>5,147,227</b>	<b>5,327,227</b>
New York City							
<b>Mega Campus: Alexandria Center<sup>®</sup> for Life Science – New York City/New York City</b>	100%	165,061	—	—	—	550,000 <sup>(2)</sup>	550,000
		<b>165,061</b>	<b>—</b>	<b>—</b>	<b>—</b>	<b>550,000</b>	<b>550,000</b>
Texas							
Alexandria Center <sup>®</sup> for Advanced Technologies at The Woodlands/ Greater Houston	100%	49,034	73,298	—	—	116,405	189,703
<i>8800 Technology Forest Place</i>							
1001 Trinity Street and 1020 Red River Street/Austin	100%	10,177	—	—	126,034	123,976	250,010
Other development and redevelopment projects	100%	136,980	—	—	—	1,694,000	1,694,000
		<b>196,191</b>	<b>73,298</b>	<b>—</b>	<b>126,034</b>	<b>1,934,381</b>	<b>2,133,713</b>
Canada							
Other development and redevelopment projects	100%	50,044	139,311	—	—	371,743	511,054
	100%	120,411	—	—	—	724,349	724,349
Total pipeline as of September 30, 2024		<b>\$ 9,340,425<sup>(3)</sup></b>	<b>4,975,327</b>	<b>492,570</b>	<b>2,163,784</b>	<b>27,582,766</b>	<b>35,214,447</b>

Refer to "Mega campus" under "Definitions and reconciliations" in the Supplemental Information for additional details.

- (1) Total square footage includes 3,376,039 RSF of buildings currently in operation that we expect to demolish or redevelop and commence future construction subject to market conditions and leasing. Refer to "Investments in real estate" under "Definitions and reconciliations" in the Supplemental Information for additional details, including development and redevelopment square feet currently included in rental properties.
- (2) During the three months ended September 30, 2024, we filed a lawsuit against the New York City Health + Hospitals Corporation and the New York City Economic Development Corporation for fraud and breach of contract concerning our option to ground lease a land parcel to develop a future world-class life science building within the Alexandria Center<sup>®</sup> for Life Science – New York City campus. Refer to our Form 8-K filed with the Securities and Exchange Commission on August 7, 2024 for additional details.
- (3) Includes \$4.3 billion of projects that are currently under construction and are 55% leased/negotiating. We also expect to commence construction on one committed near-term project aggregating \$69.5 million, which is 51% leased/negotiating, in the next two years after September 30, 2024.

# Construction Spending and Capitalization of Interest

September 30, 2024

(Dollars in thousands)



## Construction spending

Construction of Class A/A+ properties:

	Nine Months Ended September 30, 2024	Projected Midpoint for the Year Ending December 31, 2024
Active construction projects		
Under construction and committed near-term projects <sup>(1)</sup> and projects expected to commence active construction in 4Q24 <sup>(2)</sup>	\$ 1,448,736	\$ 1,913,000
Future pipeline pre-construction		
Primarily mega campus expansion pre-construction work (entitlement, design, and site work)	349,082	652,000
Revenue- and non-revenue-enhancing capital expenditures	158,229	250,000
Construction spend (before contributions from noncontrolling interests or tenants)	1,956,047	2,815,000
Contributions from noncontrolling interests (consolidated real estate joint ventures)	(272,072)	(430,000) <sup>(3)</sup>
Tenant-funded and -built landlord improvements	(107,562)	(135,000)
Total construction spending	<u>\$ 1,576,413</u>	<u>\$ 2,250,000</u>
2024 guidance range for construction spending		<u>\$1,950,000 – \$2,550,000</u>

## Projected capital contributions from partners in consolidated real estate joint ventures to fund construction

Timing	Amount <sup>(3)</sup>
4Q24	\$ 157,928
2025 through 2027	885,526
Total	<u>\$ 1,043,454</u>

## Average real estate basis used for capitalization of interest

### Key Categories of Real Estate Basis Capitalized During YTD 3Q24

	Average Real Estate Basis Capitalized During YTD 3Q24	Percentage of Total Average Real Estate Basis Capitalized
Construction of Class A/A+ properties:		
Active construction projects		
Under construction and committed near-term projects <sup>(1)</sup>	\$ 2,849,742	35%
Future pipeline pre-construction		
Priority anticipated projects	559,815 <sup>(4)</sup>	7
Primarily mega campus expansion pre-construction work (entitlement, design, and site work)	3,692,497 <sup>(4)</sup>	45
Smaller redevelopments and repositioning capital projects	1,025,019	13
	<u>\$ 8,127,073</u>	<u>100%</u>

Refer to "Definitions and reconciliations" in the Supplemental Information for additional details.

- (1) Includes projects under construction aggregating 5.0 million RSF and one committed near-term project aggregating 492,570 RSF expected to commence construction during the next two years after September 30, 2024, which are 55% leased/negotiating and expected to generate \$510 million in annual incremental net operating income primarily commencing from 4Q24 through 1Q28.
- (2) Includes certain priority anticipated development and redevelopment projects expected to commence active construction in 4Q24, subject to market conditions and leasing. Refer to "Investments in real estate" under "Definitions and reconciliations" in the Supplemental Information for additional details, including development and redevelopment square feet currently included in rental properties.
- (3) Represents contractual capital commitments from existing consolidated real estate joint venture partners to fund construction.
- (4) Average real estate basis capitalized related to our future pipeline pre-construction activities includes 31% from four key active and future development and redevelopment projects on mega campuses. Refer to the next page for additional details.



## Key Active and Future Development and Redevelopment Projects on Mega Campuses

### Alexandria Center® for Advanced Technologies – Tanforan

San Francisco Bay Area/South San Francisco  
1.9 million future SF



### Alexandria Center® for Life Science – San Carlos

San Francisco Bay Area/Greater Stanford  
1.5 million future SF



### Campus Point by Alexandria

San Diego/University Town Center  
1.7 million active and future SF



### Alexandria Center® for Life Science – South Lake Union

Seattle/Lake Union  
1.3 million active and future SF



Refer to "Mega campus" under "Definitions and reconciliations" in the Supplemental Information for additional details.

## Joint Venture Financial Information

September 30, 2024

### Consolidated Real Estate Joint Ventures

Property	Market	Submarket	Noncontrolling Interest Share <sup>(1)</sup>	Operating RSF at 100%
50 and 60 Binney Street	Greater Boston	Cambridge/Inner Suburbs	66.0%	532,395
75/125 Binney Street	Greater Boston	Cambridge/Inner Suburbs	60.0%	388,270
100 and 225 Binney Street and 300 Third Street	Greater Boston	Cambridge/Inner Suburbs	70.0%	870,106
99 Coolidge Avenue	Greater Boston	Cambridge/Inner Suburbs	25.0%	116,414 <sup>(2)</sup>
15 Necco Street	Greater Boston	Seaport Innovation District	43.3%	345,996
285, 299, 307, and 345 Dorchester Avenue	Greater Boston	Seaport Innovation District	40.0%	— <sup>(2)</sup>
Alexandria Center <sup>®</sup> for Science and Technology – Mission Bay <sup>(3)</sup>	San Francisco Bay Area	Mission Bay	75.0%	996,181
1450 Owens Street	San Francisco Bay Area	Mission Bay	74.6% <sup>(4)</sup>	— <sup>(2)</sup>
601, 611, 651 <sup>(2)</sup> , 681, 685, and 701 Gateway Boulevard	San Francisco Bay Area	South San Francisco	50.0%	853,794
751 Gateway Boulevard	San Francisco Bay Area	South San Francisco	49.0%	230,592
211 <sup>(2)</sup> and 213 East Grand Avenue	San Francisco Bay Area	South San Francisco	70.0%	300,930
500 Forbes Boulevard	San Francisco Bay Area	South San Francisco	90.0%	155,685
Alexandria Center <sup>®</sup> for Life Science – Millbrae	San Francisco Bay Area	South San Francisco	52.1%	— <sup>(2)</sup>
3215 Merryfield Row	San Diego	Torrey Pines	70.0%	170,523
Campus Point by Alexandria <sup>(5)</sup>	San Diego	University Town Center	45.0%	1,342,164
5200 Illumina Way	San Diego	University Town Center	49.0%	792,687
9625 Towne Centre Drive	San Diego	University Town Center	70.0%	163,648
SD Tech by Alexandria <sup>(6)</sup>	San Diego	Sorrento Mesa	50.0%	798,858
Pacific Technology Park	San Diego	Sorrento Mesa	50.0%	544,352
Summers Ridge Science Park <sup>(7)</sup>	San Diego	Sorrento Mesa	70.0%	316,531
1201 and 1208 Eastlake Avenue East	Seattle	Lake Union	70.0%	207,774
199 East Blaine Street	Seattle	Lake Union	70.0%	115,084
400 Dexter Avenue North	Seattle	Lake Union	70.0%	290,754
800 Mercer Street	Seattle	Lake Union	40.0%	— <sup>(2)</sup>

### Unconsolidated Real Estate Joint Ventures

Property	Market	Submarket	Our Ownership Share <sup>(8)</sup>	Operating RSF at 100%
1655 and 1725 Third Street	San Francisco Bay Area	Mission Bay	10.0%	586,208
1401/1413 Research Boulevard	Maryland	Rockville	65.0% <sup>(9)</sup>	— <sup>(10)</sup>
1450 Research Boulevard	Maryland	Rockville	73.2% <sup>(9)</sup>	42,679
101 West Dickman Street	Maryland	Beltsville	58.2% <sup>(9)</sup>	135,423

Refer to "Joint venture financial information" under "Definitions and reconciliations" in the Supplemental Information for additional details.

- (1) In addition to the consolidated real estate joint ventures listed, various joint venture partners hold insignificant noncontrolling interests in three other real estate joint ventures in North America.
- (2) Represents a property currently under construction or in our development and redevelopment pipeline. Refer to the sections under "New Class A/A+ development and redevelopment properties" in the Supplemental Information for additional details.
- (3) Includes 409 and 499 Illinois Street, 1500 and 1700 Owens Street, and 455 Mission Bay Boulevard South.
- (4) The noncontrolling interest share of our joint venture partner is anticipated to increase to 75% as our partner contributes equity to fund the construction of the project over time.
- (5) Includes 10210, 10260, 10290, and 10300 Campus Point Drive and 4110, 4135, 4155, 4161, 4165, 4224, and 4242 Campus Point Court.
- (6) Includes 9605, 9645, 9675, 9725, 9735, 9805, 9808, 9855, and 9868 Scranton Road and 10055, 10065, and 10075 Barnes Canyon Road.
- (7) Includes 9965, 9975, 9985, and 9995 Summers Ridge Road.
- (8) In addition to the unconsolidated real estate joint ventures listed, we hold an interest in one insignificant unconsolidated real estate joint venture in North America.
- (9) Represents a joint venture with a local real estate operator in which our joint venture partner manages the day-to-day activities that significantly affect the economic performance of the joint venture.
- (10) Represents a joint venture with a distinguished retail real estate developer for a retail shopping center aggregating 84,837 RSF.

## Joint Venture Financial Information (continued)

September 30, 2024

(In thousands)



### As of September 30, 2024

	Noncontrolling Interest Share of Consolidated Real Estate JVs	Our Share of Unconsolidated Real Estate JVs
Investments in real estate	\$ 4,211,942	\$ 125,029
Cash, cash equivalents, and restricted cash	164,756	3,346
Other assets	425,293	13,411
Secured notes payable	(36,103)	(95,603)
Other liabilities	(280,069)	(6,013)
Redeemable noncontrolling interests	(16,510)	—
	\$ 4,469,309	\$ 40,170

	Noncontrolling Interest Share of Consolidated Real Estate JVs		Our Share of Unconsolidated Real Estate JVs	
	September 30, 2024		September 30, 2024	
	Three Months Ended	Nine Months Ended	Three Months Ended	Nine Months Ended
Total revenues	\$ 113,479	\$ 335,786	\$ 3,141	\$ 9,472
Rental operations	(34,697)	(97,009)	(965)	(2,984)
	78,782	238,777	2,176	6,488
General and administrative	(586)	(2,268)	(10)	(80)
Interest	(284)	(753)	(952)	(2,807)
Depreciation and amortization of real estate assets	(32,457)	(94,725)	(1,075)	(3,177)
Fixed returns allocated to redeemable noncontrolling interests <sup>(1)</sup>	201	603	—	—
	\$ 45,656	\$ 141,634	\$ 139	\$ 424
Straight-line rent and below-market lease revenue	\$ 54	\$ 15,588	\$ 213	\$ 743
Funds from operations <sup>(2)</sup>	\$ 78,113	\$ 236,359	\$ 1,214	\$ 3,601

Refer to "Joint venture financial information" under "Definitions and reconciliations" in the Supplemental Information for additional details.

- (1) Represents an allocation of joint venture earnings to redeemable noncontrolling interests primarily in one property in our South San Francisco submarket. These redeemable noncontrolling interests earn a fixed return on their investment rather than participate in the operating results of the property.
- (2) Refer to "Funds from operations and funds from operations per share" in the Earnings Press Release and "Definitions and reconciliations" in the Supplemental Information for additional details.

## Investments

September 30, 2024


(Dollars in thousands)

We hold investments in publicly traded companies and privately held entities primarily involved in the life science industry. The tables below summarize components of our investment income (loss) and non-real estate investments. Refer to “Investments” under “Definitions and reconciliations” in the Supplemental Information for additional details.


	September 30, 2024		Year Ended
	Three Months Ended	Nine Months Ended	December 31, 2023
Realized gains	\$ 12,632 <sup>(1)</sup>	\$ 47,336 <sup>(1)</sup>	\$ 6,078 <sup>(2)</sup>
Unrealized gains (losses)	2,610 <sup>(3)</sup>	(32,470) <sup>(4)</sup>	(201,475) <sup>(5)</sup>
Investment income (loss)	\$ 15,242	\$ 14,866	\$ (195,397)

Investments	September 30, 2024				December 31, 2023
	Cost	Unrealized Gains	Unrealized Losses	Carrying Amount	Carrying Amount
Publicly traded companies	\$ 187,085	\$ 50,933	\$ (85,592)	\$ 152,426	\$ 159,566
Entities that report NAV	527,042	160,608	(31,225)	656,425	671,532
Entities that do not report NAV:					
Entities with observable price changes	93,982	72,862	(1,337)	165,507	174,268
Entities without observable price changes	407,261	—	—	407,261	368,654
Investments accounted for under the equity method	N/A	N/A	N/A	137,708	75,498
September 30, 2024	\$ 1,215,370 <sup>(6)</sup>	\$ 284,403	\$ (118,154)	\$ 1,519,327	\$ 1,449,518
December 31, 2023	\$ 1,177,072	\$ 320,445	\$ (123,497)	\$ 1,449,518	

### Public/Private Mix (Cost)



### Tenant/Non-Tenant Mix (Cost)



- (1) Consists of realized gains of \$23.0 million and \$85.2 million, partially offset by impairment charges of \$10.3 million and \$37.8 million during the three and nine months ended September 30, 2024, respectively.
- (2) Consists of realized gains of \$80.6 million, offset by impairment charges of \$74.6 million during the year ended December 31, 2023.
- (3) Consists of unrealized gains of \$25.8 million primarily resulting from the increase in fair values of our investments in publicly traded entities and \$23.2 million resulting from accounting reclassifications of unrealized gains recognized in prior periods into realized gains upon our realization of investments during the three months ended September 30, 2024.
- (4) Primarily relates to the accounting reclassifications of unrealized gains recognized in prior periods into realized gains upon our realization of investments during the nine months ended September 30, 2024.
- (5) Consists of unrealized losses of \$111.6 million primarily resulting from the decrease in the fair value of our investments in privately held entities that report NAV and \$89.9 million resulting from accounting reclassifications of unrealized gains recognized in prior periods into realized gains upon our sales of investments during the year ended December 31, 2023.
- (6) Represents 2.8% of gross assets as of September 30, 2024. Refer to “Gross assets” under “Definitions and reconciliations” in the Supplemental Information for additional details.

### Liquidity


# \$5.4B

(in millions)


Availability under our unsecured senior line of credit, net of amounts outstanding under our commercial paper program	\$	4,545
Outstanding forward equity sales agreements <sup>(1)</sup>		28
Cash, cash equivalents, and restricted cash		580
Availability under our secured construction loan		51
Investments in publicly traded companies		152
Liquidity as of September 30, 2024	\$	<u>5,356</u>

### Minimal Outstanding Borrowings and Significant Availability on Unsecured Senior Line of Credit


(in millions)



### Net Debt and Preferred Stock to Adjusted EBITDA<sup>(2)</sup>



### Fixed-Charge Coverage Ratio<sup>(2)</sup>



Refer to "Definitions and reconciliations" in the Supplemental Information for additional details.

(1) Represents expected net proceeds from the future settlement of 230 thousand shares of common stock under forward equity sales agreements after underwriter discounts.


(2) Quarter annualized.

# Summary of Debt

September 30, 2024

(In millions)

## Weighted-Average Remaining Term of 12.6 Years



- (1) In September 2024, we amended and restated our unsecured senior line of credit to, among other changes, extend the maturity date from January 22, 2028 to January 22, 2030, including extension options that we control. We anticipate further extending the maturity date in the next two to three years. Additionally, we have two unsecured senior notes payable maturing six months apart on July 1, 2030 and December 15, 2030.
- (2) Refer to footnotes 2 through 4 on the next page under "Fixed-rate and variable-rate debt" for additional details.

## Summary of Debt (continued)

September 30, 2024

(Dollars in thousands)

### Fixed-rate and variable-rate debt

	Fixed-Rate Debt	Variable-Rate Debt	Total	Percentage	Weighted-Average	
					Interest Rate <sup>(1)</sup>	Remaining Term (in years)
Secured notes payable	\$ 587	\$ 144,413	\$ 145,000	1.1%	8.39%	2.2
Unsecured senior notes payable	12,092,012	—	12,092,012	95.3	3.81	13.0
Unsecured senior line of credit <sup>(2)</sup> and commercial paper program <sup>(3)</sup>	—	454,589	454,589	3.6	5.05	5.3 <sup>(4)</sup>
Total/weighted average	<u>\$ 12,092,599</u>	<u>\$ 599,002</u>	<u>\$ 12,691,601</u>	<u>100.0%</u>	<u>3.91%</u>	<u>12.6<sup>(4)</sup></u>
Percentage of total debt	95.3%	4.7%	100.0%			

- (1) Represents the weighted-average interest rate as of the end of the applicable period, including expense/income related to the amortization of loan fees, amortization of debt premiums (discounts), and other bank fees.
- (2) As of September 30, 2024, we had no outstanding balance on our unsecured senior line of credit.
- (3) The commercial paper program provides us with the ability to issue up to \$2.5 billion of commercial paper notes that bear interest at short-term fixed rates and can generally be issued with a maturity of 30 days or less and with a maximum maturity of 397 days from the date of issuance. Borrowings under the program are used to fund short-term capital needs and are backed by our unsecured senior line of credit. In the event we are unable to issue commercial paper notes or refinance outstanding borrowings under terms equal to or more favorable than those under our unsecured senior line of credit, we expect to borrow under the unsecured senior line of credit at SOFR+0.855%. As of September 30, 2024, we had \$454.6 million of commercial paper notes outstanding with a weighted-average interest rate of 5.05%.
- (4) We calculate the weighted-average remaining term of our commercial paper notes by using the maturity date of our unsecured senior line of credit. Using the maturity date of our outstanding commercial paper notes, the consolidated weighted-average maturity of our debt is 12.5 years. The commercial paper notes sold during the nine months ended September 30, 2024 were issued at a weighted-average yield to maturity of 5.55% and had a weighted-average maturity term of 17 days.

	Average Debt Outstanding		Weighted-Average Interest Rate	
	September 30, 2024		September 30, 2024	
	Three Months Ended	Nine Months Ended	Three Months Ended	Nine Months Ended
Long-term fixed-rate debt	\$ 12,171,936	\$ 12,008,857	3.79%	3.76%
Short-term variable-rate unsecured senior line of credit and commercial paper program debt	545,848	471,070	5.48	5.57
Blended average interest rate	12,717,784	12,479,927	3.86	3.83
Loan fee amortization and annual facility fee related to unsecured senior line of credit	N/A	N/A	0.12	0.13
Total/weighted average	<u>\$ 12,717,784</u>	<u>\$ 12,479,927</u>	<u>3.98%</u>	<u>3.96%</u>

## Summary of Debt (continued)

September 30, 2024

(Dollars in thousands)

### Debt covenants

Debt Covenant Ratios <sup>(1)</sup>	Unsecured Senior Notes Payable		Unsecured Senior Line of Credit	
	Requirement	September 30, 2024	Requirement	September 30, 2024
Total Debt to Total Assets	≤ 60%	30%	≤ 60.0%	29.7%
Secured Debt to Total Assets	≤ 40%	0.3%	≤ 45.0%	0.3%
Consolidated EBITDA to Interest Expense	≥ 1.5x	12.3x	≥ 1.50x	3.95x
Unencumbered Total Asset Value to Unsecured Debt	≥ 150%	326%	N/A	N/A
Unsecured Interest Coverage Ratio	N/A	N/A	≥ 1.75x	12.55x

(1) All covenant ratio titles utilize terms as defined in the respective debt and credit agreements. The calculation of consolidated EBITDA is based on the definitions contained in our loan agreements and is not directly comparable to the computation of EBITDA as described in Exchange Act Release No. 47226.

### Unconsolidated real estate joint ventures' debt

Unconsolidated Joint Venture	Maturity Date	Stated Rate	Interest Rate <sup>(1)</sup>	At 100%		Our Share
				Aggregate Commitment	Debt Balance <sup>(2)</sup>	
1401/1413 Research Boulevard <sup>(3)</sup>	12/23/24	2.70%	3.31%	\$ 28,500	\$ 28,461	65.0%
1655 and 1725 Third Street <sup>(4)</sup>	3/10/25	4.50%	4.57%	600,000	599,823	10.0%
101 West Dickman Street	11/10/26	SOFR+1.95% <sup>(5)</sup>	7.39%	26,750	18,565	58.2%
1450 Research Boulevard	12/10/26	SOFR+1.95% <sup>(5)</sup>	7.45%	13,000	8,616	73.2%
				<u>\$ 668,250</u>	<u>\$ 655,465</u>	

(1) Includes interest expense and amortization of loan fees.

(2) Represents outstanding principal, net of unamortized deferred financing costs, as of September 30, 2024.

(3) We have executed a purchase and sale agreement to sell the unconsolidated real estate joint venture and expect to complete the sale in 4Q24. Our net proceeds from the sale are expected to exceed our share of the outstanding debt balance and the carrying amount of this investment as of September 30, 2024.

(4) The unconsolidated real estate joint venture is in the process of working with prospective lenders to refinance this debt. In the event that all or a portion of the debt cannot be refinanced, we may consider contributing additional equity into this unconsolidated real estate joint venture. As of September 30, 2024, our investment in this unconsolidated real estate joint venture was \$10.8 million.

(5) This loan is subject to a fixed SOFR floor of 0.75%.



## Summary of Debt (continued)

September 30, 2024

(Dollars in thousands)



Debt	Stated Rate	Interest Rate <sup>(1)</sup>	Maturity Date <sup>(2)</sup>	Principal Payments Remaining for the Periods Ending December 31,						Unamortized (Deferred Financing Cost), (Discount)/ Premium	Total	
				2024	2025	2026	2027	2028	Thereafter			
Secured notes payable												
Greater Boston <sup>(3)</sup>	SOFR+2.70%	8.40%	11/19/26	\$ —	\$ —	\$ 144,527	\$ —	\$ —	\$ —	\$ 144,527	\$ (114)	\$ 144,413
San Francisco Bay Area	6.50%	6.50	7/1/36	—	34	36	38	41	438	587	—	587
Secured debt weighted-average interest rate/ subtotal		8.39		—	34	144,563	38	41	438	145,114	(114)	145,000
Unsecured senior line of credit and commercial paper program <sup>(4)</sup>	(4)	5.05	1/22/30 <sup>(4)</sup>	—	—	—	—	—	455,000	455,000	(411)	454,589
Unsecured senior notes payable	3.45%	3.62	4/30/25	—	600,000	—	—	—	—	600,000	(518)	599,482
Unsecured senior notes payable	4.30%	4.50	1/15/26	—	—	300,000	—	—	—	300,000	(655)	299,345
Unsecured senior notes payable	3.80%	3.96	4/15/26	—	—	350,000	—	—	—	350,000	(776)	349,224
Unsecured senior notes payable	3.95%	4.13	1/15/27	—	—	—	350,000	—	—	350,000	(1,194)	348,806
Unsecured senior notes payable	3.95%	4.07	1/15/28	—	—	—	—	425,000	—	425,000	(1,418)	423,582
Unsecured senior notes payable	4.50%	4.60	7/30/29	—	—	—	—	—	300,000	300,000	(1,082)	298,918
Unsecured senior notes payable	2.75%	2.87	12/15/29	—	—	—	—	—	400,000	400,000	(2,167)	397,833
Unsecured senior notes payable	4.70%	4.81	7/1/30	—	—	—	—	—	450,000	450,000	(2,149)	447,851
Unsecured senior notes payable	4.90%	5.05	12/15/30	—	—	—	—	—	700,000	700,000	(4,926)	695,074
Unsecured senior notes payable	3.375%	3.48	8/15/31	—	—	—	—	—	750,000	750,000	(4,509)	745,491
Unsecured senior notes payable	2.00%	2.12	5/18/32	—	—	—	—	—	900,000	900,000	(7,198)	892,802
Unsecured senior notes payable	1.875%	1.97	2/1/33	—	—	—	—	—	1,000,000	1,000,000	(7,326)	992,674
Unsecured senior notes payable	2.95%	3.07	3/15/34	—	—	—	—	—	800,000	800,000	(7,425)	792,575
Unsecured senior notes payable	4.75%	4.88	4/15/35	—	—	—	—	—	500,000	500,000	(5,071)	494,929
Unsecured senior notes payable	5.25%	5.38	5/15/36	—	—	—	—	—	400,000	400,000	(4,195)	395,805
Unsecured senior notes payable	4.85%	4.93	4/15/49	—	—	—	—	—	300,000	300,000	(2,900)	297,100
Unsecured senior notes payable	4.00%	3.91	2/1/50	—	—	—	—	—	700,000	700,000	10,017	710,017
Unsecured senior notes payable	3.00%	3.08	5/18/51	—	—	—	—	—	850,000	850,000	(11,322)	838,678
Unsecured senior notes payable	3.55%	3.63	3/15/52	—	—	—	—	—	1,000,000	1,000,000	(13,782)	986,218
Unsecured senior notes payable	5.15%	5.26	4/15/53	—	—	—	—	—	500,000	500,000	(7,647)	492,353
Unsecured senior notes payable	5.625%	5.71	5/15/54	—	—	—	—	—	600,000	600,000	(6,745)	593,255
Unsecured debt weighted-average interest rate/ subtotal		3.85		—	600,000	650,000	350,000	425,000	10,605,000	12,630,000	(83,399)	12,546,601
Weighted-average interest rate/total		3.91%		\$ —	\$ 600,034	\$ 794,563	\$ 350,038	\$ 425,041	\$ 10,605,438	\$ 12,775,114	\$ (83,513)	\$ 12,691,601
Balloon payments				\$ —	\$ 600,000	\$ 794,527	\$ 350,000	\$ 425,000	\$ 10,605,068	\$ 12,774,595	\$ —	\$ 12,774,595
Principal amortization				—	34	36	38	41	370	519	(83,513)	(82,994)
Total debt				\$ —	\$ 600,034	\$ 794,563	\$ 350,038	\$ 425,041	\$ 10,605,438	\$ 12,775,114	\$ (83,513)	\$ 12,691,601
Fixed-rate debt				\$ —	\$ 600,034	\$ 650,036	\$ 350,038	\$ 425,041	\$ 10,150,438	\$ 12,175,587	\$ (82,988)	\$ 12,092,599
Variable-rate debt				—	—	144,527	—	—	455,000	599,527	(525)	599,002
Total debt				\$ —	\$ 600,034	\$ 794,563	\$ 350,038	\$ 425,041	\$ 10,605,438	\$ 12,775,114	\$ (83,513)	\$ 12,691,601
Weighted-average stated rate on maturing debt				N/A	3.45%	3.79%	3.95%	3.95%	3.74%			

(1) Represents the weighted-average interest rate as of the end of the applicable period, including amortization of loan fees, amortization of debt premiums (discounts), and other bank fees.

(2) Reflects any extension options that we control.

(3) Represents a secured construction loan held by our consolidated real estate joint venture for 99 Coolidge Avenue, of which we own a 75.0% interest. As of September 30, 2024, this joint venture has \$50.8 million available under existing lender commitments. The interest rate shall be reduced from SOFR+2.70% to SOFR+2.10% over time upon the completion of certain leasing, construction, and financial covenant milestones.

(4) Refer to footnotes 2 through 4 under "Fixed-rate and variable-rate debt" in "Summary of Debt" for additional details. In September 2024, we amended and restated our unsecured senior line of credit to, among other changes, extend the maturity date from January 22, 2028 to January 22, 2030, including extension options that we control.

## Definitions and Reconciliations

September 30, 2024

This section contains additional details for sections throughout the Supplemental Information and the accompanying Earnings Press Release, as well as explanations and reconciliations of certain non-GAAP financial measures and the reasons why we use these supplemental measures of performance and believe they provide useful information to investors. Additional detail can be found in our most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q, as well as other documents filed with or furnished to the SEC from time to time.

### Adjusted EBITDA and Adjusted EBITDA margin

The following table reconciles net income (loss), the most directly comparable financial measure calculated and presented in accordance with GAAP, to Adjusted EBITDA and calculates the Adjusted EBITDA margin:

<i>(Dollars in thousands)</i>	Three Months Ended				
	9/30/24	6/30/24	3/31/24	12/31/23	9/30/23
Net income (loss)	\$ 213,603	\$ 94,049	\$ 219,176	\$ (42,658)	\$ 68,254
Interest expense	43,550	45,789	40,840	31,967	11,411
Income taxes	1,877	1,182	1,764	1,322	1,183
Depreciation and amortization	293,998	290,720	287,554	285,246	269,370
Stock compensation expense	15,525	14,507	17,125	34,592	16,288
Gain on sales of real estate	(27,114)	—	(392)	(62,227)	—
Unrealized (gains) losses on non-real estate investments	(2,610)	64,238	(29,158)	(19,479)	77,202
Impairment of real estate	5,741	30,763	—	271,890	20,649
Impairment of non-real estate investments	10,338	12,788	14,698	23,094	28,503
Adjusted EBITDA	<u>\$ 554,908</u>	<u>\$ 554,036</u>	<u>\$ 551,607</u>	<u>\$ 523,747</u>	<u>\$ 492,860</u>
Total revenues	\$ 791,607	\$ 766,734	\$ 769,108	\$ 757,216	\$ 713,788
Adjusted EBITDA margin	70%	72%	72%	69%	69%

We use Adjusted EBITDA as a supplemental performance measure of our operations, for financial and operational decision-making, and as a supplemental means of evaluating period-to-period comparisons on a consistent basis. Adjusted EBITDA is calculated as earnings before interest, taxes, depreciation, and amortization (“EBITDA”), excluding stock compensation expense, gains or losses on early extinguishment of debt, gains or losses on sales of real estate, impairments of real estate, and significant termination fees. Adjusted EBITDA also excludes unrealized gains or losses and significant realized gains or losses and impairments that result from our non-real estate investments. These non-real estate investment amounts are classified in our consolidated statements of operations outside of total revenues.

We believe Adjusted EBITDA provides investors with relevant and useful information as it allows investors to evaluate the operating performance of our business activities without having to account for differences recognized because of investing and financing decisions related to our real estate and non-real estate investments, our capital structure, capital market transactions, and variances resulting from the volatility of market conditions outside of our control. For example, we exclude gains or losses on the early extinguishment of debt to allow investors to measure our performance independent of our indebtedness and capital structure. We believe that adjusting for the effects of impairments and gains or losses on sales of real estate, significant impairments and realized gains or losses on non-real estate investments, and significant termination fees allows investors to evaluate performance from period to period on a consistent basis without having to account for differences recognized because of investing and financing decisions related to our real estate and non-real estate investments or other corporate activities that may not be representative of the operating performance of our properties.

In addition, we believe that excluding charges related to stock compensation and unrealized gains or losses facilitates for investors a comparison of our business activities across periods without the volatility resulting from market forces outside of our control. Adjusted EBITDA has limitations as a measure of our performance. Adjusted EBITDA does not reflect our historical expenditures or future requirements for capital expenditures or contractual commitments. While Adjusted EBITDA is a relevant measure of performance, it does not represent net income (loss) or cash flows from operations calculated and presented in accordance with GAAP, and it should not be considered as an alternative to those indicators in evaluating performance or liquidity.

In order to calculate the Adjusted EBITDA margin, we divide Adjusted EBITDA by total revenues as presented in our consolidated statements of operations. We believe that this supplemental performance measure provides investors with additional useful information regarding the profitability of our operating activities.

We are not able to forecast fourth quarter net income without unreasonable effort and therefore do not provide a reconciliation for Adjusted EBITDA on a forward-looking basis. This is due to the inherent difficulty of forecasting the timing and/or amount of items that depend on market conditions outside of our control, including the timing of dispositions, capital events, and financing decisions, as well as quarterly components such as gain on sales of real estate, unrealized gains or losses on non-real estate investments, impairment of real estate, and impairment of non-real estate investments. Our attempt to predict these amounts may produce significant but inaccurate estimates, which would be potentially misleading for our investors.

### Annual rental revenue

Annual rental revenue represents the annualized fixed base rental obligations, calculated in accordance with GAAP, including the amortization of deferred revenue related to tenant-funded and -built landlord improvements, for leases in effect as of the end of the period, related to our operating RSF. Annual rental revenue is presented using 100% of the annual rental revenue from our consolidated properties and our share of annual rental revenue for our unconsolidated real estate joint ventures. Annual rental revenue per RSF is computed by dividing annual rental revenue by the sum of 100% of the RSF of our consolidated properties and our share of the RSF of properties held in unconsolidated real estate joint ventures. As of September 30, 2024, approximately 93% of our leases (on an annual rental revenue basis) were triple net leases, which require tenants to pay substantially all real estate taxes, insurance, utilities, repairs and maintenance, common area expenses, and other operating expenses (including increases thereto) in addition to base rent. Annual rental revenue excludes these operating expenses recovered from our tenants. Amounts recovered from our tenants related to these operating expenses, along with base rent, are classified in income from rentals in our consolidated statements of operations.

### Capitalization rates

Capitalization rates are calculated based on net operating income and net operating income (cash basis) annualized, excluding lease termination fees, on stabilized operating assets for the quarter preceding the date on which the property is sold, or near-term prospective net operating income.

### Capitalized interest

We capitalize interest cost as a cost of a project during periods for which activities necessary to develop, redevelop, or reposition a project for its intended use are ongoing, provided that expenditures for the asset have been made and interest cost has been incurred. Activities necessary to develop, redevelop, or reposition a project include pre-construction activities such as entitlements, permitting, design, site work, and other activities preceding commencement of construction of aboveground building improvements. The advancement of pre-construction efforts is focused on reducing the time required to deliver projects to prospective tenants. These critical activities add significant value for future ground-up development and are required for the vertical construction of buildings. If we cease activities necessary to prepare a project for its intended use, interest costs related to such project are expensed as incurred.

### Cash interest

Cash interest is equal to interest expense calculated in accordance with GAAP plus capitalized interest, less amortization of loan fees and debt premiums (discounts). Refer to the definition of fixed-charge coverage ratio for a reconciliation of interest expense, the most directly comparable financial measure calculated and presented in accordance with GAAP, to cash interest.

### Class A/A+ properties and AAA locations

Class A/A+ properties are properties clustered in AAA locations that provide innovative tenants with highly dynamic and collaborative environments that enhance their ability to successfully recruit and retain world-class talent and inspire productivity, efficiency, creativity, and success. Class A/A+ properties generally command higher annual rental rates than other classes of similar properties. AAA locations are in close proximity to concentrations of specialized skills, knowledge, institutions, and related businesses.

### Development, redevelopment, and pre-construction

A key component of our business model is our disciplined allocation of capital to the development and redevelopment of new Class A/A+ properties, and property enhancements identified during the underwriting of certain acquired properties, located in collaborative mega campuses in AAA life science innovation clusters. These projects are generally focused on providing high-quality, generic, and reusable spaces that meet the real estate requirements of a wide range of tenants. Upon completion, each development and redevelopment project is expected to generate increases in rental income, net operating income, and cash flows. Our development and redevelopment projects are generally in locations that are highly desirable to high-quality entities, which we believe results in higher occupancy levels, longer lease terms, higher rental income, higher returns, and greater long-term asset value.

Development projects generally consist of the ground-up development of generic and reusable laboratory facilities. Redevelopment projects consist of the permanent change in use of acquired office, warehouse, or shell space into laboratory space. We generally will not commence new development projects for aboveground construction of new Class A/A+ laboratory space without first securing significant pre-leasing for such space, except when there is solid market demand for high-quality Class A/A+ properties.

Priority anticipated projects are those most likely to commence future ground-up development or first-time conversion from non-laboratory space to laboratory space prior to our other future projects, pending market conditions and leasing negotiations.

Pre-construction activities include entitlements, permitting, design, site work, and other activities preceding commencement of construction of aboveground building improvements. The advancement of pre-construction efforts is focused on reducing the time required to deliver projects to prospective tenants. These critical activities add significant value for future ground-up development and are required for the vertical construction of buildings. Ultimately, these projects will provide high-quality facilities and are expected to generate significant revenue and cash flows.

Development, redevelopment, and pre-construction spending also includes the following costs: (i) amounts to bring certain acquired properties up to market standard and/or other costs identified during the acquisition process (generally within two years of acquisition) and (ii) permanent conversion of space for highly flexible, move-in-ready laboratory space to foster the growth of promising early- and growth-stage life science companies.

Revenue-enhancing and repositioning capital expenditures represent spending to reposition or significantly change the use of a property, including through improvement in the asset quality from Class B to Class A/A+.

Non-revenue-enhancing capital expenditures represent costs required to maintain the current revenues of a stabilized property, including the associated costs for renewed and re-leased space.

### Dividend payout ratio (common stock)

Dividend payout ratio (common stock) is the ratio of the absolute dollar amount of dividends on our common stock (shares of common stock outstanding on the respective record dates multiplied by the related dividend per share) to funds from operations attributable to Alexandria's common stockholders – diluted, as adjusted.

## Definitions and Reconciliations (continued)

September 30, 2024

### Dividend yield

Dividend yield for the quarter represents the annualized quarter dividend divided by the closing common stock price at the end of the quarter.

### Fixed-charge coverage ratio

Fixed-charge coverage ratio is a non-GAAP financial measure representing the ratio of Adjusted EBITDA to cash interest and fixed charges. We believe that this ratio is useful to investors as a supplemental measure of our ability to satisfy fixed financing obligations and preferred stock dividends. Cash interest is equal to interest expense calculated in accordance with GAAP plus capitalized interest, less amortization of loan fees and debt premiums (discounts).

The following table reconciles interest expense, the most directly comparable financial measure calculated and presented in accordance with GAAP, to cash interest and computes fixed-charge coverage ratio:

	Three Months Ended				
	9/30/24	6/30/24	3/31/24	12/31/23	9/30/23
<i>(Dollars in thousands)</i>					
Adjusted EBITDA	\$ 554,908	\$ 554,036	\$ 551,607	\$ 523,747	\$ 492,860
Interest expense	\$ 43,550	\$ 45,789	\$ 40,840	\$ 31,967	\$ 11,411
Capitalized interest	86,496	81,039	81,840	89,115	96,119
Amortization of loan fees	(4,222)	(4,146)	(4,142)	(4,059)	(4,059)
Amortization of debt discounts	(330)	(328)	(318)	(309)	(306)
Cash interest and fixed charges	\$ 125,494	\$ 122,354	\$ 118,220	\$ 116,714	\$ 103,165
Fixed-charge coverage ratio:					
– quarter annualized	4.4x	4.5x	4.7x	4.5x	4.8x
– trailing 12 months	4.5x	4.6x	4.7x	4.7x	4.9x

We are not able to forecast fourth quarter net income without unreasonable effort and therefore do not provide a reconciliation for fixed-charge coverage ratio on a forward-looking basis. This is due to the inherent difficulty of forecasting the timing and/or amount of items that depend on market conditions outside of our control, including the timing of dispositions, capital events, and financing decisions, as well as quarterly components such as gain on sales of real estate, unrealized gains or losses on non-real estate investments, impairment of real estate, and impairment of non-real estate investments. Our attempt to predict these amounts may produce significant but inaccurate estimates, which would be potentially misleading for our investors.

### Funds from operations and funds from operations, as adjusted, attributable to Alexandria's common stockholders

GAAP-basis accounting for real estate assets utilizes historical cost accounting and assumes that real estate values diminish over time. In an effort to overcome the difference between real estate values and historical cost accounting for real estate assets, the Nareit Board of Governors established funds from operations as an improved measurement tool. Since its introduction, funds from operations has become a widely used non-GAAP financial measure among equity REITs. We believe that funds from operations is helpful to investors as an additional measure of the performance of an equity REIT. Moreover, we believe that funds from operations, as adjusted, allows investors to compare our performance to the performance of other real estate companies on a consistent basis, without having to account for differences recognized because of real estate acquisition and disposition decisions, financing decisions, capital structure, capital market transactions, variances resulting from the volatility of market conditions outside of our control, or other corporate activities that may not be representative of the operating performance of our properties.

The 2018 White Paper published by the Nareit Board of Governors (the "Nareit White Paper") defines funds from operations as net income (computed in accordance with GAAP), excluding gains or losses on sales of real estate, and impairments of real estate, plus depreciation and amortization of operating real estate assets, and after adjustments for our share of consolidated and unconsolidated partnerships and real estate joint ventures. Impairments represent the write-down of assets when fair value over the recoverability period is less than the carrying value due to changes in general market conditions and do not necessarily reflect the operating performance of the properties during the corresponding period.

We compute funds from operations, as adjusted, as funds from operations calculated in accordance with the Nareit White Paper, excluding significant gains, losses, and impairments realized on non-real estate investments, unrealized gains or losses on non-real estate investments, impairment of real estate primarily consisting of pre-acquisition costs incurred in connection with acquisitions we decided to no longer pursue, gains or losses on early extinguishment of debt, significant termination fees, acceleration of stock compensation expense due to the resignations of executive officers, deal costs, the income tax effect related to such items, and the amount of such items that is allocable to our unvested restricted stock awards. We compute the amount that is allocable to our unvested restricted stock awards using the two-class method. Under the two-class method, we allocate net income (after amounts attributable to noncontrolling interests) to common stockholders and to unvested restricted stock awards by applying the respective weighted-average shares outstanding during each quarter-to-date and year-to-date period. This may result in a difference of the summation of the quarter-to-date and year-to-date amounts. Neither funds from operations nor funds from operations, as adjusted, should be considered as alternatives to net income (determined in accordance with GAAP) as indications of financial performance, or to cash flows from operating activities (determined in accordance with GAAP) as measures of liquidity, nor are they indicative of the availability of funds for our cash needs, including our ability to make distributions.

## Definitions and Reconciliations (continued)

September 30, 2024

### Funds from operations and funds from operations, as adjusted, attributable to Alexandria's common stockholders (continued)

The following table reconciles net income to funds from operations for the share of consolidated real estate joint ventures attributable to noncontrolling interests and our share of unconsolidated real estate joint ventures:

	Noncontrolling Interest Share of Consolidated Real Estate JVs		Our Share of Unconsolidated Real Estate JVs	
	September 30, 2024		September 30, 2024	
	Three Months Ended	Nine Months Ended	Three Months Ended	Nine Months Ended
(In thousands)				
Net income	\$ 45,656	\$ 141,634	\$ 139	\$ 424
Depreciation and amortization of real estate assets	32,457	94,725	1,075	3,177
Funds from operations	\$ 78,113	\$ 236,359	\$ 1,214	\$ 3,601

### Gross assets

Gross assets are calculated as total assets plus accumulated depreciation:

(In thousands)	9/30/24	6/30/24	3/31/24	12/31/23	9/30/23
Total assets	\$ 38,488,128	\$ 37,847,865	\$ 37,699,046	\$ 36,771,402	\$ 36,783,293
Accumulated depreciation	5,624,642	5,457,414	5,216,857	4,985,019	4,856,436
Gross assets	\$ 44,112,770	\$ 43,305,279	\$ 42,915,903	\$ 41,756,421	\$ 41,639,729

### Initial stabilized yield (unlevered)

Initial stabilized yield is calculated as the estimated amounts of net operating income at stabilization divided by our investment in the property. For this calculation, we exclude any tenant-funded and -built landlord improvements from our investment in the property. Our initial stabilized yield excludes the benefit of leverage. Our cash rents related to our development and redevelopment projects are generally expected to increase over time due to contractual annual rent escalations. Our estimates for initial stabilized yields, initial stabilized yields (cash basis), and total costs at completion represent our initial estimates at the commencement of the project. We expect to update this information upon completion of the project, or sooner if there are significant changes to the expected project yields or costs.

- Initial stabilized yield reflects rental income, including contractual rent escalations and any rent concessions over the term(s) of the lease(s), calculated on a straight-line basis, and any amortization of deferred revenue related to tenant-funded and -built landlord improvements.
- Initial stabilized yield (cash basis) reflects cash rents at the stabilization date after initial rental concessions, if any, have elapsed and our total cash investment in the property.

### Investment-grade or publicly traded large cap tenants

Investment-grade or publicly traded large cap tenants represent tenants that are investment-grade rated or publicly traded companies with an average daily market capitalization greater than \$10 billion for the twelve months ended September 30, 2024, as reported by Bloomberg Professional Services. Credit ratings from Moody's Ratings and S&P Global Ratings reflect credit ratings of the tenant's parent entity, and there can be no assurance that a tenant's parent entity will satisfy the tenant's lease obligation upon such tenant's default. We monitor the credit quality and related material changes of our tenants. Material changes that cause a tenant's market capitalization to decrease below \$10 billion, which are not immediately reflected in the twelve-month average, may result in their exclusion from this measure.

### Investments

We hold investments in publicly traded companies and privately held entities primarily involved in the life science industries. We recognize, measure, present, and disclose these investments as follows:

	Balance Sheet	Statements of Operations		
		Carrying Amount	Gains and Losses	
			Unrealized	Realized
Publicly traded companies	Fair value	Changes in fair value	Difference between proceeds received upon disposition and historical cost	
Privately held entities without readily determinable fair values that:				
Report NAV	Fair value, using NAV as a practical expedient	Changes in NAV, as a practical expedient to fair value		
Do not report NAV	Cost, adjusted for observable price changes and impairments <sup>(1)</sup>	Observable price changes <sup>(1)</sup>	Impairments to reduce costs to fair value, which result in an adjusted cost basis and the differences between proceeds received upon disposition and adjusted or historical cost	
Equity method investments	Contributions, adjusted for our share of the investee's earnings or losses, less distributions received, reduced by other-than-temporary impairments	Our share of unrealized gains or losses reported by the investee	Our share of realized gains or losses reported by the investee, and other-than-temporary impairments	

- (1) An observable price is a price observed in an orderly transaction for an identical or similar investment of the same issuer. Observable price changes result from, among other things, equity transactions for the same issuer with similar rights and obligations executed during the reporting period, including subsequent equity offerings or other reported equity transactions related to the same issuer.

## Definitions and Reconciliations (continued)

September 30, 2024

### Investments in real estate

The following table reconciles our investments in real estate as of September 30, 2024:

<i>(In thousands)</i>	<u>Investments in Real Estate</u>
Gross investments in real estate	\$ 38,576,419
Less: accumulated depreciation	(5,624,642)
Investments in real estate	<u>\$ 32,951,777</u>

The following table presents our new Class A/A+ development and redevelopment pipeline, excluding properties held for sale, as a percentage of gross assets and as a percentage of annual rental revenue as of September 30, 2024:

	<u>Percentage of</u>		
	<u>Book Value</u>	<u>Gross Assets</u>	<u>Annual Rental Revenue</u>
<i>(Dollars in thousands)</i>			
Under construction projects and one committed near-term project expected to commence construction in the next two years (55% leased/negotiating)	\$4,405,094	10%	—%
Income-producing/potential cash flows/covered land play <sup>(1)</sup>	2,861,653	6	2
Land	2,073,678	5	—
	<u>\$9,340,425</u>	<u>21%</u>	<u>2%</u>

(1) Includes projects with existing buildings that are generating or can generate operating cash flows. Also includes development rights associated with existing operating campuses.

Space Intentionally Blank

The square footage presented in the table below is classified as operating as of September 30, 2024. These lease expirations or vacant space at recently acquired properties represent future opportunities for which we have the intent, subject to market conditions and leasing, to commence first-time conversion from non-laboratory space to laboratory space, or to commence future ground-up development:

<u>Property/Submarket</u>	<u>Dev/ Redev</u>	<u>RSF of Lease Expirations Targeted for Development and Redevelopment</u>			
		<u>2024</u>	<u>2025</u>	<u>Thereafter<sup>(1)</sup></u>	<u>Total</u>
Committed near-term project:					
4161 Campus Point Court/University Town Center	Dev	—	159,884	—	159,884
Priority anticipated projects:					
311 Arsenal Street/Cambridge/Inner Suburbs	Redev	—	25,312	—	25,312
269 East Grand Avenue/South San Francisco	Redev	107,250	—	—	107,250
1020 Red River Street/Austin	Redev	—	126,034	—	126,034
		<u>107,250</u>	<u>151,346</u>	<u>—</u>	<u>258,596</u>
Future projects:					
100 Edwin H. Land Boulevard/Cambridge	Dev	104,500	—	—	104,500
446, 458, 500, and 550 Arsenal Street/Cambridge/Inner Suburbs	Dev	—	—	375,898	375,898
Other/Greater Boston	Redev	—	—	167,549	167,549
1122 and 1150 El Camino Real/South San Francisco	Dev	—	—	375,232	375,232
3875 Fabian Way/Greater Stanford	Dev	—	—	228,000	228,000
2100, 2200, and 2400 Geng Road/Greater Stanford	Dev	—	—	78,501	78,501
960 Industrial Road/Greater Stanford	Dev	—	—	112,590	112,590
Campus Point by Alexandria/University Town Center	Dev	—	109,164	226,144 <sup>(2)</sup>	335,308
Sequence District by Alexandria/Sorrento Mesa	Dev/ Redev	—	—	686,290	686,290
830 4th Avenue South/SoDo	Dev	—	—	45,615	45,615
410 West Harrison Street/Elliott Bay	Dev	—	—	17,205	17,205
Other/Seattle	Dev	—	—	75,663	75,663
100 Capitola Drive/Research Triangle	Dev	—	—	34,527	34,527
1001 Trinity Street/Austin	Dev	—	72,938	—	72,938
Canada	Redev	—	—	247,743	247,743
		<u>104,500</u>	<u>182,102</u>	<u>2,670,957</u>	<u>2,957,559</u>
		<u>211,750</u>	<u>493,332</u>	<u>2,670,957</u>	<u>3,376,039</u>

(1) Includes vacant square footage as of September 30, 2024.

(2) Represents 226,144 RSF of month-to-month leases in our University Town Center submarket primarily related to space being temporarily held over by an expiring tenant at buildings that are targeted for the future development of laboratory space, subject to market conditions and leasing.

### Joint venture financial information

We present components of balance sheet and operating results information related to our real estate joint ventures, which are not presented, or intended to be presented, in accordance with GAAP. We present the proportionate share of certain financial line items as follows: (i) for each real estate joint venture that we consolidate in our financial statements, which are controlled by us through contractual rights or majority voting rights, but of which we own less than 100%, we apply the noncontrolling interest economic ownership percentage to each financial item to arrive at the amount of such cumulative noncontrolling interest share of each component presented; and (ii) for each real estate joint venture that we do not control and do not consolidate, and are instead controlled jointly or by our joint venture partners through contractual rights or majority voting rights, we apply our economic ownership percentage to each financial item to arrive at our proportionate share of each component presented.

The components of balance sheet and operating results information related to our real estate joint ventures do not represent our legal claim to those items. For each entity that we do not wholly own, the joint venture agreement generally determines what equity holders can receive upon capital events, such as sales or refinancing, or in the event of a liquidation. Equity holders are normally entitled to their respective legal ownership of any residual cash from a joint venture only after all liabilities, priority distributions, and claims have been repaid or satisfied.

We believe that this information can help investors estimate the balance sheet and operating results information related to our partially owned entities. Presenting this information provides a perspective not immediately available from consolidated financial statements and one that can supplement an understanding of the joint venture assets, liabilities, revenues, and expenses included in our consolidated results.

The components of balance sheet and operating results information related to our real estate joint ventures are limited as an analytical tool as the overall economic ownership interest does not represent our legal claim to each of our joint ventures' assets, liabilities, or results of operations. In addition, joint venture financial information may include financial information related to the unconsolidated real estate joint ventures that we do not control. We believe that in order to facilitate for investors a clear understanding of our operating results and our total assets and liabilities, joint venture financial information should be examined in conjunction with our consolidated statements of operations and balance sheets. Joint venture financial information should not be considered an alternative to our consolidated financial statements, which are presented and prepared in accordance with GAAP.

Space Intentionally Blank

### Key items included in net income attributable to Alexandria's common stockholders

We present a tabular comparison of items, whether gain or loss, that may facilitate a high-level understanding of our results and provide context for the disclosures included in this Supplemental Information, our most recent annual report on Form 10-K, and our subsequent quarterly reports on Form 10-Q. We believe that such tabular presentation promotes a better understanding for investors of the corporate-level decisions made and activities performed that significantly affect comparison of our operating results from period to period. We also believe that this tabular presentation will supplement for investors an understanding of our disclosures and real estate operating results. Gains or losses on sales of real estate and impairments of assets classified as held for sale are related to corporate-level decisions to dispose of real estate. Gains or losses on early extinguishment of debt are related to corporate-level financing decisions focused on our capital structure strategy. Significant realized and unrealized gains or losses on non-real estate investments, impairments of real estate and non-real estate investments, and acceleration of stock compensation expense due to the resignation of an executive officer are not related to the operating performance of our real estate assets as they result from strategic, corporate-level non-real estate investment decisions and external market conditions. Impairments of non-real estate investments are not related to the operating performance of our real estate as they represent the write-down of non-real estate investments when their fair values decrease below their respective carrying values due to changes in general market or other conditions outside of our control. Significant items, whether a gain or loss, included in the tabular disclosure for current periods are described in further detail in this Supplemental Information and accompanying Earnings Press Release.

#### Mega campus

Mega campuses are cluster campuses that consist of approximately 1 million RSF or more, including operating, active development/redevelopment, and land RSF less operating RSF expected to be demolished. The following table reconciles our annual rental revenue and development and redevelopment pipeline RSF as of September 30, 2024:

<i>(Dollars in thousands)</i>	<b>Annual Rental Revenue</b>	<b>Development and Redevelopment Pipeline RSF</b>
Mega campus	\$ 1,666,759	21,957,791
Non-mega campus	517,316	9,880,617
Total	<u>\$ 2,184,075</u>	<u>31,838,408</u>
Mega campus as a percentage of annual rental revenue and of total development and redevelopment pipeline RSF	76%	69%

#### Net cash provided by operating activities after dividends

Net cash provided by operating activities after dividends includes the deduction for distributions to noncontrolling interests. For purposes of this calculation, changes in operating assets and liabilities are excluded as they represent timing differences.

## Definitions and Reconciliations (continued)

September 30, 2024

### Net debt and preferred stock to Adjusted EBITDA

Net debt and preferred stock to Adjusted EBITDA is a non-GAAP financial measure that we believe is useful to investors as a supplemental measure of evaluating our balance sheet leverage. Net debt and preferred stock is equal to the sum of total consolidated debt less cash, cash equivalents, and restricted cash, plus preferred stock outstanding as of the end of the period. Refer to the definition of Adjusted EBITDA and Adjusted EBITDA margin for further information on the calculation of Adjusted EBITDA.

The following table reconciles debt to net debt and preferred stock and computes the ratio to Adjusted EBITDA:

<i>(Dollars in thousands)</i>	9/30/24	6/30/24	3/31/24	12/31/23	9/30/23
Secured notes payable	\$ 145,000	\$ 134,942	\$ 130,050	\$ 119,662	\$ 109,110
Unsecured senior notes payable	12,092,012	12,089,561	12,087,113	11,096,028	11,093,725
Unsecured senior line of credit and commercial paper	454,589	199,552	—	99,952	—
Unamortized deferred financing costs	79,610	81,942	84,198	76,329	78,496
Cash and cash equivalents	(562,606)	(561,021)	(722,176)	(618,190)	(532,390)
Restricted cash	(17,031)	(4,832)	(9,519)	(42,581)	(35,321)
Preferred stock	—	—	—	—	—
Net debt and preferred stock	<u>\$12,191,574</u>	<u>\$11,940,144</u>	<u>\$11,569,666</u>	<u>\$10,731,200</u>	<u>\$10,713,620</u>
Adjusted EBITDA:					
– quarter annualized	\$ 2,219,632	\$ 2,216,144	\$ 2,206,428	\$ 2,094,988	\$ 1,971,440
– trailing 12 months	\$ 2,184,298	\$ 2,122,250	\$ 2,064,904	\$ 1,997,518	\$ 1,935,505
Net debt and preferred stock to Adjusted EBITDA:					
– quarter annualized	5.5x	5.4x	5.2x	5.1x	5.4x
– trailing 12 months	5.6x	5.6x	5.6x	5.4x	5.5x

We are not able to forecast fourth quarter net income without unreasonable effort and therefore do not provide a reconciliation for net debt and preferred stock to Adjusted EBITDA on a forward-looking basis. This is due to the inherent difficulty of forecasting the timing and/or amount of items that depend on market conditions outside of our control, including the timing of dispositions, capital events, and financing decisions, as well as quarterly components such as gain on sales of real estate, unrealized gains or losses on non-real estate investments, impairment of real estate, and impairment of non-real estate investments. Our attempt to predict these amounts may produce significant but inaccurate estimates, which would be potentially misleading for our investors.

### Net operating income, net operating income (cash basis), and operating margin

The following table reconciles net income (loss) to net operating income and net operating income (cash basis) and computes operating margin:

<i>(Dollars in thousands)</i>	Three Months Ended		Nine Months Ended	
	9/30/24	9/30/23	9/30/24	9/30/23
Net income	\$ 213,603	\$ 68,254	\$ 526,828	\$ 323,652
Equity in earnings of unconsolidated real estate joint ventures	(139)	(242)	(424)	(617)
General and administrative expenses	43,945	45,987	135,629	140,065
Interest expense	43,550	11,411	130,179	42,237
Depreciation and amortization	293,998	269,370	872,272	808,227
Impairment of real estate	5,741	20,649	36,504	189,224
Gain on sales of real estate	(27,114)	—	(27,506)	(214,810)
Investment (income) loss	(15,242)	80,672	(14,866)	204,051
Net operating income	558,342	496,101	1,658,616	1,492,029
Straight-line rent revenue	(29,087)	(29,805)	(125,676)	(92,331)
Amortization of deferred revenue related to tenant-funded and -built landlord improvements	(329)	—	(329)	—
Amortization of acquired below-market leases	(17,312)	(23,222)	(70,167)	(69,647)
Net operating income (cash basis)	<u>\$ 511,614</u>	<u>\$ 443,074</u>	<u>\$ 1,462,444</u>	<u>\$ 1,330,051</u>
Net operating income (cash basis) – annualized	\$ 2,046,456	\$ 1,772,296	\$ 1,949,925	\$ 1,773,401
Net operating income (from above)	\$ 558,342	\$ 496,101	\$ 1,658,616	\$ 1,492,029
Total revenues	<u>\$ 791,607</u>	<u>\$ 713,788</u>	<u>\$ 2,327,449</u>	<u>\$ 2,128,483</u>
Operating margin	<u>71%</u>	<u>70%</u>	<u>71%</u>	<u>70%</u>

Net operating income is a non-GAAP financial measure calculated as net income (loss), the most directly comparable financial measure calculated and presented in accordance with GAAP, excluding equity in the earnings of our unconsolidated real estate joint ventures, general and administrative expenses, interest expense, depreciation and amortization, impairments of real estate, gains or losses on early extinguishment of debt, gains or losses on sales of real estate, and investment income or loss. We believe net operating income provides useful information to investors regarding our financial condition and results of operations because it primarily reflects those income and expense items that are incurred at the property level. Therefore, we believe net operating income is a useful measure for investors to evaluate the operating performance of our consolidated real estate assets. Net operating income on a cash basis is net operating income adjusted to exclude the effect of straight-line rent, amortization of acquired above- and below-market lease revenue, and amortization of deferred revenue related to tenant-funded and -built landlord improvements adjustments required by GAAP. We believe that net operating income on a cash basis is helpful to investors as an additional measure of operating performance because it eliminates straight-line rent revenue and the amortization of acquired above- and below-market leases and tenant-funded and -built landlord improvements.



### Net operating income, net operating income (cash basis), and operating margin (continued)

Furthermore, we believe net operating income is useful to investors as a performance measure of our consolidated properties because, when compared across periods, net operating income reflects trends in occupancy rates, rental rates, and operating costs, which provide a perspective not immediately apparent from net income or loss. Net operating income can be used to measure the initial stabilized yields of our properties by calculating net operating income generated by a property divided by our investment in the property. Net operating income excludes certain components from net income in order to provide results that are more closely related to the results of operations of our properties. For example, interest expense is not necessarily linked to the operating performance of a real estate asset and is often incurred at the corporate level rather than at the property level. In addition, depreciation and amortization, because of historical cost accounting and useful life estimates, may distort comparability of operating performance at the property level. Impairments of real estate have been excluded in deriving net operating income because we do not consider impairments of real estate to be property-level operating expenses. Impairments of real estate relate to changes in the values of our assets and do not reflect the current operating performance with respect to related revenues or expenses. Our impairments of real estate represent the write-down in the value of the assets to the estimated fair value less cost to sell. These impairments result from investing decisions or a deterioration in market conditions. We also exclude realized and unrealized investment gain or loss, which results from investment decisions that occur at the corporate level related to non-real estate investments in publicly traded companies and certain privately held entities. Therefore, we do not consider these activities to be an indication of operating performance of our real estate assets at the property level. Our calculation of net operating income also excludes charges incurred from changes in certain financing decisions, such as losses on early extinguishment of debt, as these charges often relate to corporate strategy. Property operating expenses included in determining net operating income primarily consist of costs that are related to our operating properties, such as utilities, repairs, and maintenance; rental expense related to ground leases; contracted services, such as janitorial, engineering, and landscaping; property taxes and insurance; and property-level salaries. General and administrative expenses consist primarily of accounting and corporate compensation, corporate insurance, professional fees, rent, and supplies that are incurred as part of corporate office management. We calculate operating margin as net operating income divided by total revenues.

We believe that in order to facilitate for investors a clear understanding of our operating results, net operating income should be examined in conjunction with net income or loss as presented in our consolidated statements of operations. Net operating income should not be considered as an alternative to net income or loss as an indication of our performance, nor as an alternative to cash flows as a measure of our liquidity or our ability to make distributions.

### Operating statistics

We present certain operating statistics related to our properties, including number of properties, RSF, occupancy percentage, leasing activity, and contractual lease expirations as of the end of the period. We believe these measures are useful to investors because they facilitate an understanding of certain trends for our properties. We compute the number of properties, RSF, occupancy percentage, leasing activity, and contractual lease expirations at 100%, excluding RSF at properties classified as held for sale, for all properties in which we have an investment, including properties owned by our consolidated and unconsolidated real estate joint ventures. For operating metrics based on annual rental revenue, refer to the definition of annual rental revenue herein.

### Same property comparisons

As a result of changes within our total property portfolio during the comparative periods presented, including changes from assets acquired or sold, properties placed into development or redevelopment, and development or redevelopment properties recently placed into service, the consolidated total income from rentals, as well as rental operating expenses in our operating results, can show significant changes from period to period. In order to supplement an evaluation of our results of operations over a given quarterly or annual period, we analyze the operating performance for all consolidated properties that were fully operating for the entirety of the comparative periods presented, referred to as same properties. We separately present quarterly and year-to-date same property results to align with the interim financial information required by the SEC in our management's discussion and analysis of our financial condition and results of operations. These same properties are analyzed separately from properties acquired subsequent to the first day in the earliest comparable quarterly or year-to-date period presented, properties that underwent development or redevelopment at any time during the comparative periods, unconsolidated real estate joint ventures, properties classified as held for sale, and corporate entities (legal entities performing general and administrative functions), which are excluded from same property results. Additionally, termination fees, if any, are excluded from the results of same properties.

Space Intentionally Blank

## Definitions and Reconciliations (continued)

September 30, 2024

### Same property comparisons (continued)

The following table reconciles the number of same properties to total properties for the nine months ended September 30, 2024:

<u>Development – under construction</u>	<u>Properties</u>	<u>Redevelopment – placed into service after January 1, 2023</u>	<u>Properties</u>
201 Brookline Avenue	1	20400 Century Boulevard	1
99 Coolidge Avenue	1	140 First Street	1
500 North Beacon Street and 4 Kingsbury Avenue	2	2400 Ellis Road, 40 Moore Drive, and 14 TW Alexander Drive	3
9808 Medical Center Drive	1	9601 and 9603 Medical Center Drive	2
1450 Owens Street	1		7
230 Harriet Tubman Way	1	<u>Acquisitions after January 1, 2023</u>	<u>Properties</u>
4155 Campus Point Court	1	Other	5
10935, 10945, and 10955 Alexandria Way	3	Unconsolidated real estate JVs	5
10075 Barnes Canyon Road	1	Properties held for sale	4
421 Park Drive	1	Properties held for sale	9
4135 Campus Point Court	1	Total properties excluded from same properties	67
701 Dexter Avenue North	1	Same properties	339
	15	Total properties in North America as of September 30, 2024	406
<u>Development – placed into service after January 1, 2023</u>	<u>Properties</u>		
751 Gateway Boulevard	1		
15 Necco Street	1		
325 Binney Street	1		
9810 Darnestown Road	1		
9820 Darnestown Road	1		
1150 Eastlake Avenue East	1		
	6		
<u>Redevelopment – under construction</u>	<u>Properties</u>		
840 Winter Street	1		
40, 50, and 60 Sylvan Road	3		
Alexandria Center <sup>®</sup> for Advanced Technologies – Monte Villa Parkway	6		
651 Gateway Boulevard	1		
401 Park Drive	1		
8800 Technology Forest Place	1		
311 Arsenal Street	1		
One Hampshire Street	1		
Canada	4		
Other	2		
	21		

### Stabilized occupancy date

The stabilized occupancy date represents the estimated date on which the project is expected to reach occupancy of 95% or greater.

### Tenant recoveries

Tenant recoveries represent revenues comprising reimbursement of real estate taxes, insurance, utilities, repairs and maintenance, common area expenses, and other operating expenses and earned in the period during which the applicable expenses are incurred and the tenant's obligation to reimburse us arises.

We classify rental revenues and tenant recoveries generated through the leasing of real estate assets within revenues in income from rentals in our consolidated statements of operations. We provide investors with a separate presentation of rental revenues and tenant recoveries in "Same property performance" in this Supplemental Information because we believe it promotes investors' understanding of our operating results. We believe that the presentation of tenant recoveries is useful to investors as a supplemental measure of our ability to recover operating expenses under our triple net leases, including recoveries of utilities, repairs and maintenance, insurance, property taxes, common area expenses, and other operating expenses, and of our ability to mitigate the effect to net income for any significant variability to components of our operating expenses.

The following table reconciles income from rentals to tenant recoveries:

<i>(In thousands)</i>	<u>Three Months Ended</u>				<u>Nine Months Ended</u>	
	<u>9/30/24</u>	<u>6/30/24</u>	<u>3/31/24</u>	<u>12/31/23</u>	<u>9/30/23</u>	<u>9/30/23</u>
Income from rentals	\$ 775,744	\$ 755,162	\$ 755,551	\$ 742,637	\$ 707,531	\$2,286,457
Rental revenues	(579,569)	(576,835)	(581,400)	(561,428)	(526,352)	(1,737,804)
Tenant recoveries	\$ 196,175	\$ 178,327	\$ 174,151	\$ 181,209	\$ 181,179	\$ 548,653
						\$ 517,276

### Total equity capitalization

Total equity capitalization is equal to the outstanding shares of common stock multiplied by the closing price on the last trading day at the end of each period presented.

### Total market capitalization

Total market capitalization is equal to the sum of total equity capitalization and total debt.

## Definitions and Reconciliations (continued)

September 30, 2024

### Unencumbered net operating income as a percentage of total net operating income

Unencumbered net operating income as a percentage of total net operating income is a non-GAAP financial measure that we believe is useful to investors as a performance measure of the results of operations of our unencumbered real estate assets as it reflects those income and expense items that are incurred at the unencumbered property level. Unencumbered net operating income is derived from assets classified in continuing operations, which are not subject to any mortgage, deed of trust, lien, or other security interest, as of the period for which income is presented.

The following table summarizes unencumbered net operating income as a percentage of total net operating income:

	Three Months Ended				
	9/30/24	6/30/24	3/31/24	12/31/23	9/30/23
<i>(Dollars in thousands)</i>					
Unencumbered net operating income	\$ 553,589	\$ 544,268	\$ 546,830	\$ 533,382	\$ 495,012
Encumbered net operating income	4,753	5,212	3,964	1,108	1,089
Total net operating income	<u>\$ 558,342</u>	<u>\$ 549,480</u>	<u>\$ 550,794</u>	<u>\$ 534,490</u>	<u>\$ 496,101</u>
Unencumbered net operating income as a percentage of total net operating income	99.1%	99.1%	99.3%	99.8%	99.8%

### Weighted-average interest rate for capitalization of interest

The weighted-average interest rate required for calculating capitalization of interest pursuant to GAAP represents a weighted-average rate as of the end of the applicable period, based on the rates applicable to borrowings outstanding during the period, including expense/income related to interest rate hedge agreements, amortization of loan fees, amortization of debt premiums (discounts), and other bank fees. A separate calculation is performed to determine our weighted-average interest rate for capitalization for each month. The rate will vary each month due to changes in variable interest rates, outstanding debt balances, the proportion of variable-rate debt to fixed-rate debt, the amount and terms of interest rate hedge agreements, and the amount of loan fee and premium (discount) amortization.

Space Intentionally Blank

### Weighted-average shares of common stock outstanding – diluted

From time to time, we enter into capital market transactions, including forward equity sales agreements (“Forward Agreements”), to fund acquisitions, to fund construction of our development and redevelopment projects, and for general working capital purposes. We are required to consider the potential dilutive effect of our Forward Agreements under the treasury stock method while the Forward Agreements are outstanding. As of September 30, 2024, we had Forward Agreements outstanding to sell an aggregate of 230 thousand shares of common stock.

The weighted-average shares of common stock outstanding used in calculating EPS – diluted, FFO per share – diluted, and FFO per share – diluted, as adjusted, during each period are calculated as follows. Also shown are the weighted-average unvested shares associated with restricted stock awards used in calculating amounts allocable to unvested stock award holders pursuant to the two-class method for each of the respective periods presented below:

	Three Months Ended				Nine Months Ended	
	9/30/24	6/30/24	3/31/24	12/31/23	9/30/23	9/30/23
<i>(In thousands)</i>						
Basic shares for earnings per share	172,058	172,013	171,949	171,096	170,890	172,007
Forward Agreements	—	—	—	—	—	—
Diluted shares for earnings per share	<u>172,058</u>	<u>172,013</u>	<u>171,949</u>	<u>171,096</u>	<u>170,890</u>	<u>172,007</u>
Basic shares for funds from operations per share and funds from operations per share, as adjusted	172,058	172,013	171,949	171,096	170,890	172,007
Forward Agreements	—	—	—	—	—	—
Diluted shares for funds from operations per share and funds from operations per share, as adjusted	<u>172,058</u>	<u>172,013</u>	<u>171,949</u>	<u>171,096</u>	<u>170,890</u>	<u>172,007</u>
Weighted-average unvested restricted shares used in calculating the allocations of net income, funds from operations, and funds from operations, as adjusted	<u>2,838</u>	<u>2,878</u>	<u>2,987</u>	<u>2,734</u>	<u>2,124</u>	<u>2,901</u>